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ABSTRACT 
OBJECTIVES:  The objectives of this thesis were to review the use of outcome 
measures systematically across amyotrophic lateral sclerosis (ALS) clinical trials, and 
evaluate the utility of decomposition-enhanced spike-triggered averaging (DE-STA) 
motor unit number estimation (MUNE) as an outcome measure, with a particular focus 
on its application to the upper trapezius (UT).   
METHODS:  First, a systematic review quantified the frequency of use of outcome 
measures in ALS randomized controlled trials (Chapter 2).  Next, the intra- and inter-
rater reliability of DE-STA MUNE was evaluated in the UT of control subjects (Chapter 
3), followed by the intra-rater reliability of the technique in the UT and biceps brachii of 
subjects with ALS (Chapter 4).  To assess validity, the results of the technique in the UT 
were compared between subjects with ALS and control subjects (Chapter 4).  The 
sensitivity to change of DE-STA MUNE in the UT was compared with that of various 
clinical outcome measures in a longitudinal study of subjects with ALS (Chapter 5).  
Finally, the influence of needle electrode depth on the results of the technique in the UT 
was evaluated in control subjects (Chapter 6).   
RESULTS:  The heterogeneity in the use of outcome measures across ALS randomized 
controlled trials was demonstrated, in addition to the infrequent use of MUNE.  MUNE 
results demonstrated moderate intra- and inter-rater reliability for control subjects in the 
UT, although less favorable results were found overall for inter-rater reliability.  
Application of DE-STA MUNE to the UT in subjects with ALS demonstrated 
consistently high intra-rater reliability, the ability to detect the underlying 
pathophysiology of the disease, and a moderate degree of sensitivity to change for 
 iv 
 
MUNE results.  Further evaluation found needle electrode depth to significantly influence 
the results of the technique, with suggestions made for improved standardization of the 
protocol.      
SIGNIFICANCE:  These studies were novel in their evaluation of MUNE in the 
proximal, potentially clinically relevant UT.  The studies mark the first evaluations of the 
reliability and sensitivity to change of DE-STA MUNE in subjects with ALS, finding 
application to the UT to be practical and promising for use as an outcome measure.  
Implementation of proposed improvements to the protocol may aid in further establishing 
DE-STA MUNE for use as an outcome measure in studies of ALS.   
 
KEYWORDS:  amyotrophic lateral sclerosis (ALS), decomposition-enhanced spike-
triggered averaging (DE-STA), electromyography (EMG), motor unit number estimation 
(MUNE), outcome measure, upper trapezius.  
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CHAPTER 1 
GENERAL INTRODUCTION AND OVERVIEW 
1.0 GENERAL INTRODUCTION 
1.0.1 The motor unit 
A motor unit (MU) is defined as a single motor neuron (located in the brain stem 
or spinal cord), its peripheral axon and the muscle fibers innervated by that axon.
1, 2
  
Responsible for the production of force via reflex and voluntary contractions of skeletal 
muscle, MUs are considered the elementary functional component of the motor system.
3
  
Losses of MUs occur in aging, many peripheral neuropathies, and motor neuron diseases 
such as amyotrophic lateral sclerosis (ALS).
4
   
1.0.2 Amyotrophic lateral sclerosis 
ALS is a progressive neurodegenerative disease characterized by the selective 
death of upper and lower motor neurons.
5
  The disease has a population incidence of 1.5 
to 2.5 per 100 000 persons per year and a gender ratio of roughly 2:1 male to female, 
although there have been reports of a trend towards unity.
6
  While 5 to 10% of ALS cases 
are familial, 90 to 95% of cases are considered sporadic, characterized by an absence of 
family history.
5
  Cases are classified by region of symptom onset, with limb onset as the 
most common presentation (e.g. foot drop), followed by bulbar onset (e.g. dysphagia, 
dysarthria), and the relatively uncommon respiratory onset ALS (e.g. orthopnea).
7
  
Degeneration of LMNs (and a corresponding decline in the number of functioning 
MUs) results in denervation of skeletal muscle fibers and progressive muscle atrophy and 
weakness.
5
  The progression of the disease is highly variable from patient to patient, and 
while a small proportion of patients survive much longer, ALS is typically fatal within  
2 
 
 
3-5 years of symptom onset.
5, 8
  In general, death occurs as a result of respiratory failure.
9
  
Many unknowns remain with regard to the etiology and pathogenesis of ALS.  However, 
a common overarching hypothesis for the etiology of ALS is that it involves the coupling 
of exposure to a risk factor (proposed risk factors include strenuous physical activity, 
exposure to heavy metals, and trauma with skeletal fracture) with genetic susceptibility to 
the disease.
10, 11
  Many potentially convergent hypotheses exist as to the underlying 
causes of motor neuron degeneration, including oxidative damage, glutamate 
excitotoxicity, and aberrant RNA metabolism.
12
  With the exception of the drug riluzole 
(which has been shown to prolong survival modestly),
13
 the interventions tested in 
clinical trials thus far have not been found to modify the progression of the disease.
14
       
1.0.3 Motor unit number estimation 
Highly relevant for application to this disease population, motor unit number 
estimation (MUNE) was developed by McComas et al. (1971)
15
 as a quantitative, 
electrophysiological method for estimating the number of functioning MUs within a 
muscle or group of muscles.  This quantification may be useful to evaluate the severity 
and natural history of the disease.  Furthermore, it may be especially useful as an 
outcome measure in ALS clinical trials to assess the efficacy of interventions by 
monitoring disease progression.
16
     
MUNE uses electromyography (EMG), which detects and records the electrical 
activity of active MUs using surface and/or intramuscular electrodes.  The action 
potentials propagated along the individual muscle fibers of a MU following the discharge 
of the associated motor neuron correspond with waveforms termed muscle fiber action 
potentials.
17
  The summation of these individual waveforms yields the expression of a 
3 
 
 
waveform termed a motor unit potential (MUP) that is unique for each MU.
17
  Certain 
parameters associated with a surface-detected motor unit potential (S-MUP) or 
intramuscularly-detected MUP (hereafter simply referred to as a MUP) are related to the 
morphological and physiological characteristics of the underlying MU.  For example, the 
amplitude or area of an S-MUP is representative of the number of muscle fibers within 
the MU (i.e. the innervation ratio, or size of the MU).
3, 15, 17
  
Based on these principles, a MUNE is calculated through the division of a size 
parameter of the maximum compound muscle action potential (CMAP), representative of 
the activation of all of the motor axons in the nerve in response to supramaximal 
electrical stimulation, by the same size parameter of the mean S-MUP, representative of 
the average single MU size (Equation 1).
1, 18
   
1.0.3.1 Equation 1 
MUNE = maximum CMAP size       
       mean S-MUP size 
 
Where MUNE, motor unit number estimate; CMAP, compound muscle action potential; 
S-MUP, surface-detected motor unit potential.   
1.0.4 Outcome measures and collateral reinnervation 
The selection of primary and secondary outcome measures (also termed 
endpoints) for use in ALS clinical trials to determine the efficacy of interventions has 
been highly heterogeneous.  However, a quantitative review of ALS clinical trials has yet 
to be conducted to identify the most commonly used and underutilized measures.   
In general terms, ALS clinical trials commonly employ outcome measures that 
assess function and muscle strength.
19, 20
  However, these outcome measures are 
influenced by the compensatory process of collateral reinnervation which takes place in 
4 
 
 
chronic denervating disorders such as ALS, whereby new nerve sprouts grow out from 
surviving nerve axons to supply denervated muscle fibers (Figure 1.1).  This process, by 
maintaining muscle mass and strength, may allow these measures to remain relatively 
stable until MU loss has surpassed a critical threshold.
21
   
In contrast to these clinical outcome measures, MUNE takes into account the 
effects of collateral reinnervation, as mean S-MUP size is incorporated into its 
calculation.  Its subsequent ability to monitor the underlying progression of the disease 
(MU loss as well as collateral reinnervation) makes MUNE a valuable addition as an 
outcome measure for use in ALS clinical trials.
16, 22
     
1.0.5 Motor unit number estimation techniques 
Various types of MUNE have been developed and modified since its introduction 
over 40 years ago, with manual incremental stimulation,
15
 multiple point stimulation,
23, 24
 
the statistical method,
1
 spike-triggered averaging (STA),
25, 26
 and decomposition-
enhanced spike-triggered averaging (DE-STA)
18, 27
 used most commonly.
16, 22
  While the 
basic principles are the same for all techniques, they differ in their underlying 
assumptions, as well as their inherent benefits and limitations.   
A key difference among the techniques is the way in which the mean S-MUP is 
obtained, which influences the range of muscle groups to which the protocol can be 
applied.  Manual incremental stimulation, multiple point stimulation, and the statistical 
method (along with modifications to these techniques) employ percutaneous electrical 
stimulation of the motor nerve in order to collect a sample of S-MUPs, whereas STA and 
DE-STA utilize voluntary contractions.  MUNE techniques utilizing electrical stimulation 
to collect a sample of S-MUPs are generally limited to application to relatively distal 
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muscles with easily accessible nerve supplies, and in the case of multiple point 
stimulation, a certain length of the motor nerve available for stimulation.  In contrast, the 
use of voluntary contractions to collect a sample of S-MUPs allows for STA and DE-
STA MUNE to be applied to any muscle from which a maximum CMAP can be elicited.  
Thus, these techniques can be applied to not only distal, but proximal muscles.
16, 18, 22
   
1.0.6 Quantitative electromyography 
A further advantage of STA and DE-STA MUNE stems from the introduction of 
a needle electrode, which allows for an intramuscular EMG signal to be collected 
simultaneously with the surface EMG signal during each voluntary contraction (Figure 
1.2).
16, 18, 22
  The subsequent application of quantitative electromyography (QEMG) 
techniques allows for quantitative MUP analysis in addition to the results yielded through 
MUNE.  QEMG techniques allow for the isolation of the activity of individual MUP 
trains, representative of the repetitive firing of single MUs over a given period of time,
28
 
and subsequent determination of the prototypical MUP associated with each MUP train.  
Quantification of the distributions of various parameters characterizing the sizes, shapes, 
and firing patterns of a representative sample of MUPs from a given muscle allows for 
the evaluation of corresponding morphological and physiological features of the 
associated MU pool.  As such, quantitative MUP analysis is able to yield information 
complementary to MUNE corresponding with the severity and progression of processes 
affecting the neuromuscular system such as ALS.
29, 30
     
QEMG facilitates the process of MUNE, with STA and DE-STA utilizing 
different techniques.  The process of STA involves the application of a level or window-
based discriminator to the intramuscularly-detected EMG signal in order to isolate the 
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activity of an individual, voluntarily activated MUP train.  Each MUP firing that meets or 
falls within the limits of the discriminator acts as a trigger to isolate the time-locked S-
MUP for that specific MUP (Figure 1.2).  Next, the S-MUPs associated with each MUP 
firing for a given MUP train are ensemble-averaged to derive the S-MUP template 
associated with a given MU.
25, 26
  First described as a method of MUNE by Boe et al. 
(2004),
27
 DE-STA improves upon conventional STA MUNE by incorporating a series of 
computer-based algorithms for intramuscular EMG signal decomposition, termed 
decomposition-based quantitative electromyography (DQEMG).
18, 28, 31
   
1.0.7 Decomposition-based quantitative electromyography 
While STA is limited to the collection of one MUP train from each low-level 
voluntary contraction, the addition of DQEMG allows for the resolution of composite 
EMG signals produced from stronger voluntary contractions into their constituent MUP 
trains.  The individual MUP firings from each MUP train then serve as triggers to be used 
in STA, resulting in the collection of S-MUP templates for numerous MUs from a single 
contraction.  By collecting more than one MUP train at a time from stronger voluntary 
contractions, DE-STA MUNE both eases the level of focus required of the subject, and 
allows for more efficient collection of a sample of S-MUPs.  Furthermore, in line with 
the “size principle” of MU recruitment,32 the use of stronger voluntary contractions 
allows DE-STA MUNE to include not only low-threshold, generally smaller MUs but 
also higher-threshold, larger MUs.  This may allow for the determination of a more 
representative mean S-MUP from which to calculate a MUNE.
18, 31
  
The DQEMG algorithms involve MUP detection, clustering, and supervised 
classification, and are applied sequentially and iteratively to the composite intramuscular 
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EMG signal.  The composite signal is first bandpass filtered using a first-order difference 
filter.  Subsequently, the MUPs exceeding a certain threshold are detected and considered 
to represent a significant MUP occurrence.  Next, a shape- and temporal-based clustering 
algorithm is applied to the detected MUPs from an interval of the EMG signal in order to 
elucidate the number of contributing MUs, and the prototypical MUP shape for each MU.  
Supervised classification involves the assignment of each MUP detected initially to its 
corresponding MUP train.  Assignments are made based on shape and firing pattern 
information and utilize a certainty algorithm, with only classifications that exceed a 
specific threshold of assignment certainty being made.  Lastly, algorithms that examine 
the temporal relationships between MUP trains allow for the splitting and merging of 
MUP trains.
28, 33
 
EMG signal decomposition and subsequent STA yields a decomposition summary 
for each voluntary contraction, as depicted in Figure 1.3.  Quantitative MUP analysis 
involves the calculation of various parameters characterizing the MUP template, MUP 
shimmer plot, S-MUP template, and firing pattern associated with each MUP train using 
standard algorithms.  Finally, descriptive statistics are calculated automatically for each 
parameter based on the entire sample of accepted MUPs, S-MUPs, and MUP trains from 
the muscle under study.
28, 33
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A       B            C 
 
Figure 1.1 Collateral reinnervation.  Two functioning MUs are depicted with their motor 
neurons located in the anterior horn of a cross-section of the spinal cord and their 
peripheral axons innervating respective groups of muscle fibers.  The muscle fibers 
innervated by the MU on the left are represented as shaded circles in the inset (A).  
Degeneration of one of the MUs occurs, resulting in the denervation of its associated 
skeletal muscle fibers (B).  Collateral reinnervation is depicted, with new nerve sprouts 
from the axon of the surviving MU reinnervating many of the orphaned muscle fibers.  
The inset depicts the subsequent increase in the innervation ratio of the surviving MU 
(C).  (Modified from Stålberg E, Falck B. The role of electromyography in neurology. 
Electroencephalogr Clin Neurophysiol 1997; 103:579-598).
34
   
Abbreviation: MU, motor unit.   
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Figure 1.2 Spike-triggered averaging.  An example of the simultaneous collection of an 
intramuscular EMG signal (top panel) and surface EMG signal (bottom panel) from a 
voluntary contraction, as occurs in STA and DE-STA MUNE techniques (A).  Following 
the isolation of the activity of an individual MUP train from the intramuscular EMG 
signal using QEMG, individual MUP firings act as triggers to isolate time-locked S-
MUPs.  An S-MUP (thin line) is shown superimposed on its corresponding MUP firing 
(thick line) (B). ([B] Modified from Doherty T, Simmons Z, O'Connell B, Felice KJ, 
Conwit R, Chan KM, et al. Methods for estimating the numbers of motor units in human 
muscles. J Clin Neurophysiol 1995; 12:565-584).
18
   
Abbreviations:  DE-STA, decomposition-enhanced spike-triggered averaging; EMG, 
electromyography; MUNE, motor unit number estimation; MUP, motor unit potential; S-
MUP, surface-detected motor unit potential; STA, spike-triggered averaging; QEMG, 
quantitative electromyography. 
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Figure 1.3 Decomposition summary depicting the results of DQEMG from a single 
voluntary contraction.  Each row represents one MUP train.  The first column depicts a 
MUP template and the number of isolated MUPs used for its estimation.  The second 
column presents a MUP shimmer plot of the isolated MUPs making up the MUP train.  
The third column depicts an S-MUP template and the number of firings used for its 
estimation.  The fourth column displays an interdischarge interval histogram, as well as 
the mean interdischarge interval, and standard deviation and coefficient of variation of 
the interdischarge interval.  The fifth column depicts a firing graph, with vertical lines 
representing MU firing times and the top tracing representing the instantaneous firing rate 
plot.  (Modified from Stashuk D. EMG signal decomposition: How can it be 
accomplished and used? J Electromyogr Kinesiol 2001; 11:151-173).
33
    
Abbreviations:  DQEMG, decomposition-based quantitative electromyography; MU, 
motor unit;  MUP, motor unit potential; S-MUP, surface-detected motor unit potential.   
 
 
 
 
11 
 
 
1.0.8 Upper trapezius muscle 
Thus far, the use of MUNE as an outcome measure in ALS clinical trials has been 
limited.  Taking into consideration the many advantages associated with DE-STA 
MUNE, this technique may be very useful in such a role.   
In evaluating the potential utility of DE-STA MUNE as an outcome measure, the 
role of the muscle under study becomes an important consideration.  As previously 
mentioned, respiratory failure is generally the cause of death in ALS.
9
  Thus, it would be 
clinically relevant to study muscles of respiration in this population.  While the principal 
muscles of respiration (i.e. diaphragm, intercostal muscles) are not feasible to study using 
MUNE, the upper trapezius (UT) muscle is an accessory muscle of respiration
9
 that 
would be practical to assess, given its superficial position and easily accessible nerve 
supply.   
The UT (descending fibers), together with the middle (transverse fibers) and 
lower (ascending fibers) trapezii, compose the trapezius muscle.  The UT originates from 
the external occipital protuberance, the medial third of the superior nuchal line, and the 
ligamentum nuchae, and inserts into the posterior border of the lateral third of the 
clavicle.  This muscle acts with the levator scapulae to perform scapular elevation.
35
  The 
primary source of motor innervation for the UT is the spinal accessory nerve, which is the 
spinal branch of cranial nerve XI, termed the accessory nerve.
35-38
  The spinal accessory 
nerve is a motor nerve that supplies both the trapezius and sternocleidomastoid muscles, 
and originates from motor neurons lying in the lateral portion of the gray matter of the 
upper cervical spinal cord (C1-C6).  Rootlets exit the lateral aspect of the spinal cord, 
forming a trunk which ascends through the foramen magnum, exiting the skull soon after 
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through the jugular foramen.  The spinal accessory nerve then travels inferiorly, 
innervating the SCM, and on through the posterior triangle of the neck to innervate the 
UT (Figure 1.4).
35, 36
 
As an accessory muscle of respiration, the UT aids with inspiration in the 
presence of impaired diaphragmatic function, as occurs with progressive denervation in 
ALS.
9
  Quantification of the number and characteristics of MUs associated with a muscle 
related to respiratory function may offer insight into the severity and progression of the 
disease, as well as the potential efficacy of interventions.  Additionally, as a proximal 
muscle, examination of the UT would be novel, as the majority of previous studies using 
MUNE have utilized techniques that limited their evaluations to distal muscles.   
A preliminary study by Lewis (2009)
39
 examined the application of DE-STA 
MUNE to the UT in a small sample that included three control subjects and one subject 
with ALS.  Their results suggest that the application of DE-STA MUNE to this proximal 
muscle is feasible and warrants further study.   
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Figure 1.4 Innervation of the upper trapezius by the spinal accessory nerve.  (Modified 
from Mosby’s medical dictionary. Mosby/Elsevier: St. Louis; 2009. 2056 p.).40 
Abbreviation: CN, cranial nerve.    
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1.0.9 Evaluation of decomposition-enhanced spike-triggered averaging MUNE 
In order to assess the utility of DE-STA MUNE as an outcome measure, its 
reliability, validity, and sensitivity to change must be evaluated.
41, 42
  With respect to 
reliability, the results of any useful measurement technique must be reproducible, both in 
the hands of the same evaluator at two or more points in time (intra-rater reliability) and 
of different evaluators (inter-rater reliability).
43
  Previous studies have established the 
intra-
27, 44
 and inter-rater reliability
45
 of DE-STA MUNE in various muscle groups in 
control subjects, in addition to the intra-rater reliability of subsets of data collected using 
DQEMG
46
, and the intra- and inter-rater reliability
46, 47
 of the analysis of this data.  
However, the reliability of DE-STA MUNE as applied to the UT in control subjects 
remains to be assessed.  Additionally, the reliability of DE-STA MUNE has yet to be 
studied in any muscle group in subjects with ALS.    
In addition to reliability, a critical property of any outcome measure is its validity.  
That is, its ability to measure what it purports to measure in an accurate fashion.
43
  We 
currently lack a gold standard technique to quantify the number of MUs in a given 
muscle group in a living subject, and normative anatomical data for many muscle groups 
with which to compare the results of DE-STA MUNE.  A single previous study 
compared the results of DE-STA MUNE between subjects with ALS and control 
subjects, demonstrating the ability of the technique to detect the underlying 
pathophysiology of the disease in the biceps brachii (BB) and first dorsal interosseous.
48
  
However, such an evaluation of the validity of the technique in the UT has yet to be 
conducted.     
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Finally, an important property of any outcome measure is sensitivity to change, 
which is the ability of an instrument to detect minimal change over time, and thus 
monitor the potential efficacy of an intervention.
43
  A cross-sectional study by Boe et al. 
(2009)
49
 compared DE-STA MUNE in the first dorsal interosseous and BB alongside 
several clinical outcome measures in subjects with ALS to normative results for the same 
measures.  The study demonstrated the ability of DE-STA MUNE to detect underlying 
pathophysiological features of the disease despite better-preserved functional 
performance.  However, a longitudinal study comparing the sensitivity to change between 
DE-STA MUNE and clinical outcome measures in subjects with ALS has yet to be 
conducted.     
Sources of error associated with a measurement technique may negatively 
influence its reliability, validity, and sensitivity to change.
43
  Thus, investigation into 
potential sources of error associated with DE-STA MUNE may lead to improvements in 
these properties of the technique that are essential to its utility as an outcome measure.  It 
is well established that the position of the detecting electrode relative to the muscle fibers 
of a MU influences the characteristics of the corresponding EMG signal.
17
  Thus, the 
influence of the depth of the needle electrode on the results of DE-STA MUNE may be 
important to assess.  This component of the technique’s data collection protocol has not 
been evaluated systematically.     
It is the overall objective of this thesis to review the use of outcome measures 
systematically across ALS clinical trials, and to evaluate the utility of DE-STA MUNE as 
an outcome measure, with a particular focus on its application to the UT.      
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1.1 OVERVIEW OF THESIS CHAPTERS 
The objectives of this thesis were addressed through the conduct of a series of five 
studies.  First, a review of the frequency of use of outcome measures across ALS clinical 
trials, in addition to the advantages and disadvantages of select measures was conducted 
(Chapter 2).  In order to assess the utility of DE-STA MUNE as an outcome measure, the 
reliability (Chapters 3 and 4), validity (Chapter 4), and sensitivity to change (Chapter 5) 
of the technique was evaluated.  The findings from the study reported in Chapter 5 
indicated the need for further study regarding potential sources of error associated with 
the technique.  Thus, continuing the assessment of the utility of DE-STA MUNE as an 
outcome measure, the influence of the depth of the needle electrode on the results of the 
technique was evaluated (Chapter 6).   
1.1.1 Chapter 2 study objectives 
 To conduct a systematic review quantifying the frequency of use of outcome 
measures as primary and secondary endpoints in ALS randomized controlled 
trials published since 1990, classifying these outcome measures according to 
common categories from the ALS literature. 
 To briefly review the advantages and disadvantages associated with select 
outcome measures identified by the review. 
1.1.2 Chapter 3 study objective 
 To assess the intra- and inter-rater reliability of DE-STA MUNE and quantitative 
MUP analysis in the UT of control subjects. 
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1.1.3 Chapter 4 study objectives 
 To assess the intra-rater reliability of DE-STA MUNE and quantitative MUP 
analysis in the UT and BB of subjects with ALS. 
 To compare the results of DE-STA MUNE and quantitative MUP analysis in the 
UT of subjects with ALS to data obtained previously (study 2) in control subjects 
in the same muscle.    
1.1.4 Chapter 5 study objective 
 To compare the sensitivity to change of DE-STA MUNE and quantitative MUP 
analysis in the UT to that of various clinical outcome measures in subjects with 
ALS.  More specifically, to make comparisons with manual muscle testing in five 
upper extremity muscle groups, scapular elevation and elbow flexion peak force 
measured using hand-held dynamometry, forced vital capacity, sniff nasal 
inspiratory pressure, and the Revised Amyotrophic Lateral Sclerosis Functional 
Rating Scale.     
1.1.5 Chapter 6 study objective 
 To evaluate the influence of needle electrode depth on the results of DE-STA 
MUNE and quantitative MUP analysis in the UT of control subjects by comparing 
the results obtained across superficial, intermediate, and deep needle electrode 
depths.  
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CHAPTER 2 
USE OF OUTCOME MEASURES IN ALS RANDOMIZED CONTROLLED 
TRIALS:  A SYSTEMATIC REVIEW 
2.0 INTRODUCTION 
Clinical trials aimed at identifying interventions to modify the progression of 
amyotrophic lateral sclerosis (ALS) are underway constantly.  To date, only one drug 
(riluzole) has been shown to prolong survival modestly.
1
  The process of drug 
development typically begins with basic science investigations, followed by sequential 
phases of human clinical trials.  Early phase trials (phase I and II) focus on examination 
of pharmacokinetic characteristics, the clinical safety and toxicity profile, feasibility, and 
dosing of the pharmacologic agent, with some phase II trials opting to include a 
preliminary assessment of efficacy.
2
     
If the results of these early phase trials show promise for treatment efficacy, a 
potential intervention would then be studied in a phase III clinical trial.  A phase III 
clinical trial is conducted in a large sample of patients, and the primary aim of these trials 
is to assess the efficacy and safety of an intervention.  A randomized controlled trial 
(RCT) is the gold standard design for a phase III clinical trial.  These trials are typically 
randomized, double-blind, and placebo-controlled in order to promote high levels of 
internal validity.
3
   
As previously stated, the vast majority of interventions studied in RCTs for ALS 
thus far have not been shown to alter the course of the disease significantly.  This may be 
due to their genuine ineffectiveness or, alternatively, to the design or conduct of the 
RCTs themselves.  A critical component of trial design is the selection of outcome 
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measures, which are the variables used to monitor the efficacy of an intervention.  
Outcome measures are also termed ‘endpoints’ and are designated as either the primary 
or secondary outcomes in clinical trials.  While more than one may occasionally be 
selected, trials typically employ a single primary outcome measure, which is used in the 
power calculation to determine the required sample size and whether the end result of the 
trial is ‘positive’ or ‘negative’.  Secondary outcome measures are considered to be less 
clinically important than the primary outcome measure for a particular trial.
2
   
The power of a clinical trial may be impacted by the chosen primary outcome 
measure.  Calculation of the sample size required in order for a trial to reach a desired 
level of statistical power is dependent in large part on the sensitivity to change and 
variability of the chosen primary endpoint.  In addition, the degree of complexity and 
burden added to study visits by the primary and secondary measures may influence the 
amount of missing data and subject dropouts.  Missing data may also result if the measure 
becomes more difficult to assess with progression of the disease; an important issue in 
ALS trials.  The selected primary outcome measure also impacts the required duration of 
the trial, thus acting as a critical determinant in the cost and time required for a single 
study.  These are particularly important issues when studying a relatively rare disease for 
which resources (subjects and money) are often limited.  The amount of time spent on 
individual trials is also of key importance given the sense of urgency accompanying the 
fatal nature of the disease, and considering the large number of potential agents waiting 
to be tested.
4, 5
   
While survival is obviously a clinically meaningful outcome for a fatal disease, its 
use as a primary endpoint typically necessitates long trials with large sample sizes in 
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order for studies to reach statistical power.
4
  The additional consideration of other 
disadvantages associated with the use of survival (as will be discussed in detail) has led 
to the utilization of other outcome measures in ALS clinical trials.  These outcome 
measures fall under categories of muscle strength, pulmonary function, functional rating 
scales/timed functional tests, electrophysiological indices, biomarkers, imaging and 
quality of life (QoL).
2, 6
     
Assessment of muscle strength is a highly relevant outcome measure given that 
muscle wasting and weakness are core features of disease progression.  The strength of a 
muscle or group of muscles during a voluntary contraction can be assessed quantitatively 
with a strain-gauge, determining maximal voluntary isometric contraction (MVIC) or 
with hand-held dynamometry, as well as by manual muscle testing (MMT) using the 
Medical Research Council scale.
7
  
Given that respiratory failure as a result of progressive respiratory muscle 
weakness is generally the cause of death in ALS, clinical trials also commonly employ 
outcome measures of pulmonary function.  As the diaphragm is the major muscle 
responsible for inspiration, these measures largely aim to monitor changes in the strength 
of this muscle over time, and include such measures as vital capacity and forced vital 
capacity (FVC).
8
  
Functional outcome measures such as timed functional tests and functional rating 
scales (e.g. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-
R]) are measures of the impact of an intervention on activities of daily living and other 
functional tasks which may be specifically affected by the disease process.  These types 
of measures are highly relevant, given that preservation of function is likely of great 
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importance to the patient and their family.
9
  Functional rating scales can be generic or 
disease-specific, and utilize the patient’s self-report or a clinician’s report.10  
Unlike measures of muscle strength and function,
11
 electrophysiological indices 
assess the underlying pathophysiology and progression of the disease, providing 
quantitative information on the upper motor neuron (UMN) or lower motor neuron 
(LMN) component.  The quantitative techniques assessing the LMN rely on 
electromyography (EMG) (e.g. motor unit number estimation [MUNE], 
neurophysiological index, various needle EMG parameters) and those assessing the UMN 
component of the disease currently utilize transcranial magnetic stimulation.
12, 13
   
Biomarkers are objective laboratory measurements (e.g. cerebrospinal fluid levels 
of prostaglandin E2, blood markers of oxidative damage) that function as potential 
indicators of pathogenesis and biological response to pharmacologic intervention.  These 
markers may be highly sensitive to disease progression and early therapeutic effects as 
outcome measures in clinical trials.
14, 15
  Although in their relatively early stages of use as 
outcome measures, neuroimaging techniques such as magnetic resonance spectroscopy 
may be highly valuable given their unique capacity to detect and monitor the UMN 
component of the disease non-invasively and objectively.
16
 
Incorporation of measures of QoL as outcome measures for an ALS clinical trial 
allows for a more complete evaluation of the effect of an intervention, and may be 
especially important to the patient given the fatal nature of the disease.
2, 17
  QoL 
questionnaires can be generic, meaning that their items assess general health concepts not 
specific to any age, disease, or treatment group
18
 (e.g. 36-item Short-Form survey [SF-
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36]), or specific, having been developed for the ALS patient population (e.g. Sickness 
Impact Profile/ALS-19).
19
        
Selection of primary and secondary endpoints to be used in a clinical trial may be 
aided by the consensus guidelines on ALS trial design and execution published by the 
World Federation of Neurology
20
 or by guidelines published by Leigh et al. (2004)
9
.  
Although outdated, the World Federation of Neurology guidelines suggest the use of 
change in muscle strength or survival as the primary outcome measure, and make a broad 
recommendation for the inclusion of measures of muscle strength (recommending 
quantitative myometry [i.e. MVIC]), pulmonary function (recommending FVC), bulbar 
function and time to death in every trial.  The guidelines by Leigh et al. (2004)
9
 
recommend the use of either survival or, preferentially, the ALSFRS-R as the primary 
outcome measure, with both sets of guidelines recommending the inclusion of a disease-
specific QoL measure alongside the SF-36 generic measure as secondary endpoints.   
  Heterogeneity in the use of outcome measures as a result of: a) the absence of an 
unequivocal primary outcome measure selection; b) the presence of a multitude of 
options available for secondary outcome measures; and c) limited guidelines for the use 
of these measures, is widely apparent.  However, a systematic review quantifying the 
frequency of use of available outcome measures across ALS RCTs has yet to be 
completed.     
Various reviews have documented the use of primary and, less commonly, 
secondary outcome measures across only select ALS clinical trials.
3, 9, 21, 22
  A systematic 
review of ALS RCTs was conducted by Beghi et al. (2011)
23
, reporting on various 
aspects of trial design and conduct, but without reporting on the use of outcome 
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measures.  Lastly, a systematic review of ALS RCTs by de Carvalho et al. (2005)
12
 with 
highly selective inclusion criteria chose to focus on the sensitivity to change of various 
primary outcome measures, but not on their frequency of use.   
A systematic, quantitative synthesis of the literature would allow for identification 
of all of the outcome measures that have been used in ALS clinical trials to date and 
serve to pinpoint the most commonly used as well as underutilized outcome measures.  
This would act as a resource to facilitate discussion regarding the selection of outcome 
measures for future ALS clinical trials; a critical component of trial design impacting 
largely on their potential for success.   
Thus, the objectives of this systematic review were to quantify the frequency of 
use of outcome measures as primary and secondary endpoints in ALS RCTs published 
since 1990, classifying these outcome measures according to the previously mentioned 
categories common in the ALS literature.  A secondary objective was to briefly review 
the advantages and disadvantages of select outcome measures identified by the review.   
2.1 METHODS 
Relevant studies were identified through a literature search encompassing the time 
period from January 1990 to July 2011.  The following databases were searched:  
MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials.  Search terms 
varied slightly across databases and are listed in Box 2.1.    
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Box 2.1 Search terms 
 
amyotrophic lateral sclerosis OR ALS OR MND OR motor neuron disease OR 
(MEDLINE only) motor neurone disease OR (MEDLINE only) motoneuron disease 
OR motoneurone disease OR Lou Gehrig's disease OR Charcot's disease 
 
AND 
 
placebo OR placebos 
 
AND 
 
double blind OR double blinded OR double-blind* 
 
AND 
 
randomized controlled trial OR randomized controlled trials OR randomize* OR 
randomization OR controlled clinical trial OR controlled clinical trials OR 
(MEDLINE only) clinical trial, phase III  
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2.1.1 Inclusion criteria 
Studies were included if they: i) purported to assess an intervention for 
efficacy/effectiveness solely in patients with ALS, regardless of phase (i.e. phase II trials 
including assessments of efficacy were included); ii) compared subjects receiving the 
intervention to a control group receiving placebo (in any form, frequency, dosage or in 
combination with other products); and were iii) randomized or quasi-randomized (i.e. 
alternate allocation); iv) double-blind; and v) prospective clinical trials.  There were no 
restrictions made with respect to study design (e.g. parallel group, cross-over), and 
studies with multiple intervention and/or control groups were included.   
2.1.2 Exclusion criteria 
Review articles, editorials and other non-clinical trials were excluded, as were 
abstracts that were published subsequently as full studies.  Abstracts which lacked 
sufficient reporting detail and abstracts/full-text articles that were unobtainable were also 
excluded.  Additionally, studies pertaining to symptomatic therapies for ALS (e.g. for 
pseudobulbar affect, sialorrhoea, muscle cramps), ongoing studies, and non-English 
studies were excluded.   
Review of all search results and data extraction was performed by one author 
(CI).  First, titles and abstracts identified by the literature search were screened for 
eligibility.  For all retained abstracts (including all those for which eligibility remained in 
question) an attempt was made to obtain the full-text articles and either the full-text 
article or abstract (when the full-text was unavailable) was reviewed in detail to 
determine eligibility.  Upon determination of the eligible studies to be included in the 
review, specific data were extracted from the methods section: the intervention, first 
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author, year of publication, sample size (n), trial duration, and primary and secondary 
outcome measures. The methodological quality of the studies was not assessed, as it was 
not relevant to the assessment of outcome measure selection.  If the study did not clearly 
identify which outcome measures were primary and which were secondary, or listed 
more than one endpoint as the primary outcome measure, the variable for which the study 
was powered statistically (where identified) was considered to be the primary outcome 
measure.   
Each identified outcome measure was classified into one of the following 
common categories of outcome measures used in ALS clinical trials:  survival, muscle 
strength, pulmonary function, functional rating scales/timed functional tests, 
electrophysiological indices, biomarkers, imaging, or QoL.
2, 6
 
2.2 RESULTS 
2.2.1 Literature search results 
The results of the literature search and the reasons for exclusion are presented in 
Figure 2.1.  From a total of 1127 titles and abstracts identified by the search strategy, 85 
potentially relevant papers were identified from the initial screening and subsequently 
reviewed in detail.  Fifty-seven of these papers were ultimately determined to be eligible 
for inclusion in the review.  One of these papers reported the results of 2 RCTs
24
 and 
thus, 58 clinical trials were identified in total.  A summary of all of the included clinical 
trials is presented in Appendix A.  The trials were published from 1992 to 2011.  The 
average sample size of these trials was 207 ± 278 participants (median: 99), ranging from 
10
25
 to 1210 participants,
24
 with trial durations ranging from 72 hr
26
 to 24 months.
27, 28
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With the exception of 5 studies,
28-32
 all trials were assessments of pharmaceutical 
compounds.   
2.2.2 Primary outcome measures  
The primary outcome measure was clearly stated in 45 (78%) of the clinical trials, 
and these trials were incorporated into the descriptive analysis in Box 2.2.  From these 
clinical trials, 13 different primary outcome measures were identified.  Twenty trials 
(44%) utilized a primary outcome measure falling under the functional rating 
scales/timed functional tests classification, 13 trials (29%) used survival, and 10 trials 
(22%) used an outcome measure that assessed muscle strength.  None of the trials in the 
review utilized a primary outcome measure that evaluated pulmonary function, an 
electrophysiological index, a biomarker, or QoL.  Examining the most frequently used 
individual outcome measures within these categories, survival was the most often used 
primary outcome measure overall (13 trials; 29%), followed by MVIC – upper extremity 
(UE) and the ALSFRS-R in 6 trials (13%) each.  A megascore that incorporated more 
than one outcome measure was used as the primary endpoint in 2 trials.
33, 34
     
2.2.3 Secondary outcome measures  
Forty-eight trials (83%) made it clear which endpoints (if any) were used as 
secondary outcome measures, and these trials were incorporated into the descriptive 
analysis in Box 2.3.  On average, these trials utilized 4 ± 3 (median: 4) secondary 
outcome measures, ranging from 0
34-37
 to 10 outcome measures.
38
 
Sixty different secondary outcome measures were identified across these 48 trials.  
Measures classified as functional rating scales/timed functional tests were used most 
frequently (73 times), followed by measures of muscle strength (35 times), pulmonary 
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function (34 times), and QoL (16 times).  Imaging was not used as a secondary outcome 
in any of the trials.  Examining the most frequently used individual outcome measures 
within these categories, FVC was the most often used secondary outcome measure 
overall, employed in 21 trials (44%), followed by MMT in 19 trials (40%), MVIC and 
survival in 13 trials (27%), respectively, patient visual analogue scales and the ALSFRS-
R in 9 trials (19%), respectively, Amyotrophic Lateral Sclerosis Functional Rating Scale 
(ALSFRS) in 8 trials (17%), and the Sickness Impact Profile in 6 trials (13%).  The 
modified Norris score, Norris score, Global Clinical Impression of Change scale, and 
vital capacity were used in 5 trials (10%) each, while the SF-36 and MUNE were used in 
4 trials (8%) each.   
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Figure 2.1 Flow of studies through the systematic review   
Abbreviation:  ALS, amyotrophic lateral sclerosis. 
 
Titles and abstracts screened  
(n = 1127) 
Potentially relevant papers for which 
full-text retrieved or abstract evaluated 
in detail (n = 85) 
Papers included in review (n = 57) 
 
Number of clinical trials reported in 
these papers (n = 58) 
 
Papers excluded after screening titles/abstracts      
(n = 1042)   
 Duplicates (n = 285) 
 Non-ALS study (n = 551) 
 Non-clinical trial (n = 94) 
 Ancillary study to clinical trial (n = 29) 
 Symptomatic therapy (n = 14) 
 Included participants without ALS (n = 5) 
 Not a randomized, double-blind, placebo-
controlled trial (n = 41) 
 Abstract subsequently published as full 
study (n = 14) 
 Non-English (n = 6) 
 Unobtainable paper (n = 2) 
 Ongoing study (n = 1) 
Papers excluded after detailed evaluation  
(n = 28) 
 
 Non-clinical trial (n = 2) 
 Included participants without ALS (n = 1) 
 Not a randomized, double-blind, placebo-
controlled trial (n = 21) 
 Abstract subsequently published as full study 
(n = 2) 
 Unable to obtain full-text for abstract lacking 
sufficient detail (n = 1) 
 Ongoing study (n = 1) 
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Box 2.2 Frequency of use of primary outcome measures reported in ALS RCTs
*
 
 
Survival (13) 
Muscle strength (10) 
- MVIC39, 40 
o MVIC – UE (6)  
o MVIC – UE and lower extremity (1) 
- MMT41 (2) 
- Tufts Quantitative Neuromuscular Exam 
o Tufts Quantitative Neuromuscular Exam – arm strength megascore40, 42 (1) 
Functional rating scales/timed functional tests (20) 
- ALSFRS-R  (6) 
- Appel ALS Rating Scale43 (4) 
- ALSFRS44 (2) 
- Modified Norris score45  
o Modified Norris score (2) 
o Modified Norris score – limb scale45 (1) 
- Number of patients becoming non-self-supporting, based on subset of Norris score (1) 
- Decrease ≥ 6 points on ALSFRS-R or death (1) 
- Summated megascore:  Body weight, Norris score, Jamar grip strength, % FVC, % 
maximum voluntary ventilation (1) 
- Tufts Quantitative Neuromuscular Exam40 (1) 
- Modification of Tufts Quantitative Neuromuscular Exam46 (1) 
Imaging (1) 
- N-acetylaspartate/(creatine + choline) ratio in motor cortex assessed by magnetic 
resonance spectroscopy (1) 
Other (1) 
- MVIC and FVC combination megascore (1) 
 
*
Based on 45 trials for which primary outcome measure clearly stated. 
Outcome measures that are bolded and italicized were used most frequently within category. 
Abbreviations:  ALS, amyotrophic lateral sclerosis; ALSFRS, Amyotrophic Lateral Sclerosis 
Functional Rating Scale; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional 
Rating Scale; FVC, forced vital capacity; MMT, manual muscle testing; MVIC, maximal 
voluntary isometric contraction; RCT, randomized controlled trial; UE, upper extremity. 
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Box 2.3 Frequency of use of secondary outcome measures reported in ALS RCTs
*
 
 
Survival (13) 
Muscle strength (35) 
- MMT 41 (19) 
- MVIC (13) 
- Muscle fatigue (1) 
- Semiquantitative estimation of bulbar function (1) 
- Tufts Quantitative Neuromuscular Exam  
o Tufts Quantitative Neuromuscular Exam – leg strength megascore40, 42 (1) 
Pulmonary function (34) 
- FVC (21) 
- Vital capacity (5) 
- Slow vital capacity (3) 
- Vital capacity ratio (1) 
- Forced expiratory volume (1) 
- Incidence of select respiratory  events (1) 
- Peak inspiratory flow (1) 
- Ventilatory function (1) 
Electrophysiological indices (13) 
- MUNE (4) 
- Neurophysiological index (3) 
- Compound muscle action potential (CMAP) 
o CMAP amplitude (2) 
o CMAP latency, amplitude and duration (1) 
- Spontaneous activity (1) 
- Fiber density (1) 
- Cortical threshold and motor evoked potential/CMAP ratios to magnetic stimulation (1) 
Biomarkers (3) 
- Cerebrospinal fluid prostaglandin E2 levels (1) 
- Cerebrospinal fluid levels of amino acids (1) 
- Various serum levels/blood markers of oxidative damage (1) 
 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, Amyotrophic Lateral Sclerosis 
Functional Rating Scale; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional 
Rating Scale; CMAP, compound muscle action potential; FVC, forced vital capacity; MMT, 
manual muscle testing; MUNE, motor unit number estimation; MVIC, maximal voluntary 
isometric contraction; QoL, quality of life; RCT, randomized controlled trial; SF-12, 12-item 
Short-Form survey; SF-36, 36-item Short-Form survey. 
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Box 2.3 continued. Frequency of use of secondary outcome measures reported in ALS RCTs
*
 
 
Functional rating scales/timed functional tests (73) 
- Patient visual analogue scales45 (9) 
- ALSFRS-R47 (9) 
- ALSFRS44 (8) 
- Modified Norris score (5) 
- Norris score48  
o Norris score (5) 
o Norris score – bulbar scale48 (1) 
- Global Clinical Impression of Change scale44 (5) 
- Spasticity scale (3) 
- Time to walk 15 ft (3) 
- Syllable repetition (PATA)/oral-labial-lingual dexterity (2) 
- Frenchay Dysarthria Assessment (modification)49 (1) 
- Ashworth scale50 (1) 
- Modified clinical global impression scale (1) 
- Spinal and bulbar score51 (1) 
- Medical visual analogue scale (1) 
- 16-item Quick Inventory of Depressive Symptomatology – Self-Report52 (1) 
- Addenbrooke’s Cognitive Examination53 (1) 
- Rankin scale54 (1) 
- Barthel Index55 (1) 
- Appel ALS Rating Scale43 (1) 
- Modified Appel ALS Rating Scale 
o Modified Appel ALS Rating Scale – bulbar section (1) 
- Sickness Impact Profile 
o Sickness Impact Profile – Physical Dimension Score56 (1) 
- Modified Schwab and England Scale57 (1) 
- ALS Severity Scale58 (1) 
- ALS Health State Scale59 (1) 
- Activities of daily living scores60 (1) 
- Clinical deficit scores (1) 
- Time to dial phone no. (1) 
- No. rotations of pencil in 30 s (1) 
- 6-minute walk test61 (1) 
- Timed rapid alternating movement task (1) 
- Rapid foot taps (1) 
- Purdue pegboard test (1) 
QoL (16) 
- Sickness Impact Profile56 (6) 
- SF-3618 (4) 
- 12-item Short-Form survey (SF-12)62 (2) 
- McGill single item QoL score63 (2)   
- Sickness Impact Profile/ALS-1919 (1)   
- ALS-Specific Quality of Life Instrument64 (1) 
 
*
Based on 48 trials for which secondary outcome measures clearly stated.    
Outcome measures that are bolded and italicized were used most frequently within category. 
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2.3 DISCUSSION 
Widely apparent from this review was the vast array of outcome measures that 
have been employed in ALS RCTs.  It was the aim of this study to quantify the frequency 
of use of these outcome measures as either primary or secondary endpoints.  However, a 
number of trials did not clearly define their outcome measures as primary or secondary 
endpoints and, therefore, were not able to be included in the analysis.  This deficiency 
points to the potential need for clearer reporting of outcome measure classification 
(primary vs. secondary) in ALS RCTs.                   
2.3.1 Primary outcome measures   
Of the 45 clinical trials that clearly specified a single primary outcome measure, 
43 utilized either a functional rating scale/timed functional test, survival, or a measure of 
muscle strength.  Within these classifications, the selection of primary outcome measures 
was relatively homogeneous, with the majority of trials choosing to employ either 
survival, MVIC – UE, or the ALSFRS-R.  These findings demonstrate alignment with 
ALS clinical trial design guidelines which recommend the use of survival,
9, 20
 the 
ALSFRS-R,
9
 or muscle strength
20
 as primary outcome measures.    
2.3.1.1 Survival 
As mentioned, survival was found to be the most frequently used primary 
endpoint.  Survival is certainly a clinically relevant endpoint given the fatal nature of the 
disease.  Use of survival also acts as a definitive measure that reduces missing data.
65
  
However, as previously mentioned, its use typically requires trials of long duration with 
large sample sizes.
4
  Further complicating the use of survival as a primary endpoint is the 
fact that clinical practice associated with potentially confounding factors may vary across 
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sites in a multicenter trial.
3, 9
  Survival is known to be affected by non-invasive 
ventilation,
66
 and may be extended by other confounding variables such as care in a 
multidisciplinary clinic
67
 and enteral tube feeding.
68
   Furthermore, whether prolonged 
survival is clinically meaningful is questionable if, for example, it is realized in the 
presence of QoL deterioration, or if prolongation is observed only during the advanced 
stages of the disease.
9
  In the face of the disadvantages associated with the use of 
survival, other endpoints are being utilized increasingly.
6
       
2.3.1.2 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale     
The ALSFRS-R is a disease-specific functional rating scale that assesses activities 
of daily living, consisting of 12 items rated from 0 to 4 for a total possible score ranging 
from 0 (unable to attempt any task) to 48 (normal function).  Four domains are assessed: 
bulbar, fine motor, gross motor, and respiratory function, with each domain containing 3 
items.  The ALSFRS-R improves upon the disproportionate weighting given to 
assessments of limb and bulbar function in the original ALSFRS with the inclusion of 
additional items assessing respiratory function.
47
  The validity, strong internal 
consistency, and excellent inter- and intra-rater reliability of this scale have been 
established.
47, 69
  It has also been shown to predict survival, and to be more sensitive to 
change than the original ALSFRS.
47
  In addition to being inexpensive and not requiring 
any specialized equipment, the ALSFRS-R is simple and efficient to administer 
independent of disease status,
2
 potentially reducing the amount of missing data/subject 
dropout compared to other outcome measures.  The scale can be administered through the 
caregiver if the subject is unable to communicate, and/or over the telephone if the subject 
is unable to attend a study visit.
69, 70
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2.3.1.3 Maximal voluntary isometric contraction  
Another measure commonly employed as a primary outcome was MVIC of the 
UE.  This quantitative assessment of muscle strength involves the use of an examination 
table with vertical metal bars and adjustable rings.  A strap positioned on the limb being 
tested is connected to an electronic strain-gauge tensiometer, which is attached to a ring 
on the fixed bars.  The force measured by the strain gauge during a test is recorded on a 
computer system.
39, 40
  For an assessment of MVIC in the UE, bilateral shoulder and 
elbow flexion and extension are tested and, as was the case for some of the trials in this 
review, bilateral grip strength with a Jamar dynamometer may be assessed as well.
39
  The 
validity of this method has been established, in addition to its reliability with rigorous 
training and monitoring of the clinical evaluators.
40, 71
  However, in addition to requiring 
specialized, technically complex, expensive equipment, MVIC is time-consuming and 
fatiguing for the patient, limiting the number of muscle groups that can be tested.  
Inclusion of MVIC as a clinical trial outcome measure has been associated with missing 
data and subject dropout related to the patient’s inability to perform the protocol as a 
result of disease progression.
2-4, 9
   
2.3.2 Secondary outcome measures 
The review demonstrated the striking heterogeneity across ALS RCTs in the 
selection of secondary outcome measures.  This lack of consensus was also apparent in 
the choice of how many secondary outcome measures to employ.  Heterogeneity in the 
selection of endpoints certainly adds difficulty to the potential for comparisons of results 
between trials.
72
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Measures from each of the previously outlined categories were represented, with 
the exception of imaging.  The most frequently used categories were functional rating 
scales/timed functional tests, followed by muscle strength and pulmonary function.  
While trials consistently selected from a small number of outcome measures in the latter 
two categories, there were a remarkable assortment of outcome measures utilized from 
the functional rating scales/timed functional tests category, with trials frequently utilizing 
more than one of these measures.  Perhaps, given that they are in the early stages of 
development, it is not surprising that imaging endpoints were not used.       
2.3.2.1 Forced vital capacity 
Overall, the most commonly used secondary outcome measure was FVC, which 
was incorporated into 44% of trials.  Defined as the volume of air exhaled from total lung 
capacity,
8
 FVC is a non-invasive measure assessed using a portable, relatively 
inexpensive standard spirometer.  FVC has been shown to be a reliable measure with 
specialized evaluator training,
73
 in addition to being a good predictor of disease 
progression and survival.
74, 75
  However, the presence of bulbar or facial weakness may 
prevent a subject from performing the proper maneuver or forming a tight lip seal around 
the mouthpiece.  This may lead to increased variability of the measurement, an 
underestimation of the subject’s true values, and the required use of a facemask or 
alternate mouthpiece.
4, 8
    
2.3.2.2 Manual muscle testing 
Following FVC, the next most commonly used secondary outcome measure was 
MMT.  This assessment of muscle strength uses the standardized Medical Research 
Council grading scale, which subjectively grades strength according to the patient’s 
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ability to move against gravity and contract against the examiner’s manual resistance.41  
MMT is a quick, inexpensive technique that doesn’t require any specialized equipment.  
However, inherent to the ordinal nature of this scale, the difference between grades is not 
linear.  To illustrate, for the original 5-point version of the Medical Research Council 
grading scale (0 representing no muscle movement, 5 representing normal strength), 
grades 4 and 5 cover much larger ranges of muscle strength as measured by percentage 
predicted MVIC than grades 0-3, diminishing the scale’s sensitivity to early change in 
strength.
76, 77
  
2.3.2.3 Maximal voluntary isometric contraction and survival 
In addition to their frequent use as primary outcome measures, MVIC and 
survival were commonly employed as secondary endpoints.  While neither set of ALS 
clinical trial guidelines makes many specific suggestions for the selection of secondary 
endpoints, the use of these measures is not surprising, given that the World Federation of 
Neurology guidelines suggest quantitative myometry and time to death are included in 
every trial.
20
   
2.3.2.4 Functional rating scales/timed functional tests 
Functional rating scales/timed functional tests was the category from which 
secondary outcome measures were most commonly pulled.  Within this category, the 
most frequently used outcome measures were patient visual analogue scales, the 
ALSFRS-R (previously described) and the original ALSFRS.  Patient visual analogue 
scales are subjective self-evaluations of various symptoms on a 100 mm horizontal line 
flanked by descriptors at each end.
45
  The subject places a mark on the line that represents 
their perception of their symptoms and the distance to that mark is measured to derive a 
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score.  The majority of studies employing these scales in this review assessed each of the 
following symptoms: fasciculations, cramps, fatigue/tiredness/sleeping, and stiffness.  
These scales are quick to complete, generally simple for participants to understand, and 
capable of capturing aspects of the disease that are difficult to measure otherwise.  
However, a disadvantage of being self-administered is that these scales may become 
difficult to complete for patients who experience UE weakness or cognitive dysfunction.   
2.3.2.5 Quality of life  
One specific guideline that was made pertaining to the use of secondary outcome 
measures in ALS clinical trials is the inclusion of a disease-specific QoL measure along 
with the SF-36.
9, 20
  While four trials in this review employed the SF-36, none of these 
four trials included a disease-specific measure of QoL.  Used more commonly than any 
other measure of QoL was the Sickness Impact Profile, which is a generic QoL 
questionnaire with 136 items in 12 subscales.  While the validity, reliability and internal 
consistency of this scale have been demonstrated,
56
 its length may make it burdensome 
for the participant to fill out.
9
   
2.3.2.6 Motor unit number estimation 
As mentioned, measures from each of the outlined categories were represented, 
with the exception of assessments using imaging.  Used relatively infrequently, however, 
were biomarkers and electrophysiological indices.   
With the exception of one measure involving transcranial magnetic stimulation, 
each of the electrophysiological indices identified were assessments of LMN 
involvement.  Unlike any other available electrophysiological measures of the LMN 
component of the disease, MUNE is capable of directly quantifying the number of 
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functioning motor units (MUs) within a muscle or group of muscles.
78
  This 
quantification is invaluable, given that MU loss is a fundamental component of the 
disease process, at which interventions are often aimed at slowing or stopping.
79
   
Measures of muscle strength, pulmonary function, and activities of daily living 
are affected by the compensatory process of collateral reinnervation, which may allow 
these measures to remain relatively stable until the loss of MUs surpasses a critical 
threshold.
11
  In contrast, collateral reinnervation is taken into account by MUNE, 
allowing for the monitoring of the underlying progression of the disease and any response 
to treatment.
80
   
2.3.2.7 Use of motor unit number estimation in ALS clinical trials 
What follows is a brief description of each trial identified by this review that 
employed MUNE as an outcome measure.  For each of these trials, MUNE was 
incorporated as a secondary endpoint and there were no significant beneficial effects of 
treatment found for any outcome measure.      
Not included in the analysis in Box 2.3, as the trial failed to differentiate between 
which measures were used as primary vs. secondary endpoints, a single-center, cross-
over trial of dextromethorphan was the earliest RCT identified that included MUNE as an 
outcome measure.
81
  The trial applied a PC-based modification of manual incremental 
stimulation to the abductor digiti minimi muscle and found a decline of 22% in the 
treatment group, but an increase of 21% in the placebo group when MUNE was measured 
at baseline and 3 month time points.  Nevertheless, this difference was not statistically 
significant, with the authors acknowledging a high degree of intra-individual variability 
associated with their use of the technique.    
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A 2-center, 3-arm trial of amino acid therapy was the next to incorporate MUNE, 
in this case applying spike-triggered averaging to the biceps brachialis muscle at baseline 
and 6 month time points.
38, 82
  Combining data across trial arms, MUNE was found to 
decline over the duration of the trial.  However, this decline was not significant, with the 
authors citing trial duration and the examination of a potentially slowly-progressing 
proximal muscle as possible contributing factors.
82
   
A modification of statistical MUNE was included as an outcome measure in a 14-
center trial of creatine monohydrate, which involved monthly assessments (7 evaluations 
in total) of 1 of 4 intrinsic hand muscles.
83, 84
  Combining data from both groups, MUNE 
was shown to decline over 6 months by 23%, which was more than MVIC (20%) and the 
ALSFRS-R (12%).  While MUNE demonstrated good reproducibility, technical problems 
as a result of MU instability were encountered.  Surface-detected motor unit potential 
instability resulted in the overrepresentation of small units in response to the repeated 
stimuli required for this technique over the course of the trial.  These issues were 
corrected for partially with post-study data censuring, and the authors proposed 
modifications for the technique prior to use in future trials.     
A trial of celecoxib implemented this newly modified version of statistical MUNE 
at 16 of 27 sites, evaluating the same intrinsic hand muscles as the previous study at 7 
time points over 12 months.
85, 86
  Combining data across all subjects demonstrated a 
decline in MUNE of 49% over 12 months.  However, the same technical issues persisted, 
necessitating the conclusion that statistical MUNE is unsuitable for use as a measurement 
technique in any disease associated with MU instability. 
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Finally, a recent single-center trial of memantine employed manual incremental 
stimulation at baseline, 6, and 12 month time points, choosing to take the average value 
calculated across both abductor digiti minimi for each subject.
87
  MUNE was found to be 
the most sensitive out of all of the outcome measures, declining by 5.17%/month in the 
treatment group and 5.85%/month in the placebo group.     
As the review demonstrates, the use of MUNE in clinical trials to date has been 
infrequent.  This may stem in part from the lack of consensus surrounding which is the 
most optimal technique.
88
  Focused efforts to improve one or two techniques may 
accelerate more widespread incorporation of MUNE into clinical trials.
89
  
Decomposition-enhanced spike-triggered averaging MUNE offers a number of 
advantages over other available MUNE techniques, making it potentially valuable in this 
regard.
90
 
2.3.3 Limitations and future study 
Potential limitations of this systematic review include that we did not search for 
unpublished studies, nor hand search the reference lists of included studies, which may 
have recovered more RCTs for inclusion in the analysis.  Additionally, the 
methodological quality of the included studies was not assessed; the results may have 
differed had only RCTs of high internal validity been included.  Improvement to the 
number of trials included in the data analysis may have been possible had the authors 
been contacted for the manuscripts in which a clear discernment between primary and 
secondary outcome measures was not made.  Lastly, decisions surrounding study 
eligibility and data extraction were made by a single author.  However, from the 
perspective of this author, such decisions were highly straightforward.       
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Future reviews in this area focusing on the appropriateness of the measures 
reported herein for use in an ALS population (i.e. disease-specific validity, reliability) 
would be highly useful.  This suggestion stems from the observation that many studies 
failed to make reference to a source of rationale behind their use of an outcome measure 
in an ALS population.  This was particularly the case for many functional rating 
scales/timed functional tests.  In addition, a future quantitative review should focus on the 
various outcome assessment methodologies used to collect and analyze data for any given 
outcome measure (e.g. training of assessors, timing of assessment, use of megascores).  
Such a review may promote discussion aimed at reducing heterogeneity in these areas, 
facilitating the comparison of results across future studies.   
2.3.4 Summary 
In summary, this review demonstrates the wide array of outcome measures that 
have been used in ALS RCTs, each with various advantages and limitations.  In 
particular, striking heterogeneity between trials was observed in the selection of 
secondary outcome measures.  Offering unique information concerning the underlying 
disease process, there is room for the increased integration of MUNE into future clinical 
trials.  As the first review to quantify the frequency of use of outcome measures across 
ALS RCTs systematically, this synthesis highlights the need for a clear consensus 
regarding the most optimal primary and secondary outcome measures to include in the 
design of future clinical trials.   
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CHAPTER 3 
RELIABILITY OF DECOMPOSITION-ENHANCED SPIKE-TRIGGERED 
AVERAGING MOTOR UNIT NUMBER ESTIMATION IN THE UPPER 
TRAPEZIUS IN CONTROL SUBJECTS
1
 
3.0 INTRODUCTION  
Degeneration of lower motor neurons and, subsequently, a decrease in the number 
of functioning motor units (MUs) of a given muscle, occurs in aging, and a variety of 
neuromuscular diseases such as amyotrophic lateral sclerosis (ALS).
1
  Highly relevant for 
application to the study of these processes, motor unit number estimation (MUNE) is able 
to estimate the number of functioning MUs within a muscle or group of muscles.
2
   
ALS clinical trials aimed at finding treatments to alter the natural history of the 
disease frequently employ outcome measures that assess function and muscle strength 
(Chapter 2).  However, as a result of collateral reinnervation, these measures may remain 
relatively stable until MU loss has surpassed a critical threshold.  In contrast, MUNE 
takes into account the effects of collateral reinnervation.
3
  The subsequent ability of 
MUNE to quantify underlying disease progression makes it a potentially valuable 
outcome measure for use in ALS clinical trials.
4, 5
 
 First described as a MUNE method by Boe et al. (2004),
6
 a key advantage of 
decomposition-enhanced spike-triggered averaging (DE-STA) over many other MUNE 
techniques is its ability to study proximal muscle groups.  It also improves upon other 
techniques in its collection of not only surface, but also intramuscular electromyographic 
                                                 
1
 A version of this chapter has been published. 
Ives CT, Doherty TJ. Intra- and inter-rater reliability of motor unit number estimation and 
quantitative motor unit analysis in the upper trapezius. Clin Neurophysiol 2012; 123:200-205. 
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(EMG) data, allowing for quantitative motor unit potential (MUP) analysis.
7
  
Incorporation of a series of computer-based algorithms for intramuscular EMG signal 
decomposition (termed decomposition-based quantitative electromyography [DQEMG])
8
 
gives DE-STA MUNE a number of specific advantages over conventional spike-triggered 
averaging MUNE, which have been previously described (Chapter 1).
7, 9
  
In evaluating the potential utility of DE-STA MUNE as an outcome measure in 
ALS clinical trials, the role of the upper trapezius (UT) as an accessory muscle of 
respiration
10
 may make it a particularly relevant muscle to study.  Beginning an 
evaluation of the technique, its results must be shown to be reproducible, both in the 
hands of the same evaluator at two or more points in time (intra-rater reliability) and of 
different evaluators (inter-rater reliability).
11
   
The intra-rater reliability of DE-STA MUNE has been established in the thenar,
6
 
first dorsal interosseous and biceps brachii (BB)
12
 muscles, and the inter-rater reliability 
in the tibialis anterior of control subjects.
13
  However, reliability of the technique as 
applied to the UT remains to be examined.  Thus, the purpose of this study was to assess 
the intra- and inter-rater reliability of DE-STA MUNE and quantitative MUP analysis in 
the UT of control subjects.  
3.1 METHODS 
3.1.1 Subjects 
Individuals between the ages of 40-65 (in order to allow for future comparison to 
data from subjects with ALS) with no known neuromuscular or musculoskeletal disease 
were eligible to participate in this study (n = 10).  All subjects gave written, informed 
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consent in accordance with The University of Western Ontario Health Sciences Research 
Ethics Board, which approved this study.     
3.1.2 Electromyographic data collection protocol 
EMG signals were acquired using DQEMG (version 3.2) and Acquire EMG 
software on a Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX).  Self-
adhering Silver Mactrode
® 
electrodes (GE Medical Systems, Milwaukee, WI) were used 
to detect surface signals, and 25 mm x 30 gauge TECA
™
 elite Disposable Concentric 
Needle Electrodes (CareFusion, Middleton, WI) were used to detect intramuscular 
signals, with bandpass settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.
6, 9
   
The right UT was tested for each subject and subjects were seated upright in a 
straight back chair with their feet on the floor.  Surface electrodes were cut in strips (1 cm 
x 3.5 cm) for use as the active and reference electrodes, with a full-sized electrode 
serving as a ground.  The skin was cleansed with isopropyl alcohol and surface electrodes 
positioned appropriately.  The active electrode was positioned transversely over the belly 
of the muscle, approximately midway between the acromion process and C7 spinous 
process, with the reference electrode placed over the acromion process, and the ground 
electrode over the deltoid.
14
    
A handheld bipolar stimulator was used in order to elicit a maximum compound 
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to 
the sternocleidomastoid.
14
  If necessary, the active electrode was moved in small 
increments to a position where the CMAP negative peak amplitude was maximized and 
the rise time minimized.  Following optimal positioning of the active electrode, the 
surface electrode positions were reinforced with surgical tape to ensure that no movement 
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occurred during the study.  Gradually, the stimulation intensity was increased until the 
CMAP negative peak amplitude reached a plateau.  Automatically positioned markers 
indicating onset, negative peak, positive peak, and end of the maximum CMAP were 
reviewed and manually adjusted if necessary.  Subsequently, size-related parameters of 
the maximum CMAP including negative peak amplitude were calculated automatically.      
Subjects then performed a 3-4 s voluntary contraction by way of scapular 
elevation against resistance provided by the evaluator.  Subjects were encouraged to 
produce their maximal effort, and visual and auditory feedback was provided by the 
surface EMG signal.  The maximal root mean square value of the EMG signal over a 1 s 
interval was calculated automatically and the intensity of subsequent sub-maximal 
contractions was described as a percentage of this maximal voluntary contraction-root 
mean square (% MVC-RMS).      
Next, the concentric needle electrode was inserted into the UT, approximately 2-
10 mm proximal or distal to the active surface electrode.  Subjects were asked to perform 
minimal isometric contractions while an optimal needle position was located that 
minimized the rise times of the MUPs of the first two to three recruited MUs.  With the 
needle manually maintained in this position by the evaluator, the subject was instructed to 
increase the contraction force to approximately 10-20% of the MVC-RMS.  Each sub-
maximal isometric contraction was maintained for 30 s, during which the subject 
received visual and auditory feedback from the EMG signal and % MVC-RMS 
information displayed on the screen to assist in the maintenance of a stable contraction.  
Contractions were performed until a minimum of 20 MUP trains were collected, with 
each contraction separated by a rest period of approximately 30-60 s, or as required by 
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the subject.  The needle position was adjusted between contractions to collect data from 
different portions of the muscle, and, if necessary, inserted at a new site to complete the 
collection of MUP trains.
6, 9
    
3.1.3 Electromyographic signal decomposition and analysis 
DQEMG and its associated algorithms have been described in detail previously 
(Chapter 1).
8, 9
  Briefly, DQEMG decomposes the composite intramuscular EMG signal 
into its constituent MUP trains.  The individual MUP firings from each MUP train then 
serve as triggers to isolate the time-locked surface-detected motor unit potentials (S-
MUPs) from the surface-recorded EMG signal.  The S-MUPs associated with each MUP 
firing are then ensemble-averaged to derive the S-MUP template associated with a given 
MU.
7, 15
   
During offline analysis, the acceptability of acquired MUP templates, S-MUP 
templates, and MUP trains were reviewed based on specific criteria, with those failing to 
meet the inclusion criteria excluded from further analysis.
6, 16
  Accepted MUP trains 
demonstrated a consistent and physiological firing rate quantified by an interdischarge 
interval histogram displaying a Gaussian-shaped main peak, a coefficient of variation < 
0.3 for the interdischarge interval,
8, 17
 and by visual examination of the instantaneous 
firing rate plot.  Additionally, MUP trains were required to have MUP and S-MUP 
templates derived from a minimum of 51 detected potentials each.  When two MUP 
trains within a contraction were identified by the software as ‘disparate’ (i.e. never firing 
simultaneously and thus suspected to stem from the same MU), one of these MUP trains 
was excluded following confirmation based on visual inspection of their raster plots.  The 
onset, positive peak, negative peak, and end markers of the MUP templates and the 
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negative onset, negative peak, and positive peak markers of the S-MUP templates were 
checked visually and repositioned if necessary.  Finally, the onsets of the MUP and S-
MUP templates were required to occur within 10 ms of each other in order for the 
corresponding MUP train to be accepted.  MUP templates consistent with cannula 
potentials (inverted MUPs as a result of a larger contribution from the cannula than from 
the core detection surface of the concentric needle electrode) were excluded, as they 
express different information than typical MUPs.
18
  However, their corresponding S-
MUP templates from the same MUP train were retained for further analysis, as the ability 
of cannula potentials to serve as an accurate triggering source for spike-triggered 
averaging is not compromised.    
Descriptive statistics for various parameters were calculated automatically based 
on all accepted MUPs, S-MUPs, and MUP trains.  Additionally, the mean S-MUP was 
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned 
based on their onsets.  Lastly, the MUNE was calculated automatically through division 
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of 
the maximum CMAP previously obtained.
6
   
3.1.4 Intra-rater reliability 
The experimental protocol and subsequent review of the data was performed 
twice on the same day by the same evaluator (C.I.; rater 1) for each subject.  This 
evaluator was a new user of DE-STA MUNE and had been trained with regard to data 
collection and analysis by an individual experienced with the technique (T.D.).  
Following completion of the first test (data reported under rater 1a), all electrodes were 
removed and, with a minimum of 15 min between sessions, a new set of electrodes was 
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applied for the repeat test (data reported under rater 1b).  The electrode positions were not 
marked during the first assessment.  Data analysis was completed only following 
collection of both sets of data so that the evaluator was blinded to the results of both 
assessments until data collection was complete.
6, 12
 
3.1.5 Inter-rater reliability   
At a separate time point (ranging from 15 min to 76 days before/after rater 1), a 
different evaluator (T.D.; rater 2) performed the experimental protocol and subsequent 
review of the data on the same subject tested by C.I.  The electrode positions were not 
marked during the first assessment.  Data analysis was performed independently by each 
evaluator, with the exception of the repositioning of markers for MUP templates, which 
was performed by rater 1 for rater 1 and 2 data due to issues of time.  Evaluators 
remained blind to the results of the other evaluator until the completion of data collection 
for a given subject.
13
   
3.1.6 Statistics 
Mean values along with their standard deviations and ranges are presented 
throughout.  Relative intra-rater reliability was assessed using a Model 3 (two-way 
mixed, consistency) single measure intraclass correlation coefficient (ICC) [ICC (3,1)], 
and relative inter-rater reliability using a Model 2 (two-way random, absolute agreement) 
single measure ICC [ICC (2,1)] (IBM
®
 SPSS
®
 Statistics 19, SPSS, Inc., Chicago, IL).  
ICC point estimates <0.50 were considered poor, 0.50-0.75 considered moderate, and 
>0.75 considered good reliability.
11
  Also, ICC point estimates > 0.90 were classified as 
excellent reliability.  If the F-test associated with between-subjects variance from the ICC 
output was not significant, the corresponding ICC value was deemed potentially 
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inaccurate.  This conclusion was made because between-subject heterogeneity is a 
necessary condition for reliability testing, without which the actual limits of the ICC may 
deviate from the theoretical limits of 0.00-1.00.
11
   
To augment the ICC, a standard error of measurement (SEM) was calculated as a 
measure of absolute intra- and inter-rater reliability for maximum CMAP, mean S-MUP, 
and MUNE values (Equation 1).
19
  
3.1.6.1 Equation 1 
SEM = sd/√2          
Where SEM, standard error of measurement; sd, standard deviation of difference scores 
between the two tests.  
Lastly, a two-tailed, paired t-test was used to test for systematic biases between 
tests for each parameter, with an a priori alpha level of 0.05 used to denote significance 
(IBM
®
 SPSS
® 
Statistics 19, SPSS, Inc., Chicago, IL).   
3.2 RESULTS 
3.2.1 Subjects 
Ten subjects (5 males, 5 females) aged 51 ± 7 years (40-62 years) participated in 
this study.  These subjects had an average height of 167 ± 5 cm (158-175 cm), and weight 
of 76.3 ± 13.6 kg (61.3-99.0 kg). 
3.2.2 Data collection results and S-MUP frequency distributions 
On average, 28 ± 7, 27 ± 5, and 23 ± 6 acceptable S-MUPs were obtained (from 
38 ± 9, 37 ± 7, and 28 ± 7 MUP trains collected in total) for each subject from 6 ± 1, 6 ± 
2, and 5 ± 1 contractions for rater 1a, 1b, and 2, respectively.  Thus, on average, 5 ± 2 
acceptable S-MUPs per contraction were collected by each evaluator.  Mean MU 
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identification rates (percentage of expected firings detected) based on the samples of 
accepted MUP trains were 59.5 ± 7.3% (rater 1a), 58.5 ± 8.3% (rater 1b), and 64.0 ± 
7.0% (rater 2).  The frequency distributions of S-MUP negative peak amplitudes, as a 
percentage of maximum CMAP negative peak amplitudes for rater 1a (0.47 ± 0.23 % 
maximum CMAP [0.06-1.51 % maximum CMAP]), rater 1b (0.52 ± 0.32 % maximum 
CMAP [0.01-1.92 % maximum CMAP]), and rater 2 (0.52 ± 0.27 % maximum CMAP 
[0.03-1.31 % maximum CMAP]) are illustrated in Figure 3.1.     
3.2.3 Maximum CMAP, mean S-MUP, and MUNE 
3.2.3.1 Intra-rater reliability  
Analysis using the ICC revealed good intra-rater reliability for maximum CMAP 
(ICC = 0.77) and moderate reliability for MUNE (ICC = 0.69).  Insufficient between-
subject heterogeneity for mean S-MUP values resulted in a potentially inaccurate ICC 
value.
11
  The SEMs for maximum CMAP, mean S-MUP, and MUNE were 0.9 mV, 11 
µV, and 70 MUs, respectively.  Using a paired t-test, there were no significant 
differences between tests for maximum CMAP t(9) = -0.40, p = 0.70 (-1.13, 0.79), mean 
S-MUP t(9) = -0.82, p = 0.43 (-14.65, 6.85), or MUNE t(9) = 0.59, p = 0.57 (-52.47, 
89.67) (Table 3.1).  
3.2.3.2 Inter-rater reliability 
Consistent with the intra-rater reliability results, inter-rater reliability was found 
to be good for maximum CMAP (ICC = 0.79) and moderate for MUNE (ICC = 0.73).  
The ICC value for mean S-MUP (ICC = 0.42) indicated poor inter-rater reliability.  The 
SEMs for maximum CMAP, mean S-MUP, and MUNE were 1.1 mV, 9 µV, and 41 
MUs, respectively.  Using a paired t-test, there was no significant difference between 
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tests for maximum CMAP t(9) = -0.43, p = 0.68 (-1.38, 0.93), while significant 
differences between rater 1a and 2 were found for mean S-MUP t(9) = -3.06, p < 0.05 (-
20.36, -3.04) and MUNE t(9) = 4.19, p < 0.01 (35.36, 118.40) (Table 3.1).   
3.2.4 Motor unit potential parameters  
3.2.4.1 Intra-rater reliability 
Analysis using the ICC revealed the highest level of intra-rater reliability for 
mean firing rate (ICC = 0.87).  Good reliability was also found for area-to-amplitude ratio 
(AAR) (ICC = 0.79), with moderate reliability found for duration (ICC = 0.68) and area 
(ICC = 0.53).  Insufficient between-subject heterogeneity for peak-to-peak voltage, 
phases, and turns resulted in potentially inaccurate ICC values.
11
  Using a paired t-test, 
there were no significant differences between tests for any of the MUP parameters (Table 
3.2). 
3.2.4.2 Inter-rater reliability 
Analysis using the ICC revealed moderate reliability for MUP mean firing rate 
(ICC = 0.74).  Insufficient between-subject heterogeneity for each of the other MUP 
parameters resulted in potentially inaccurate ICC values.
11
  Consistent with the paired t-
test results for intra-rater reliability, there were no significant differences between rater 
1a and 2 for any of the MUP parameters (Table 3.2). 
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Figure 3.1 Frequency distributions of S-MUP data from all subjects for rater 1a (closed 
bars) (281 S-MUPs), rater 1b (open bars) (273 S-MUPs), and rater 2 (checkered bars) 
(225 S-MUPs).  The negative peak amplitudes of the S-MUPs have been normalized to 
the negative peak amplitude of the maximum CMAP measured by each rater for each 
subject.  The y-axis represents the percentage of the total number of S-MUPs per rater.   
Abbreviations:  CMAP, compound muscle action potential; S-MUP, surface-detected 
motor unit potential 
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Table 3.1 Intra- and inter-rater reliability of maximum CMAP, mean S-MUP, and MUNE  
 
Parameter Rater 1a  Rater 1b Rater 2 Intra-rater  
(1a vs. 1b) 
Inter-rater  
(1a vs. 2) 
ICC SEM ICC SEM 
Maximum CMAP 
neg. peak amp. (mV) 
8.5 ± 2.1 
(6.1-12.9) 
8.6 ± 1.9  
(5.8-13.0)  
8.7 ± 2.7  
(4.7-13.1) 
0.77 0.9 0.79 
 
1.1 
Mean S-MUP   
neg. peak amp. (µV) 
27 ± 7  
(16-38) 
31 ± 13  
(17-58) 
38 ± 17
*
  
(11-67) 
-0.01
†
 11 0.42 
 
9 
MUNE (MUs) 339 ± 121 
(172-586) 
320 ± 131 
(153-590) 
262 ± 115
*
 
(135-466) 
0.69 70 0.73 
 
41 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
* 
Significantly different from rater 1a (p < 0.05).   
† 
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC value. 
Abbreviations:  CMAP, compound muscle action potential; ICC, intraclass correlation coefficient; MU, motor unit; MUNE, motor 
unit number estimation; neg. peak amp., negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected 
motor unit potential.  
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Table 3.2 Intra- and inter-rater reliability of MUP parameters  
 
Parameter Rater 1a  Rater 1b  Rater 2 Intra-rater  
(1a vs. 1b) 
ICC  
Inter-rater  
(1a vs. 2) 
ICC 
Peak-to-peak  
voltage (µV) 
373.2 ± 72.5 
(264.6-504.5) 
382.4 ± 106.7 
(259.0-592.0) 
384.3 ± 96.7 
(201.4-545.6) 
0.44
† 
0.13
† 
Duration (ms) 13.3 ± 2.5 
(8.6-17.4) 
13.2 ± 2.6 
(9.7-16.9) 
13.8 ± 1.7 
(10.6-16.9) 
0.68 -0.13
† 
Area (µVms) 688.0 ± 204.6 
(490.1-1073.2) 
701.3 ± 206.9 
(411.9-1055.5) 
643.2 ± 126.7 
(356.6-774.0) 
0.53 0.21
† 
AAR (ms) 1.9 ± 0.4 
(1.3-2.7) 
1.9 ± 0.3 
(1.4-2.5) 
1.8 ± 0.2 
(1.5-2.1) 
0.79 0.19
† 
Phases 2.7 ± 0.4 
(2.2-3.3) 
2.7 ± 0.4 
(2.0-3.5) 
2.6 ± 0.3 
(2.0-3.1)
 
0.09
† 
0.10
† 
Turns 3.2 ± 0.6 
(2.6-4.2) 
3.3 ± 0.6 
(2.6-4.6) 
3.2 ± 0.4 
(2.6-3.6)
 
0.12
† 
0.10
† 
Mean firing  
rate (Hz) 
11.0 ± 1.1 
(9.1-13.1) 
10.9 ± 1.1 
(9.8-13.0) 
10.8 ± 1.1 
(8.9-13.2) 
0.87 0.74 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
† 
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC value. 
Abbreviations:  AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient; MUP, motor unit potential. 
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3.3 DISCUSSION  
This study has established a set of normative data pertaining to the 
electrophysiological properties of MUs and the size of the MU pool in the UT using DE-
STA MUNE.  While anatomical estimates of the number of MUs in the UT could not be 
located in the literature for comparative purposes, average MUNE values in this study 
(Table 3.1) are similar to a preliminary study of DE-STA MUNE in the UT, which found 
an average peak-to-peak amplitude MUNE of 270 ± 19 MUs for control subjects (n = 
3).
14
  In the current study, a great degree of variability between subjects was found for 
MUNE values, ranging, for example, from 172 to 586 MUs for rater 1a.  This is 
consistent with the considerable between-subject variability reported for MUNE values 
obtained using DE-STA in other muscles such as the BB (159-547 MUs)
20
 and tibialis 
anterior (68-214 MUs)
13
 in control subjects.   
Frequency distributions of S-MUP data revealed size distributions characterized 
by large proportions of small S-MUPs (Figure 3.1).  These results are similar to previous 
studies in control subjects, including an evaluation of DE-STA MUNE in various 
muscles of the hand,
6 
and studies using other types of MUNE in various muscles 
groups.
21-23
   
In order for DE-STA MUNE applied to the UT to be useful as an outcome 
measure in ALS clinical trials, it is critical that the results it generates are reliable.  Based 
on the ICC, maximum CMAP and MUNE demonstrated good and moderate levels of 
reliability, respectively, both when collected by the same evaluator at two different time 
points and by two different evaluators.  However, poor reliability and a systematic bias 
for mean S-MUP results were found in the inter-rater reliability portion of the study, 
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which carried over into the MUNE inter-rater reliability results.  These results reflect 
systematic difference(s) between evaluators with respect to the performance of the data 
collection and analysis protocol.     
The CMAP reliability results demonstrate the limited training required in order 
for a less experienced evaluator to produce not only consistent results, but results that are 
consistent with those of a highly experienced evaluator.  The ease with which a 
maximum CMAP can be elicited from the UT reflects the accessibility of its nerve 
supply, and lies in contrast to the relative difficulty in obtaining a maximum CMAP from 
more commonly studied muscles such as the BB.
14
   
Variability in mean S-MUP results may stem from any of the numerous factors 
involved in data collection (e.g. surface and needle electrode positions, contractile levels) 
and analysis (e.g. inclusion/exclusion of S-MUPs, manual adjustment of markers) which 
influence the sample of S-MUPs ultimately used to derive the mean.  While variability 
from test to test is inherent in the process of sampling, undesirably high levels may result 
from failure to collect a representative sample of S-MUPs and point to opportunities to 
better control for differences in the collection of S-MUPs.  The ability to sample a wide 
range and subsequently representative subset of S-MUPs may have been particularly 
difficult in the UT muscle, given its depth and relatively large surface area.  Rarely, less 
than 20 acceptable S-MUPs were able to be collected for a given data collection session.  
However, this was not clearly associated with higher levels of S-MUP variability. 
Variability between tests may also result from inconsistent contractile levels 
which, in a way, alter the pool from which S-MUPs are being sampled.  Owing to the size 
principle of MU recruitment,
24
 contraction intensity has been shown to influence the size 
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of the S-MUPs sampled, and subsequently the mean S-MUP.
16, 25
  The importance of 
contraction intensity may be magnified in a large, proximal muscle such as the UT, given 
its likely reliance on recruitment over rate coding.
26
  While the protocol attempted to 
control for levels of voluntary contraction, the calculation of referential MVC-RMS 
values was unaided by a dynamometer for this proximal muscle.  The use of such an 
instrument may have decreased the variability in the results.  It may also be useful in the 
future to carefully instruct the subject to maintain a consistent arm/shoulder position in 
order to ensure a contraction strategy throughout the series of sub-maximal contractions 
that is comparable to their initial contraction used to calculate the MVC-RMS.  Despite 
any variability associated with the mean S-MUP results, MUNE, which is the primary 
parameter of interest, demonstrated favorable levels of reliability.  
As mentioned, the use of DE-STA MUNE offers the advantage over other 
methods of MUNE of not only being able to study proximal muscles, but of the 
performance of quantitative MUP analysis.  Analysis of the reliability of the MUP 
parameter values found high ICCs for mean firing rate (particularly for intra-rater 
reliability).  The limited between-subject heterogeneity found for many of the other 
quantitative MUP parameters (resulting in artificially low and sometimes negative ICC 
values) is likely an inherent property of these parameters, as similar results have been 
encountered in reliability studies involving quantitative MUP data obtained using 
DQEMG in other muscles in control subjects.
13, 27
  
A potential limitation of this research was the inconsistent interval of time 
separating inter-rater reliability tests.  However, as this research involved control 
subjects, it is unlikely that any important changes in MU numbers took place between 
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tests.  In addition, the current study was limited by a small sample size.  However, the 
majority of previous reliability studies utilizing DE-STA MUNE have also used 10 or 
fewer subjects.
12, 13
   
This study has been the first to establish normative data and assess the intra- and 
inter-rater reliability of DE-STA MUNE and quantitative MUP analysis in the UT, which 
may be a highly relevant muscle to study in patients with ALS.  Thus, building on the 
present study of control subjects, it is necessary to examine the intra-rater reliability of 
the technique in this muscle group in subjects with ALS.  Together, these studies are 
essential to establishing DE-STA MUNE’s potential utility as an outcome measure for 
use in ALS clinical trials.     
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CHAPTER 4 
EVALUATION OF DECOMPOSITION-ENHANCED SPIKE-TRIGGERED 
AVERAGING MOTOR UNIT NUMBER ESTIMATION IN SUBJECTS WITH 
AMYOTROPHIC LATERAL SCLEROSIS
2
   
4.0 INTRODUCTION 
The degeneration of lower motor neurons (LMNs) associated with amyotrophic 
lateral sclerosis (ALS) results in denervation of skeletal muscle fibers and a 
corresponding decline in the number of functioning motor units (MUs) within a given 
muscle.  Collateral reinnervation is eventually outpaced by MU loss, leading to 
progressive muscle atrophy and weakness.
1
  Outcome measures assessing function and 
muscle strength are used in ALS clinical trials commonly, but are influenced by collateral 
reinnervation.  In contrast, motor unit number estimation (MUNE) is able to detect the 
underlying progression of the disease, and may thus be useful as an outcome measure in 
ALS clinical trials.
2, 3
       
As previously described, decomposition-enhanced spike-triggered averaging (DE-
STA) MUNE carries a number of advantages over other MUNE techniques, making it 
valuable to evaluate further regarding its utility as an outcome measure (Chapter 1, 3).  A 
key advantage of DE-STA MUNE is that it can be applied to the study of proximal 
muscles.
4
  One such muscle, the upper trapezius (UT) may be particularly relevant to 
study in subjects with ALS, given its role as an accessory muscle of respiration.
5
  In 
addition to the UT, the current study examined the biceps brachii (BB).  Application of 
the technique to multiple muscles representing different sources of innervation is relevant 
                                                 
2
 A version of this chapter has been submitted for publication. 
Ives CT, Doherty TJ. Intra-rater reliability of motor unit number estimation and quantitative motor 
unit analysis in subjects with amyotrophic lateral sclerosis. Clin Neurophysiol; May, 2012. 
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given the highly variable distribution and progression of muscle involvement associated 
with the disease.
2
   
In order for a measurement technique to be useful, its results must be reproducible 
in the hands of the same evaluator at two or more points in time (intra-rater reliability).
6
  
Among other muscle groups, the intra-rater reliability of DE-STA MUNE has been 
studied in the BB
7
 and UT (Chapter 3) in control subjects.  However, despite being 
applied to the study of subjects with ALS in the BB,
8-10
 and to a single subject in the 
UT,
11
 the intra-rater reliability of DE-STA MUNE has yet to be examined in these or any 
other muscle groups in this patient population.   
In addition to reliability, a critical property of any outcome measure is its validity.  
In the absence of a gold standard technique, or normative anatomical data with which to 
compare the results of DE-STA MUNE, the ability of the technique to detect the 
underlying pathophysiology of the disease can be evaluated by comparing the results 
between subjects with ALS and control subjects, as was done previously in the BB and 
first dorsal interosseous.
8
     
Thus, the objectives of this study were twofold.  First, to assess the intra-rater 
reliability of DE-STA MUNE and quantitative motor unit potential (MUP) analysis in the 
UT and BB of subjects with ALS.  Second, to compare the results of DE-STA MUNE 
and quantitative MUP analysis in the UT of subjects with ALS to data obtained 
previously in control subjects in the same muscle (Chapter 3).      
 
 
 
76 
 
 
4.1 METHODS  
4.1.1 Subjects 
In total, 14 patients diagnosed with clinically probable or definite ALS as defined 
by the revised El Escorial criteria
12
 were recruited from the Motor Neuron Diseases 
Clinic at University Hospital, London Health Sciences Centre to participate in this study.  
Patients were included if they were between the ages of 18-90, were within 10 years of 
symptom onset, and were judged as having sufficient upper extremity (UE) strength to 
perform the degree of scapular elevation and/or elbow flexion required for the MUNE 
protocol.  Patients were excluded if they had evidence of other neuromuscular or 
musculoskeletal disease.   
Each subject completed testing in one or both of the muscles of interest, with 10 
subjects participating in the UT portion of the study and 9 subjects participating in the 
BB portion of the study.  All subjects gave written, informed consent in accordance with 
The University of Western Ontario Health Sciences Research Ethics Board, which 
approved this study.     
4.1.2 Electromyographic data collection and analysis  
Electromyographic (EMG) signals were acquired using decomposition-based 
quantitative electromyography (DQEMG) (version 3.2) and Acquire EMG software on a 
Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX).  Self-adhering Silver 
Mactrode
® 
electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface 
signals, and 25 mm x 30 gauge TECA
™
 elite Disposable Concentric Needle Electrodes 
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass 
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.
13, 14
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Testing was conducted unilaterally on the arm identified by the subject as having 
less weakness.  If the patient was unable to determine which arm was stronger, the right 
arm was selected.  For the UT, subjects were seated upright in a straight back chair or 
wheelchair, and for the BB, subjects were supine on an examination table or, if this was 
not tolerated, positioned in a semi-reclined or seated position.  For the BB, the arm being 
tested was supported in partial abduction with the forearm supinated.   
Surface electrodes were cut in strips (1 cm x 3.5 cm) for use as the active and 
reference electrodes, with a full-sized electrode serving as a ground.  For both muscle 
groups, the skin was cleansed with isopropyl alcohol and surface electrodes positioned 
appropriately.  For the UT, the active electrode was positioned transversely over the belly 
of the muscle, approximately midway between the acromion process and C7 spinous 
process, with the reference electrode placed over the acromion process, and the ground 
electrode over the deltoid.
11
  For the BB, the active electrode was again positioned 
transversely over the belly of the muscle, with the reference electrode placed over the 
tendon at the elbow and the ground electrode over the forearm just distal to the elbow 
crease.
7
   
A handheld bipolar stimulator was used in order to elicit a maximum compound 
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to 
the sternocleidomastoid for the UT
11
 and the musculocutaneous nerve stimulated at the 
axilla for the BB.
7, 8
  If necessary, the active electrode was moved in small increments to 
a position where the CMAP negative peak amplitude was maximized and the rise time 
minimized.  Following optimal positioning of the active electrode, the surface electrode 
positions were reinforced with surgical tape to ensure that no movement occurred during 
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the study.  Gradually, the stimulation intensity was increased until the CMAP negative 
peak amplitude reached a plateau.  Automatically positioned markers indicating onset, 
negative peak, positive peak, and end of the maximum CMAP were reviewed and 
manually adjusted if necessary.  Subsequently, size-related parameters of the maximum 
CMAP including negative peak amplitude were calculated automatically.      
Subjects then performed a 3-4 s voluntary contraction by way of scapular 
elevation (UT) or elbow flexion (BB) against resistance provided by the evaluator.  
Subjects were encouraged to produce their maximal effort, and visual and auditory 
feedback was provided by the surface EMG signal.  The maximal root mean square value 
of the EMG signal over a 1 s interval was calculated automatically and the intensity of 
subsequent sub-maximal contractions was described as a percentage of this maximal 
voluntary contraction-root mean square (% MVC-RMS).      
Next, the concentric needle electrode was inserted into the UT or BB, 
approximately 2-10 mm proximal or distal to the active surface electrode.  Subjects were 
asked to perform minimal isometric contractions while an optimal needle position was 
located that minimized the rise times of the MUPs of the first two to three recruited MUs.  
With the needle manually maintained in this position by the evaluator, the subject was 
instructed to increase the contraction force to approximately 10-20% of the MVC-RMS.  
Each sub-maximal isometric contraction was maintained for 30 s, during which the 
subject received visual and auditory feedback from the EMG signal and % MVC-RMS 
information displayed on the screen to assist in the maintenance of a stable contraction.  
Contractions were performed until a minimum of 20 MUP trains were collected, with 
each contraction separated by a rest period of approximately 30-60 s or as required by the 
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subject.  The needle position was adjusted between contractions to collect data from 
different portions of the muscle, and, if necessary, inserted at a new site to complete the 
collection of MUP trains.
13, 14
    
 Following EMG signal decomposition and the review of the acceptability of 
acquired MUPs, surface-detected motor unit potentials (S-MUPs), and MUP trains, as has 
been previously described (Chapters 1, 3), the onset, positive peak, negative peak, and 
end markers of the MUP templates and the negative onset, negative peak, and positive 
peak markers of the S-MUP templates were checked visually and repositioned if 
necessary.   
Descriptive statistics for various parameters were calculated automatically based 
on all accepted MUPs, S-MUPs, and MUP trains.  Additionally, the mean S-MUP was 
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned 
based on their onsets.  Lastly, the MUNE was calculated automatically through division 
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of 
the maximum CMAP previously obtained.
13
   
4.1.3 Intra-rater reliability   
The experimental protocol and subsequent review of the data was performed 
twice by the same evaluator (C.I.) for each subject.  Tests took place on the same day for 
each subject, with the exception of a single subject, for whom the tests were performed 
on consecutive days.  Following completion of the first test (data reported under rater 1a), 
all electrodes were removed and, with a minimum of 15 min between sessions, a new set 
of electrodes was applied for the repeat test (data reported under rater 1b).  The electrode 
positions were not marked during the first assessment.  Data analysis was completed only 
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following collection of both sets of data so that the evaluator was blinded to the results of 
both assessments until data collection was complete.
7, 13
   
4.1.4 Statistics   
Mean values along with their standard deviations and ranges are presented 
throughout.  Relative intra-rater reliability was assessed using a Model 3 (two-way 
mixed, consistency) single measure intraclass correlation coefficient (ICC) [ICC (3,1)] 
(IBM
®
 SPSS
®
 Statistics 19, SPSS, Inc., Chicago, IL).  ICC point estimates <0.50 were 
considered poor, 0.50-0.75 considered moderate, and >0.75 considered good reliability.
6
  
Also, ICC point estimates > 0.90 were classified as excellent reliability.  If the F-test 
associated with between-subjects variance from the ICC output was not significant, the 
corresponding ICC value was deemed potentially inaccurate.  This conclusion was made 
because between-subject heterogeneity is a necessary condition for reliability testing, 
without which the actual limits of the ICC may deviate from the theoretical limits of 
0.00-1.00.
6
   
To augment the ICC, a standard error of measurement (SEM) was calculated as a 
measure of absolute intra-rater reliability for maximum CMAP, mean S-MUP, and 
MUNE values (Equation 1).
15
 
4.1.4.1 Equation 1 
SEM = sd/√2    
Where SEM, standard error of measurement; sd, standard deviation of difference scores 
between the two tests.  
From the SEM, a margin of error (me) was calculated for MUNE based on a 95% 
confidence level using Equation 2.  
81 
 
 
4.1.4.2 Equation 2 
me = 1.96 * SEM        
Where me, margin of error; SEM, standard error of measurement.   
Additionally, a minimal detectable difference (MDD) was calculated for MUNE 
as an index of the smallest amount of change that can be considered to be above the 
threshold of measurement error (Equation 3).
6
   
4.1.4.3 Equation 3 
MDD95 = 1.96 * SEM * √2        
Where MDD95, minimal detectable difference based on a 95% confidence level; SEM, 
standard error of measurement.   
A two-tailed, paired t-test was used to test for systematic biases between tests for 
each parameter, with an a priori alpha level of 0.05 used to denote significance (IBM
®
 
SPSS
®
 Statistics 19, SPSS, Inc., Chicago, IL).   
Rater 1a parameter values from the UT were compared with rater 1a values from 
a study of control subjects (Chapter 3) using two-tailed, unpaired t-tests, with an a priori 
alpha level of 0.05 used to denote significance (IBM
® 
SPSS
®
 Statistics 19, SPSS, Inc., 
Chicago, IL).  As the purposes of this study were exploratory in nature, Bonferroni 
adjustments were not applied.   
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4.2 RESULTS   
4.2.1 Subjects 
A summary of subject demographic and clinical characteristics is found in Table 
4.1.   
4.2.2 Data collection results and S-MUP frequency distributions  
4.2.2.1 Upper trapezius 
On average, 18 ± 5 and 16 ± 5 acceptable S-MUPs were obtained (from 33 ± 13 
and 30 ± 13 MUP trains collected in total) for each subject from the first test (rater 1a) 
and second test (rater 1b), respectively.  For both tests, these S-MUPs were obtained from 
6 ± 2 contractions.  Thus, on average, 4 ± 2 and 3 ± 2 acceptable S-MUPs per contraction 
were collected for rater 1a and 1b, respectively.  The mean MU identification rate 
(percentage of expected firings detected) based on the sample of accepted MUP trains 
was 61 ± 10% for both tests.  The frequency distributions of  UT S-MUP negative peak 
amplitudes, as a percentage of maximum CMAP negative peak amplitudes from rater 1a 
(1.36 ± 1.59 % maximum CMAP [0.13-8.10 % maximum CMAP]) and rater 1b (0.99 ± 
1.14 % maximum CMAP [0.08-6.18 % maximum CMAP]) are illustrated in Figure 4.1A.   
4.2.2.2 Biceps brachii   
On average, 13 ± 7 acceptable S-MUPs were obtained for both tests (from 34 ± 12 
and 33 ± 16 MUP trains collected in total from the first test [rater 1a] and second test 
[rater 1b], respectively) for each subject.  The S-MUPs were obtained from 5 ± 2 and 6 ± 
1 contractions for rater 1a and 1b, respectively.  Thus, on average, 3 ± 2 acceptable S-
MUPs per contraction were collected for both tests.  The mean MU identification rates 
(percentage of expected firings detected) based on the samples of accepted MUP trains 
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were 63 ± 12% and 59 ± 13% for rater 1a and 1b, respectively.  The frequency 
distributions of BB S-MUP negative peak amplitudes, as a percentage of maximum 
CMAP negative peak amplitudes from rater 1a (2.29 ± 3.80 % maximum CMAP [0.21-
21.24 % maximum CMAP]), and rater 1b (2.10 ± 4.57 % maximum CMAP [0.14-26.33 
% maximum CMAP]) are illustrated in Figure 4.1B.   
4.2.3 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE  
4.2.3.1 Upper trapezius 
Analysis using the ICC revealed good intra-rater reliability for maximum CMAP 
(ICC = 0.88), mean S-MUP (ICC = 0.87), and MUNE (ICC = 0.88).  The SEMs for 
maximum CMAP, mean S-MUP, and MUNE were 0.7 mV, 19 µV, and 40 MUs, 
respectively.  For MUNE, the margin of error was ±79 MUs, and the MDD95 was 111 
MUs.  Using a paired t-test, there were no significant differences between tests for 
maximum CMAP t(9) = -1.29, p = 0.23 (-1.16, 0.32) or mean S-MUP t(9) = 1.19, p = 
0.26 (-8.87, 28.67), while a significant difference between tests was found for MUNE t(9) 
= -2.83, p < 0.05 (-91.03, -10.17) (Table 4.2).     
4.2.3.2 Biceps brachii   
Analysis using the ICC revealed moderate intra-rater reliability for maximum 
CMAP (ICC = 0.61), and excellent intra-rater reliability for mean S-MUP (ICC = 0.94), 
and MUNE (ICC = 0.93).  The SEMs for maximum CMAP, mean S-MUP, and MUNE 
were 1.0 mV, 26 µV, and 30 MUs, respectively.  For MUNE, the margin of error was ± 
59 MUs, and the MDD95 was 83 MUs.  Using a paired t-test, there were no significant 
differences between tests for maximum CMAP t(8) = 1.29, p = 0.23 (-0.48, 1.71), mean 
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S-MUP t(8) = 1.33, p = 0.22 (-12.17, 45.06) or MUNE t(8) = -1.11, p = 0.30 (-47.96, 
16.85) (Table 4.3).      
4.2.4 Intra-rater reliability of motor unit potential parameters  
4.2.4.1 Upper trapezius 
Analysis using the ICC revealed excellent levels of intra-rater reliability for area 
(ICC = 0.96), and good levels for peak-to-peak voltage (ICC = 0.86), mean firing rate 
(ICC = 0.84), duration (ICC = 0.81), and area-to-amplitude ratio (AAR) (ICC = 0.79).  
Insufficient between-subject heterogeneity for phases and turns resulted in potentially 
inaccurate ICC values.
6
  Using a paired t-test, there was a significant difference between 
tests for phases (p = 0.04) (Table 4.4).   
4.2.4.2 Biceps brachii 
Analysis using the ICC revealed excellent levels of intra-rater reliability for mean 
firing rate (ICC = 0.93), good intra-rater reliability for duration (ICC = 0.87), AAR (ICC 
= 0.86), area (ICC = 0.80), and peak-to-peak voltage (ICC = 0.79), and moderate intra-
rater reliability for turns (ICC = 0.70).  Insufficient between-subject heterogeneity for 
phases resulted in a potentially inaccurate ICC value.
6
  Using a paired t-test, there were 
no significant differences between tests for any of the parameters (Table 4.5).   
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Table 4.1 Subject demographics and clinical summary 
 
Variable All subjects  
(n = 14) 
UT subjects  
(n = 10) 
BB subjects  
(n = 9) 
Age (years) 59 ± 11 (41-77) 59 ± 11 (41-75) 60 ± 13 (41-77) 
Sex   5 male, 9 female 3 male, 7 female 4 male, 5 female 
Height (cm) 166 ± 10 (151-185) 164 ± 10 (151-178) 168 ± 10 (155-185) 
Weight (kg) 70.9 ± 15.6  
(37.5-108.0) 
71.1 ± 17.5  
(37.5-108.0) 
71.4 ± 8.2  
(54.4-81.9) 
Time from symptom 
onset (months) 
27 ± 14 (12-61) 28 ± 15 (12-61) 25 ± 11 (12-41) 
Area of onset  2 bulbar, 12 limb  
(11 UE, 1 LE) 
2 bulbar, 8 limb  
(7 UE, 1 LE) 
1 bulbar, 8 limb  
(7 UE, 1 LE) 
ALS classification  13 sALS, 1 fALS 9 sALS, 1 fALS 9 sALS 
Side of muscle testing 3 left, 11 right 2 left, 8 right 2 left, 7 right 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Abbreviations:  ALS, amyotrophic lateral sclerosis; BB, biceps brachii; fALS, familial 
amyotrophic lateral sclerosis; LE, lower extremity; sALS, sporadic amyotrophic lateral 
sclerosis; UE, upper extremity; UT, upper trapezius. 
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Table 4.2 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE in the 
upper trapezius 
 
Parameter Rater 1a  Rater 1b ICC SEM 
Maximum CMAP 
neg. peak amp. (mV) 
5.9 ± 1.7 
(3.1-8.2)  
6.4 ± 2.5 
(2.8-10.0) 
0.88 0.7 
Mean S-MUP   
neg. peak amp. (µV) 
63 ± 54 
(19-200) 
53 ± 49 
(18-145) 
0.87 19 
MUNE (MUs) 145 ± 91 
(27-294) 
196 ± 131
* 
(37-373) 
0.88 40 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
* 
Significantly different from rater 1a (p < 0.05).   
Abbreviations:  CMAP, compound muscle action potential; ICC, intraclass correlation 
coefficient; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp., 
negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected 
motor unit potential 
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Table 4.3 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE in the 
biceps brachii 
 
Parameter Rater 1a  Rater 1b  ICC SEM 
Maximum CMAP 
neg. peak amp. (mV) 
4.9 ± 1.7 
(2.9-8.7) 
4.3 ± 1.5  
(2.6-7.3) 
0.61 1.0 
Mean S-MUP   
neg. peak amp. (µV) 
104 ± 125 
(11-417) 
88 ± 97  
(12-321) 
0.94 26 
MUNE (MUs) 115 ± 104  
(12-319) 
130 ± 122  
(8-324) 
0.93 30 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Abbreviations:  CMAP, compound muscle action potential; ICC, intraclass correlation 
coefficient; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp., 
negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected 
motor unit potential 
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Table 4.4 Intra-rater reliability of MUP parameters in the upper trapezius 
 
Parameter Rater 1a  Rater 1b  ICC 
Peak-to-peak voltage (µV) 628.3 ± 346.6 
(291.1-1466.2) 
610.5 ± 439.3 
(304.3-1755.9) 
0.86 
Duration (ms) 16.7 ± 3.2 
(13.0-23.7) 
16.6 ± 4.3 
(11.8-25.3) 
0.81 
Area (µVms) 1505.6 ± 1229.4 
(610.0-4648.3) 
1385.1 ± 1304.8 
(508.7-4760.4) 
0.96 
AAR (ms) 2.3 ± 0.6 
(1.6-3.4) 
2.2 ± 0.5 
(1.6-3.1) 
0.79 
Phases 2.6 ± 0.4 
(1.9-3.0) 
3.0 ± 0.4
* 
(2.4-3.8) 
0.13
† 
Turns 3.4 ± 1.0 
(2.0-5.6) 
3.5 ± 0.7 
(2.8-5.1) 
-0.23
† 
Mean firing rate (Hz) 11.5 ± 2.3 
(7.4-14.9) 
11.1 ± 2.2 
(6.9-15.4) 
0.84 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
* 
Significantly different from rater 1a (p < 0.05).   
† 
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC 
value. 
Abbreviations:  AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient; 
MUP, motor unit potential. 
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Table 4.5 Intra-rater reliability of MUP parameters in the biceps brachii 
 
Parameter Rater 1a Rater 1b ICC 
Peak-to-peak voltage (µV) 765.0 ± 342.2 
(429.8-1446.8) 
897.4 ± 558.5 
(403.5-2221.0) 
0.79 
Duration (ms) 20.1 ± 7.1 
(9.2-34.5) 
22.5 ± 8.6 
(12.3-38.5) 
0.87 
Area (µVms) 2272.6 ± 1788.0 
(687.2-6577.6) 
3095.5 ± 3327.3 
(808.8-11503.5) 
0.80 
AAR (ms) 2.7 ± 0.9 
(1.6-4.7) 
3.1 ± 1.2 
(1.7-5.9) 
0.86 
Phases 2.8 ± 0.5 
(2.0-3.5) 
2.8 ± 0.4  
(2.0-3.4) 
0.28
†
 
Turns 4.0 ± 1.3 
(2.0-6.1) 
3.9 ± 1.2 
(2.0-5.6) 
0.70 
Mean firing rate (Hz) 14.2 ± 5.1 
(9.2-24.1) 
14.9 ± 6.9 
(8.7-26.8) 
0.93 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
† 
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC 
value. 
Abbreviations:  AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient; 
MUP, motor unit potential. 
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4.2.5 Comparison of upper trapezius data between ALS and control subjects 
Figure 4.1C depicts a comparison of frequency distributions of S-MUP negative 
peak amplitudes, as a percentage of maximum CMAP negative peak amplitudes in the 
UT between rater 1a in subjects with ALS (1.36 ± 1.59 % maximum CMAP [0.13-8.10 % 
maximum CMAP]) and control subjects (data previously reported in Chapter 3) (0.47 ± 
0.23 % maximum CMAP [0.06-1.51 % maximum CMAP]).   
Comparison of UT data from subjects with ALS in the present study to control 
subjects (5 females, 5 males) from a previous study of similar ages, ranging from 40-62 
years (51 ± 7 years) (Chapter 3) found significant differences between groups for 
maximum CMAP, mean S-MUP and MUNE values.  Maximum CMAP values were 
significantly lower in subjects with ALS (5.9 ± 1.7 mV [3.1-8.2 mV]) compared to 
control subjects (8.5 ± 2.1 mV [6.1-12.9 mV]) t(18) = 3.00, p < 0.01 (0.75, 4.27), while 
mean S-MUP values were significantly greater in the ALS group (63 ± 54 µV [19-200 
µV]) compared to the control group (27 ± 7 µV [16-38 µV]) t(18) = -2.12, p < 0.05 (-
72.72, -0.28), and MUNE values were significantly lower in the ALS group (145 ± 91 
MUs [27-294 MUs]) compared to the control group (339 ± 121 MUs [172-586 MUs]) 
t(18) = 4.05, p < 0.001 (93.19, 294.0) (Figure 4.2).   
Comparison of MUP parameters between groups found significantly greater peak-
to-peak voltage (628.3 ± 346.6 µV [291.1-1466.2 µV] ALS; 373.2 ± 72.5 µV [264.6-
504.5 µV] control) (p = 0.035) and longer duration (16.7 ± 3.2 ms [13.0-23.7 ms] ALS; 
13.3 ± 2.5 ms [8.6-17.4 ms] control) (p = 0.017) values for subjects with ALS.  Although 
not statistically significant, a trend was found in the direction of larger area (1505.6 ± 
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1229.4 µVms [610.0-4648.3 µVms] ALS; 688.0 ± 204.6 µVms [490.1-1073.2 µVms] 
control) (p = 0.053) for subjects with ALS.   
AAR (2.3 ± 0.6 ms [1.6-3.4 ms] ALS; 1.9 ± 0.4 ms [1.3-2.7 ms] control), phases 
(2.6 ± 0.4 [1.9-3.0] ALS; 2.7 ± 0.4 [2.2-3.3] control), turns (3.4 ± 1.0 [2.0-5.6] ALS; 3.2 
± 0.6 [2.6-4.2] control), and mean firing rate (11.5 ± 2.3 Hz [7.4-14.9 Hz] ALS; 11.0 ±1.1 
Hz [9.1-13.1 Hz] control) were not significantly different between groups.   
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Figure 4.1 Frequency distributions of S-MUP data from all subjects for rater 1a (closed 
bars) (183 S-MUPs) and rater 1b (open bars) (161 S-MUPs) for the UT (A) , for rater 1a 
(closed bars) (120 S-MUPs) and rater 1b (open bars) (119 S-MUPs) for the BB (B), and 
comparing rater 1a data from the UT between subjects with ALS (closed bars) (183 S-
MUPs) and control subjects (open bars) (281 S-MUPs) (data previously reported in 
Chapter 3) (C).  The negative peak amplitudes of the S-MUPs have been normalized to 
the negative peak amplitude of the maximum CMAP for each subject.  The y-axis 
represents the percentage of the total number of S-MUPs per subject group.  
Abbreviations:  ALS, amyotrophic lateral sclerosis; BB, biceps brachii; CMAP, 
compound muscle action potential; S-MUP, surface-detected motor unit potential; UT, 
upper trapezius. 
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Figure 4.2 Comparison of rater 1a data from the UT between control subjects from a 
previous study (Chapter 3) and subjects with ALS in the present study.  
* 
indicates a 
significant difference between groups.  Maximum CMAP (p < 0.01) (A), mean S-MUP 
(p < 0.05) (B), and MUNE (p < 0.001) (C).  Note: Removing the 200 µV mean S-MUP 
value from the ALS group, the significant difference is retained (p < 0.05) (B).   
Abbreviations:  ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action 
potential; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp., 
negative peak amplitude; S-MUP, surface-detected motor unit potential; UT, upper 
trapezius. 
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4.3 DISCUSSION 
 This is the first study to assess the reliability of DE-STA MUNE and quantitative 
MUP analysis in subjects with ALS.  The results demonstrated the ability of the 
technique to collect highly reliable data in two separate muscle groups.  This study also 
established the technique’s ability to detect the underlying pathophysiology of the disease 
in a potentially clinically relevant muscle group not previously studied using MUNE.   
4.3.1 Data collection and S-MUP frequency distributions  
On average, less than the target of 20 acceptable S-MUPs for each subject were 
collected for both muscle groups, reflective of the more challenging nature of the data 
collection protocol as applied to subjects with ALS.  The collection of fewer acceptable 
S-MUPs was likely due in large part to the difficulty experienced by some subjects in 
maintaining a series of sub-maximal contractions at consistent contraction intensities, 
resulting in some cases in MUP trains with inconsistent firing patterns that did not meet 
the inclusion criteria.  Unfortunately, the performance of additional contractions in order 
to obtain at least 20 acceptable S-MUPs was sometimes limited in this patient population 
due to the energy expended for each contraction, and the underlying weakness and 
fatigue associated with the disease.  Nevertheless, the collection of less than 20 
acceptable S-MUPs did not appear to influence the results greatly, as evidenced by the 
high levels of reliability found for mean S-MUP and MUNE values in both muscle 
groups.  Despite the sampling of a smaller absolute number of S-MUPs, the MU loss 
associated with the disease would have often resulted in the collection of S-MUPs from a 
larger proportion of the total population of MUs, preserving the representativeness of the 
sample.   
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S-MUP frequency distributions were unimodal and positively skewed for both the 
UT and BB data (Figures 4.1A, 4.1B).  These distributions were similar between muscle 
groups, with the exception of the finding that a number of S-MUPs collected from the BB 
of a single subject were between 17.6% and 26.3% of the size of the maximum CMAP.  
While enlarged S-MUPs are reflective of collateral reinnervation, none of the other S-
MUPs collected from either muscle group exceeded 9% of the size of the maximum 
CMAP, indicating a unique degree of compensation in response to LMN degeneration for 
the MUs of this one particular subject.     
4.3.2 Intra-rater reliability 
4.3.2.1 Upper trapezius 
The levels of intra-rater reliability based on the ICC for UT MUNE and the 
components of its equation were higher than results from a study of the technique in the 
same muscle group performed in control subjects (Chapter 3).  Similarly, the levels of 
intra-rater reliability of each of the MUP parameters (all either good or excellent) were at 
greater levels than the results from the study in control subjects (with the exception of 
AAR and mean FR, which remained at similar levels) (Chapter 3).  Similar findings of 
enhanced reliability in subjects with ALS compared to control subjects have been 
reported for other MUNE techniques in various muscle groups
16, 17
 and are likely as a 
result of the smaller MU pool under study in these subjects.  As mentioned previously, 
the ability to collect a representative, and thus, reliable sample of MUPs and associated 
S-MUPs is likely enhanced given that it is possible to collect potentials from a larger 
proportion of the total number of MUs.
17
  Additionally, any wasting of the UT associated 
with the disease process may have facilitated the sampling of a representative group of 
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MUPs and associated S-MUPs from various positions in the muscle with the concentric 
needle electrode, further enhancing the reliability of the technique.  
An additional contributor to the higher ICCs found for subjects with ALS is likely 
the positive impact that between-subject heterogeneity has on the coefficient.
6
  This was 
especially apparent for mean S-MUP and peak-to-peak voltage values, for which accurate 
ICCs could not be calculated for control subjects as a result of insufficient between-
subject heterogeneity (Chapter 3).  Conversely, good levels of reliability were found for 
the same parameters in subjects with ALS, for whom the heterogeneity was much greater.   
Consistent with the previous study in control subjects (Chapter 3), insufficient 
between-subject heterogeneity was found for the number of phases and turns for MUPs 
from the UT, (also the case for phases for the BB), calling into question the validity of 
the ICC values.  This may be indicative of the between-subject homogeneity of these 
indices of MUP complexity across health and disease.   
Unlike the ICC, the SEM is unaffected by the heterogeneity of the data, and 
serves as a measure of the amount of variation expected if one subject was tested 
numerous times at a single testing session.
15, 18
  Based on the SEM and a 95% confidence 
level, it was calculated that a subject’s observed MUNE could vary ± 79 MUs as a result 
of measurement error.  It follows that in constructing a confidence interval, we would be 
95% confident that a subject with an observed MUNE of 200 MUs had a true value 
between 121 MUs and 279 MUs.
6
  Similar estimations can be calculated for maximum 
CMAP and mean S-MUP values based on their SEMs.  The calculated MDD95 represents 
the amount of change in MUNE that would be considered to represent a true change 
between testing sessions, above and beyond measurement error, for 95% of patients with 
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characteristics similar to those in the present study.  The results found that a change ≥ 
111 MUs for the UT would be considered to exceed the threshold of measurement error.  
Requiring such a threshold to detect change may hinder the technique in its ability to 
follow progression in clinical trials and natural history studies of subjects with ALS.  
However, it should be noted that a conservative 95% confidence level was chosen for the 
calculation.  For example, using an MDD80 (which would still apply to 80% of patients 
with characteristics similar to those in the present study), a difference of 73 MUs would 
be considered a true change.  It should also be noted that, in general, the MDD is a very 
conservative measure of change.
6
   
Lastly, while significant differences were not found between tests for the 
components of the MUNE equation, their dividend (MUNE) was found to be 
significantly higher for rater 1b than for rater 1a (Table 4.2).  Nevertheless, the 95% 
confidence interval for the mean difference (-91.03, -10.17 MUs) encompassed values 
that were less than the calculated MDD95 (111 MUs), and the other reliability statistics 
calculated for MUNE and each of its components demonstrated the strong reliability of 
the technique in this muscle group in subjects with ALS.  Furthermore, no significant 
differences were found between tests for any of these three parameters in a previous 
study in this muscle group in control subjects (Chapter 3), nor in the present study in the 
BB in subjects with ALS.  The significant difference between tests for MUNE values 
may have been avoided had the technique been examined with a larger sample size.       
4.3.2.2 Biceps brachii  
ICC levels representative of excellent intra-rater reliability were calculated for 
mean S-MUP and MUNE for application of the technique to the BB (Table 4.3).  
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However, only moderate levels of reliability were found for maximum CMAP, likely 
attributable in large part to the challenges associated with stimulation of the 
musculocutaneous nerve.  The relatively deep position of this nerve, in conjunction with 
its close proximity at the axilla to the median and ulnar nerves made its isolated 
stimulation difficult; issues which have been raised previously in the study of this muscle 
group.
11, 19, 20
  While steps were taken to avoid activation of these nearby nerves, any 
enduring volume conduction from their associated muscle groups would have certainly 
impacted the reliability of the results.  In addition, the high stimulation intensity and 
repeated attempts required to activate the musculocutaneous nerve in isolation often 
resulted in longer testing sessions involving more subject discomfort than for study of the 
UT.   
Based on the SEM and a 95% confidence level, it was calculated that a subject’s 
observed MUNE could vary ± 59 MUs as a result of measurement error.  It follows that 
in constructing a confidence interval, we would be 95% confident that a subject with an 
observed MUNE of 200 MUs had a true value between 141 MUs and 259 MUs.
6
  Similar 
estimations can be calculated for maximum CMAP and mean S-MUP values based on 
their SEMs.  Also, a change ≥ 83 MUs for the BB was found to exceed the threshold of 
measurement error.  While this benchmark for the recognition of change over time was 
more favorable than the MDD95 calculated for the UT, the practical challenges associated 
with the collection of a reliable maximum CMAP from the BB likely outweigh this 
benefit.  Apart from the maximum CMAP, the reliability results were very similar for 
application of the technique to the UT and BB.  Thus, study of the UT seems to be more 
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advantageous; while retaining the benefits associated with the study of a proximal muscle 
group, it is innervated by a superficial, easily accessible nerve supply.             
4.3.3 Comparison of upper trapezius data between ALS and control subjects  
The comparison of data between subject groups revealed MUNE values that were 
significantly lower in subjects with ALS.  This ability of DE-STA MUNE to define the 
underlying pathophysiology of the disease resulted from its detection of significant 
differences from control subjects for each of the components of the equation (Figure 4.2).  
Collateral reinnervation, and the associated increase in the innervation ratios of surviving 
MUs,
21
 was reflected in the findings of significantly larger mean S-MUP values for 
subjects with ALS (Figure 4.2B).  Initially, this compensatory process is sufficient to 
maintain maximum CMAP amplitude and clinical muscle strength at levels that are 
normal or close to normal.
1, 22, 23
  However, with the eventual outpacing of reinnervation 
by denervation, progressive muscular atrophy and weakness occur, associated with a 
diminished maximum CMAP, as was seen in the results (Figure 4.2A).
23, 24
  These 
findings of a reduced maximum CMAP, increased mean S-MUP and reduced MUNE in 
the UT in subjects with ALS are consistent with results from previous studies using other 
MUNE techniques in various muscle groups.
16, 25, 26
   
The subjects in this study demonstrated varying levels of disease involvement for 
both the UT and BB muscle groups.  This was evident in the high degree of between-
subject variability for maximum CMAP, mean S-MUP and MUNE values for both 
muscle groups (Tables 4.2, 4.3), and was in keeping with the findings of a previous study 
of DE-STA MUNE in subjects with ALS.
8
  To illustrate using the present data from the 
UT, some subjects demonstrated values for all three parameters that were within the 
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range of control values previously reported (Chapter 3), while other subjects displayed 
signs of effective collateral reinnervation, with an enlarged mean S-MUP size 
maintaining a normal (or nearly normal) maximum CMAP level in the face of a 
substantially reduced complement of MUs.  For example, the mean S-MUP for one 
subject was 200 µV, with an estimated 27 MUs producing a maximum CMAP of 5.5 mV 
(lower limit for control subjects was 6.1 mV) (Chapter 3).  The level of variability 
between subjects with ALS was particularly high for mean S-MUP values, emphasizing 
differing stages of the subjects’ MU pools in the dynamic process of collateral 
reinnervation (Figure 4.2B).   
While the frequency distribution of S-MUP sizes from the UT in subjects with 
ALS was similar to that previously reported for control subjects (Chapter 3) in that both 
were unimodal and positively skewed toward small S-MUPs, it differed from the control 
distribution in that it revealed a much greater proportion of large S-MUPs (Figure 4.1C).  
Consistent with the mean S-MUP results, this is once again reflective of collateral 
reinnervation.  These findings are consistent with numerous studies of MUNE techniques 
comparing S-MUP frequency distributions between control subjects and subjects with 
ALS in various muscle groups.
1, 17, 23, 25, 27
  
As established electrophysiological signs of chronic denervation, increases in 
MUP amplitude, duration and the number of polyphasic potentials are known to be 
associated with ALS.
12, 28
  An additional sign of LMN loss in ALS is an increase in MU 
discharge frequency.
12
  Comparing the results to control data (Chapter 3), such 
neurogenic changes reflective of collateral reinnervation were identified with respect to 
increased MUP peak-to-peak voltage and duration, and a statistical trend toward larger 
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area (a measure related to these two parameters).  While it was anticipated that subjects 
with ALS would have exhibited a higher mean MU firing rate, the negative influence of 
upper motor neuron loss on the descending drive necessary for rate coding may have 
played a role in these non-significant findings.
12, 29
 
The only other study to compare DE-STA MUNE results between subjects with 
ALS and control subjects was applied to the BB and first dorsal interosseous.
8
  Consistent 
with the present results, the study found significantly lower maximum CMAP and 
MUNE values across both muscle groups for subjects with ALS.  While they did not find 
the same significant difference between groups for mean S-MUP values, they did also 
report a higher proportion of large-amplitude S-MUPs for subjects with ALS.  Consistent 
with the literature
28, 30
 and the present results, their study found subjects with ALS to 
have MUPs with significantly larger amplitudes and longer durations.  However, 
consistent with the present data, complexity and firing rate values were not significantly 
different between groups.  It may be of interest to compare each measure of MUP 
morphology between groups in larger studies of the technique to determine whether these 
findings are replicable or stem from an issue of sample size.    
4.3.4 Limitations and future study   
 This study was limited in sample size to those patients who were well enough to 
participate in a research study, and had sufficient remaining UE strength (although this 
was less of an issue).  Despite the challenges associated with recruitment in this disease 
population, the sample size for each component of the study was similar to that of 
previous studies of the technique in control subjects.
7, 8
  Given the multicenter nature of 
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the majority of ALS clinical trials, future study should evaluate the inter-rater reliability 
of the technique as applied to subjects with ALS.    
4.3.5 Summary  
The results of this study demonstrate that DE-STA MUNE and quantitative MUP 
analysis is capable of producing reliable results in subjects with ALS and detecting the 
underlying pathophysiology of the disease.  Taken together with some advantages of DE-
STA MUNE over other available MUNE techniques, these results suggest promise for its 
use an outcome measure.   
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CHAPTER 5 
SENSITIVITY TO CHANGE OF DECOMPOSITION-ENHANCED SPIKE-
TRIGGERED AVERAGING MOTOR UNIT NUMBER ESTIMATION IN 
SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS 
5.0 INTRODUCTION   
 Outcome measure selection is a critical component of amyotrophic lateral 
sclerosis (ALS) clinical trial design.  Motor unit number estimation (MUNE) is unique in 
its ability to measure motor unit (MU) loss and the effects of collateral reinnervation 
directly, making it an advantageous choice for use as an outcome measure in clinical 
trials.
1
     
Despite these advantages, the use of MUNE in ALS clinical trials has been 
limited (Chapter 2).  The trials that have incorporated MUNE have employed manual 
incremental stimulation,
2, 3
 spike-triggered averaging,
4
 and modified versions of the 
statistical method.
5, 6
  The use of the statistical method met with technical challenges as a 
result of MU instability, prompting the conclusion that the technique was unsuitable for 
application to this patient population.
6
  In selecting from the other available MUNE 
techniques, decomposition-enhanced spike-triggered averaging (DE-STA) MUNE is a 
relatively new method that offers a number of advantages (previously discussed in 
Chapters 1, 3, 4), making it promising for use as an outcome measure.
7, 8
  
 An important property of any outcome measure is sensitivity to change, which is 
the ability of an instrument to detect minimal change over time, and thus monitor the 
potential efficacy of an intervention.
9
  Longitudinal studies of the sensitivity to change of 
MUNE in comparison with various outcome measures have been conducted.  These have 
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involved evaluations of multiple point stimulation,
10, 11
 the statistical method,
12
 manual 
incremental stimulation,
13-15
 and less common techniques such as the microstimulation 
method
16
 and high-density MUNE.
17
     
A cross-sectional study by Boe et al. (2009)
18
 compared DE-STA MUNE and 
motor unit potential (MUP) peak-to-peak voltage results from the first dorsal interosseous 
and biceps brachii, maximal voluntary isometric contractions (MVICs) for each of these 
muscle groups, a modified form of the Tufts Quantitative Neuromuscular Exam, forced 
vital capacity (FVC), and the Revised Amyotrophic Lateral Sclerosis Functional Rating 
Scale (ALSFRS-R) in subjects with ALS to normative results for the same measures.  
The study found DE-STA MUNE in both muscle groups to differ more from control 
values than almost all of the clinical outcome measures, reflecting the ability of the 
technique to detect underlying pathophysiological features of the disease despite better-
preserved functional performance.  However, a longitudinal study allowing for a 
comparison of the sensitivity to change between DE-STA MUNE and clinical outcome 
measures in subjects with ALS has yet to be undertaken.       
The study of any MUNE technique requires the selection of one or more muscle 
groups for evaluation.  Application of DE-STA MUNE to the upper trapezius (UT) is an 
appealing choice given the potential clinical relevance of studying a muscle related to 
respiratory function, and the practical nature of the data collection protocol (Chapters 3, 
4).
19
  As a proximal muscle, its examination would also be novel, as each of the 
previously mentioned longitudinal studies of MUNE utilized techniques that restricted 
their evaluations to distal muscle groups of the hands and feet.  Apart from the BB, the 
UT is also the only muscle for which the intra-rater reliability of DE-STA MUNE has 
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been established in subjects with ALS (Chapter 4).  Additionally, the technique as 
applied to the UT has been shown to detect the underlying pathophysiology of the disease 
(Chapter 4).   
In comparing the sensitivity to change of DE-STA MUNE in the UT with clinical 
outcome measures, it would be valuable to select from measures of muscle strength, 
measures of pulmonary function, and functional rating scales, which are the most 
commonly used types of outcome measures in ALS clinical trials (Chapter 2).   
Manual muscle testing (MMT) assesses muscle strength in terms of a patient’s 
ability to move against gravity and contract against the evaluator’s manual resistance,20 
and is one of the most commonly used secondary outcome measures in ALS clinical trials 
(Chapter 2).  Another technique for the assessment of muscle strength is hand-held 
dynamometry (HHD), which involves the quantification of the force generated by an 
MVIC against a portable electronic dynamometer held by the evaluator.  Both MMT and 
HHD are simple, inexpensive, and efficient measures of muscle strength
21
 that can be 
used to assess the strength of scapular elevation, in which the UT is involved.  It may be 
useful to compare the sensitivity to change of DE-STA MUNE in the UT to that of the 
strength of scapular elevation, in addition to other upper extremity (UE) muscle groups.     
With respect to measures of pulmonary function, FVC assesses the volume of air 
exhaled from total lung capacity using a portable, standard spirometer.
22
  FVC was found 
to be the most frequently used secondary outcome measure in a review of ALS clinical 
trials (Chapter 2).  In contrast, sniff nasal inspiratory pressure (SNIP) is a relatively novel 
measurement technique that assesses the pressure generated by a subject’s maximal short, 
sharp, sniffing maneuver.  SNIP avoids the challenges associated with the use of a 
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mouthpiece related to bulbar or facial weakness, and has a protocol that is generally 
natural and simple for subjects to perform.
23, 24
  Lastly, the ALSFRS-R is a disease-
specific functional rating scale that assesses activities of daily living
25
 and is used 
frequently as a primary and secondary outcome measure in ALS clinical trials (Chapter 
2).   
The purpose of this study was to compare the sensitivity to change of DE-STA 
MUNE and quantitative MUP analysis in the UT to that of various clinical outcome 
measures in subjects with ALS.  More specifically, to make comparisons with MMT in 
five UE muscle groups, scapular elevation and elbow flexion peak force measured using 
HHD, FVC, SNIP, and the ALSFRS-R.     
5.1 METHODS 
5.1.1 Subjects 
Ten patients diagnosed with clinically probable or definite ALS as defined by the 
revised El Escorial criteria
26
 were recruited from the Motor Neuron Diseases Clinic at 
University Hospital, London Health Sciences Centre to participate in this study.  Patients 
were included if they were between the ages of 18-90, were within 10 years of symptom 
onset, and were judged as having sufficient UE strength to perform the MUNE protocol.  
Patients were excluded if they had evidence of other neuromuscular or musculoskeletal 
disease.  All subjects gave written, informed consent in accordance with The University 
of Western Ontario Health Sciences Research Ethics Board, which approved this study.    
5.1.2 Experimental protocol 
Subjects were assessed at baseline (T0), 2 (T2), 4 (T4) and 6 (T6) month time 
points.  Expressed differently, they were assessed at baseline (T0), approximately 56 days 
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(T2), 112 days (T4), and 168 days (T6).  At each time point, subjects completed 
assessments in the following sequence (with few exceptions): MMT, HHD, MUNE, 
FVC, SNIP, and ALSFRS-R, and were given the opportunity to rest between tests.  
Muscle strength and MUNE assessments were conducted unilaterally on the arm 
identified by the subject at T0 as having less weakness in order to best facilitate 
longitudinal evaluations.
10, 11, 27
  If the subject was unable to determine which arm was 
stronger, the right arm was selected.  Tests either required subjects to be seated upright in 
a straight back chair or wheelchair or, for HHD and portions of MMT testing, supine on 
an examination table with one pillow elevating their head.  If subjects were unable to 
tolerate the supine position, they were positioned in a semi-reclined position, or the test 
was modified to be performed from a seated position.    
5.1.2.1 Manual muscle testing  
Muscle strength was assessed with MMT for five UE muscle groups.  Scapular 
elevation, shoulder abduction, elbow flexion, wrist extension and elbow extension were 
tested.  The muscle groups were graded from 0-5 using a modification of the Medical 
Research Council grading scale,
20
 with 0 representing paralysis and 5 representing 
normal strength (Appendix B).  Previously standardized protocols were followed for each 
muscle group
28
 with the exception of scapular elevation, for which a protocol was derived 
with the assistance of the Motor Neuron Diseases Clinic physical therapist and ALS 
clinical trials site evaluator.     
Muscle groups were tested in a consistent sequence, with the number of required 
position changes minimized by completing any testing requiring a seated position first, 
followed by testing in the supine position.  For each muscle group, the movement was 
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demonstrated and the subject instructed to attempt the same movement through their full 
range of motion, following which the evaluator applied force in the opposite direction.  If 
necessary, the muscle group was also tested in its alternate, gravity-eliminated position.  
Next, for the purpose of calculating a final MMT score, the grade assigned to each 
muscle group was converted to a 10-point version of the Medical Research Council 
grading scale and these grades summed across muscle groups to yield a total value out of 
50.  
5.1.2.2 Hand-held dynamometry  
Muscle strength was also measured quantitatively using a MicroFET 2
™ 
HHD 
(HOGGAN Health Industries, West Jordan, UT) to assess the peak force generated by 
scapular elevation and elbow flexion.  Prior to testing, the HHD was calibrated, and 
subjects positioned supine with their arms at their sides on an examination table which 
was elevated to the evaluator’s hip level.  A curved transducer pad was utilized for both 
muscle groups, and the HHD was set to ‘low’ threshold.   
Scapular elevation was assessed first for each study visit, with the subject 
instructed to elevate their shoulder partially, and the HHD held by the evaluator just 
proximal to the acromioclavicular joint.  To assess elbow flexion, the subject’s arm was 
positioned in 90 degrees of elbow flexion, with the upper arm in contact with the 
examination table and the forearm in neutral position.  The transducer pad of the HHD 
was held by the examiner on the radial surface of the forearm, just proximal to the radial 
styloid process.   
For both muscle groups, the subject was instructed to hold a maximal voluntary 
contraction against the HHD, while the evaluator applied matching force in the opposite 
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direction, simultaneously providing subject encouragement.  After matching the subject’s 
level of force for at least 2 s, the evaluator increased the force of resistance to attempt to 
break the contraction.  The resulting peak force value on the HHD in pounds was 
recorded and note was made as to whether the contraction was broken.  If it was 
suspected that pain was an important contributing factor in breaking the contraction, this 
was also noted.  Following a brief rest period, the protocol was repeated.  A third trial 
was performed if the percentage difference between the first two tests was greater than 
15% (Equation 1).  Lastly, the maximum peak force value from the greatest two trials 
demonstrating a percentage difference of less than 15% was recorded as the subject’s 
result.
29
 
5.1.2.3 Equation 1 
% difference = ([maximum value – minimum value]/maximum value)*100    
5.1.2.4 Motor unit number estimation  
Electromyographic (EMG) signals were acquired using decomposition-based 
quantitative electromyography (DQEMG) (version 3.2) and Acquire EMG software on a 
Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX).  Data collection was 
performed by one evaluator (C.I.), with the exception of one subject at one time point, for 
whom another evaluator (T.D.) completed the protocol.  Self-adhering Silver Mactrode
® 
electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface signals, 
and 25 mm x 30 gauge TECA
™
 elite Disposable Concentric Needle Electrodes 
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass 
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.
7, 30
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Surface electrodes were cut in strips (1 cm x 3.5 cm) for use as the active and 
reference electrodes, with a full-sized electrode serving as a ground.  The skin was 
cleansed with isopropyl alcohol and surface electrodes positioned appropriately.  The 
active electrode was positioned transversely over the belly of the muscle, approximately 
midway between the acromion process and C7 spinous process, with the reference 
electrode placed over the acromion process, and the ground electrode over the deltoid.
19
    
A handheld bipolar stimulator was used in order to elicit a maximum compound 
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to 
the sternocleidomastoid.
19
  If necessary, the active electrode was moved in small 
increments to a position where the CMAP negative peak amplitude was maximized and 
the rise time minimized.  Following optimal positioning of the active electrode, the 
surface electrode positions were reinforced with surgical tape to ensure that no movement 
occurred during the study.  Gradually, the stimulation intensity was increased until the 
CMAP negative peak amplitude reached a plateau.  Automatically positioned markers 
indicating onset, negative peak, positive peak, and end of the maximum CMAP were 
reviewed and manually adjusted if necessary.  Subsequently, size-related parameters of 
the maximum CMAP including negative peak amplitude were calculated automatically.      
Following the determination of the maximal voluntary contraction-root mean 
square (MVC-RMS) (described in Chapter 3), the concentric needle electrode was 
inserted into the UT, approximately 2-10 mm proximal or distal to the active surface 
electrode.  Subjects were asked to perform minimal isometric contractions while an 
optimal needle position was located that minimized the rise times of the MUPs of the first 
two to three recruited MUs.  With the needle manually maintained in this position by the 
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evaluator, the subject was instructed to increase the contraction force to approximately 
10-20% of the MVC-RMS.  Each sub-maximal isometric contraction was maintained for 
30 s, during which the subject received visual and auditory feedback from the EMG 
signal and % MVC-RMS information displayed on the screen to assist in the maintenance 
of a stable contraction.  Contractions were performed until a minimum of 20 MUP trains 
were collected, with each contraction separated by a rest period of approximately 30-60 s, 
or as required by the subject.  The needle position was adjusted between contractions to 
collect data from different portions of the muscle, and, if necessary, inserted at a new site 
to complete the collection of MUP trains.
7, 30
 
Following EMG signal decomposition and the review of the acceptability of 
acquired MUPs, surface-detected motor unit potentials (S-MUPs), and MUP trains, as has 
been previously described (Chapters 1, 3), the onset, positive peak, negative peak, and 
end markers of the MUP templates and the negative onset, negative peak, and positive 
peak markers of the S-MUP templates were checked visually and repositioned if 
necessary.      
Descriptive statistics for various parameters were calculated automatically based 
on all accepted MUPs, S-MUPs, and MUP trains.  Additionally, the mean S-MUP was 
calculated by way of data point-by-data point averaging all accepted S-MUPs, aligned 
based on their onsets.  Lastly, the MUNE was calculated automatically through division 
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of 
the maximum CMAP previously obtained (Equation 2).
7
  MUNE, maximum CMAP, 
mean S-MUP, and MUP peak-to-peak voltage values were recorded for each subject. 
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5.1.2.5 Equation 2 
MUNE = maximum CMAP size      
       mean S-MUP size 
 
Where MUNE, motor unit number estimate; CMAP, compound muscle action potential; 
S-MUP, surface-detected motor unit potential.   
5.1.2.6 Forced vital capacity  
FVC was assessed using a Renaissance
®
 II Spirometry System (Puritan 
Bennett™, Boulder, CO), which was calibrated prior to each study visit.  A disposable, 
single-patient use FSII Flow Sensor pneumotach (Puritan Bennett™, Boulder, CO) was 
attached, and a determination made prior to or during the initial trial as to whether the 
subject was able to form a tight lip seal around the pneumotach or required an alternate 
mouthpiece (VacuMed, Ventura, CA) attached with an adaptor.  Having set up the 
mouthpiece, the subject’s nose clip was positioned and the flow sensor zeroed.   
The flow sensor was held by the evaluator or subject and, with a seal around the 
mouthpiece, the subject was instructed to inhale maximally, subsequently exhaling 
forcefully and fully by continuing for as long as possible.  Encouragement was provided 
to each subject during every trial.  The result of the trial was recorded in liters and, 
following a brief rest period, the protocol repeated.  A minimum of three trials were 
conducted for each subject, and if the percentage difference between the two highest 
trials was greater than 10%, or one or more trials were considered unacceptable due to 
deviations from the protocol, additional trials were performed up to a maximum of five 
trials.  Trial results were printed and the maximum value from the two highest acceptable 
trials demonstrating a percentage difference of less than 10% was recorded as the 
subject’s result.  Both the raw value (L) and percentage of the subject’s predicted FVC 
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based on height, age, and sex (calculated automatically) were documented for this final 
value.  If a mouthpiece attachment was employed, it was used at all future time points for 
that subject.
29
 
5.1.2.7 Sniff nasal inspiratory pressure  
A pressure transducer was fashioned in line with the methods of previous 
studies.
23, 24
  A silicone ear plug (PharmaSystems uSwim soft silicone Ear Plugs, 
Toronto, ON) was formed around the tip of a 100 cm piece of polyethylene tubing (I.D. 
1.14 mm [0.045”], O.D. 1.57 mm [0.062”]) (Intramedic™, Sparks, MD) which was 
connected to a manometer (120 cm H2O maximum pressure).  A new silicone plug was 
used at each study visit, while the tubing was recycled for each subject.  A small piece of 
silicone was used to seal the point of entry of the tubing into the manometer.  The 
manometer was calibrated in our institution’s pulmonary function department prior to the 
onset of this study.     
The evaluator formed an appropriate amount of silicone around the tip of the 
tubing for the subject’s nostril size, which was inserted into one nostril.  The right nostril 
or the nostril without obstruction (according to the subject) was tested, and the same 
nostril tested at each time point.  In order to check that a proper seal had been made, the 
subject’s other nostril was closed manually and a sniff performed.  If any air leakage was 
noted, adjustments to the size of the plug were made.  Finally, the manometer was 
positioned flat on a table and its dial set to 0 cm H2O.   
Subjects were instructed to perform 10 maximal short, sharp sniffing maneuvers 
through their open nostril with their mouth closed, starting from the lung volume attained 
following exhalation of a quiet breath with their mouth closed (functional residual 
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capacity).  Feedback was provided by the evaluator, and each sniff was separated by 
approximately 5-30 s.  If the 10
th
 trial provided the highest value, additional trials were 
performed until no further increase was noted.  All maneuvers were recorded in cm H2O, 
and the highest value was taken as the subject’s result.23, 24   
5.1.2.8 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale 
Completion of the ALSFRS-R was performed according to standardized 
guidelines.
29, 31
  The questionnaire was prefaced at each study visit by stating: “I am 
going to ask you the questions on the ALS functional rating scale about how you are 
currently functioning at home.  The ALS functional rating scale compares how you are 
doing today versus prior to having any signs or symptoms of ALS”.  Questions were 
asked of the subject, but if the subject was unable to communicate their response or 
understand the question, an informant (spouse or other caregiver) was used for 
assistance.
32
  Subject responses to each of the 12 questions were recorded to the closest 
available score from 0-4, with each response clarified through further probing to ensure a 
higher or lower score was not more appropriate.  A total possible score ranging from 0 
(unable to attempt any task) to 48 (normal function) was recorded (Appendix C).
25
       
5.1.3 Evaluator training and reliability assessment 
Each outcome measure was assessed by one evaluator (C.I.) trained in MMT, 
HHD, FVC and ALSFRS-R evaluation by the Motor Neuron Diseases Clinic physical 
therapist.  Additional training in the performance of the ALSFRS-R was obtained through 
a DVD of standard patient vignettes.
31
  The evaluator had been previously trained in data 
collection and analysis for DE-STA MUNE by an individual experienced with the 
technique (T.D.).   
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To ensure that the evaluator was able to obtain reliable results in the performance 
of these outcome measures, the study included a variety of assessments of intra- and 
inter-rater reliability in control subjects prior to the beginning of the study, and in a 
subset of subjects with ALS at T0.  For each assessment, the protocols outlined above 
were followed.     
5.1.3.1 Manual muscle testing  
 An examination of the inter-rater reliability of MMT was performed in subjects 
with ALS, with the clinic physical therapist acting as the second evaluator.  For each 
subject, grades were compared for each muscle group with the goal of achieving perfect 
agreement between evaluators for at least four of the muscle groups, with a difference in 
the summed total score (max. 50) of no greater than 2 points.  If this level of agreement 
was not attained, the experienced evaluator offered feedback, and additional subjects 
were tested until acceptable results were obtained for two subjects.  
5.1.3.2 Hand-held dynamometry  
 Intra-rater reliability of HHD was assessed and subsequently confirmed in two 
control subjects and two subjects with ALS, with the protocol performed twice for both 
scapular elevation and elbow flexion.  Assessments were performed on the same day for 
each subject and separated by a minimum of 1 hr.  The accepted maximum peak force 
values from each assessment were compared and the percentage difference was required 
to fall below 15% for each muscle group.   
5.1.3.3 Forced vital capacity and sniff nasal inspiratory pressure 
 Intra-rater reliability of FVC and SNIP was assessed and subsequently confirmed 
in two control subjects each, with each protocol performed twice on the same day and 
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separated by a minimum of 1 hr.  The percentage difference between the accepted values 
from each FVC assessment was required to fall below 10%, and SNIP below 15%.   
5.1.3.4 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale 
The intra-rater reliability of assessments using the ALSFRS-R was established 
through the comparison of initial scoring based on interviews conducted in two standard 
patient vignettes with the re-scoring of these vignettes 1 month later.
31
  Inter-rater 
reliability was established through comparison of the initial scoring with scoring of these 
same vignettes by the clinic physical therapist.  Acceptable reliability involved no more 
than a 1 point difference on any single question, and no more than a 2 point difference in 
the total score, which subsequently was achieved.
29
  
5.1.4 Statistics 
For each outcome measure, all statistical analyses were performed on the data of 
those subjects who had complete T0 and T6 results.  Descriptive statistics were also 
calculated for each outcome measure based on the subjects who had complete data across 
all time points.  To facilitate statistical and graphical analyses, change scores (Equation 
3) and percentage change values (Equation 4) were calculated for each subject with 
complete T0 and T6 data for a given outcome measure.  For each change score and 
percentage change value, negative values denote decline in the outcome measure.  
5.1.4.1 Equation 3 
Change score = (T6 – T0)         
5.1.4.2 Equation 4 
Percentage change = ([T6 – T0]/T0) * 100          
Where T6, 6 month value; T0, baseline value. 
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To test for differences within each outcome measure from T0 to T6, a two-tailed, 
paired t-test was used, with the exception of the ordinal variables (MMT and ALSFRS-
R), for which a two-tailed Wilcoxon signed-ranks test was performed.
9
  An a priori alpha 
level of 0.05 was used to denote significance.  As the purpose of this study was 
exploratory in nature, a Bonferroni adjustment was not applied.   
To facilitate an evaluation of the relative sensitivities to change of the outcome 
measures under study, a unitless index was used.  A standardized response mean (SRM) 
was calculated for each outcome measure (Equation 5),
33
 with larger absolute values 
representing a larger magnitude of change.  Cohen’s criteria for effect sizes were used to 
interpret the calculated SRMs: a value of 0.20 was considered small, 0.50 considered 
moderate, and 0.80 considered large.
33, 34
   
5.1.4.3 Equation 5  
SRM = change / schange         
Where SRM, standardized response mean; change, mean change score; schange, standard 
deviation of change scores. 
All statistical analyses were performed using GraphPad Prism
®
 4.02 (GraphPad 
Software, Inc., San Diego, CA), with the exception of the Wilcoxon signed-ranks test, for 
which IBM
®
 SPSS
®
 Statistics 19 (SPSS, Inc., Chicago, IL) was used.  
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5.2 RESULTS 
5.2.1 Subjects 
A summary of subject demographic and clinical characteristics is found in Table 
5.1. 
5.2.2 Missing data  
Three subjects were lost to follow-up in this study.  One subject died after their T2 
study visit, one was not well enough to return for subsequent visits following their T2 
study visit, and one subject was unable to attend their T6 study visit for reasons unrelated 
to their health.  The only other missing data point for the majority of outcome measures 
was for one subject who was unable to attend their T2 study visit for reasons unrelated to 
their health.  Additional missing data was encountered for FVC and SNIP, related to the 
inability of one subject with frontotemporal dementia to follow instructions for either 
measure at all 4 time points, and for one subject with possible cognitive deficits to follow 
the instructions to perform an FVC at their final study visit (T2).  
Lastly, a single muscle group was not assessed for various reasons for three MMT 
total scores.  In these cases, the last observation for the muscle group was carried forward 
as a conservative estimate of change, in order to avoid the loss of the entire MMT score.   
5.2.3 Hand-held dynamometry data collection 
For scapular elevation, the contraction was broken for only one subject at a single 
time point (T0), and pain during the contraction was likely an important contributing 
factor.  For elbow flexion, six subjects’ contractions were broken at every time point that 
they were assessed, two subjects that were able to maintain contractions at initial time 
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point(s) had their contractions broken at later time point(s), and two subjects’ 
contractions were not broken at any time point that they were assessed. 
With respect to deviations from the protocol, two subjects were unable to be 
tested in a supine position at their final time point, and instead were assessed in a seated 
position.  For one subject at a single time point, the maximum peak force value recorded 
for elbow flexion demonstrated a percentage difference greater than 15% (24%) from the 
other trial performed (only two trials were conducted), in part contributed to by the small 
absolute nature of the values (3.4 lb [trial 1], 2.6 lb [trial 2]).  Lastly, for the assessment 
of elbow flexion for one subject at T2, T4, and T6, the dynamometer was repositioned to 
be in contact with the volar forearm, avoiding pain caused by positioning on the radial 
surface of the forearm.   
5.2.4 Results of data analysis  
With respect to electrophysiological indices, no significant differences between T0 
and T6 were found for MUNE t(6) = -1.66, p = 0.15 (-110.10, 21.28), maximum CMAP 
t(6) = 0.43, p = 0.68 (-1.32, 1.90), mean S-MUP t(6) = 0.57, p = 0.59 (-51.05, 82.19), or 
MUP peak-to-peak voltage t(6) = 1.81, p = 0.12 (-180.9, 1209) (Table 5.2, Figure 5.1).  
Similarly, for measures of muscle strength, no significant differences between T0 and T6 
were found for MMT (z = -1.70, p = 0.089), HHD – scapular elevation t(6) = -1.64, p = 
0.15 (-14.26, 2.81), or HHD – elbow flexion t(6) = -2.11, p = 0.079 (-15.91, 1.16) (Table 
5.2, Figure 5.2).  Lastly, for measures of pulmonary function, no significant differences 
between T0 and T6 were found for FVC t(5) = -1.94, p = 0.11 (-1.25, 0.18) or SNIP t(5) = 
0.28, p = 0.79 (-16.24, 20.24) (Table 5.2, Figure 5.3).  The only outcome measure for 
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which there was a significant difference between T0 and T6 was ALSFRS-R, for which 
there was a significant decrease over time (z = -2.12, p = 0.034) (Table 5.2, Figure 5.3C).   
ALSFRS-R was found to have the largest absolute SRM, followed in decreasing 
order by MMT, HHD – elbow flexion, and FVC, which each also had large SRMs.  
Moderate SRMs (from highest to lowest) were found for MUP peak-to-peak voltage, 
MUNE, and HHD – scapular elevation.  Small SRMs (from highest to lowest) were 
found for mean S-MUP, maximum CMAP, and SNIP.  Positive SRMs were found for 
MUP peak-to-peak voltage, mean S-MUP, SNIP, and maximum CMAP (indicative of an 
increase from T0 to T6) and negative SRMs were found for each of the other outcome 
measures (indicative of a decrease from T0 to T6) (Table 5.2).       
The greatest absolute mean percentage change from T0 to T6 was found for MUP 
peak-to-peak voltage, followed in decreasing order by mean S-MUP, SNIP, HHD – 
elbow flexion, ALSFRS-R, MMT, FVC, MUNE, HHD – scapular elevation, and 
maximum CMAP.  Consistent with the SRM results, MUP peak-to-peak voltage, mean S-
MUP, SNIP, and maximum CMAP increased from T0 to T6 while each of the other 
outcome measures decreased from T0 to T6 on average (Table 5.2).       
On average, 18 ± 6 and 15 ± 6 acceptable S-MUPs were obtained (from 36 ± 14 
and 45 ± 25 MUP trains collected in total) for each subject at T0 and T6, respectively.  
These S-MUPs were obtained from 6 ± 2 contractions at T0 and 6 ± 1 contractions at T6.  
Thus, on average, 3 ± 2 acceptable S-MUPs per contraction were collected at both time 
points.  The mean MU identification rates (percentage of expected firings detected) based 
on the samples of accepted MUP trains were 58 ± 5% at T0 and 59 ± 11% at T6.  The 
frequency distributions of S-MUP negative peak amplitudes, as a percentage of 
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maximum CMAP negative peak amplitudes from T0 (1.88 ± 2.10 % maximum CMAP 
[0.09-8.10 % maximum CMAP]) and T6 (2.06 ± 3.29 % maximum CMAP [0.16-16.14 
maximum CMAP]) are illustrated in Figure 5.4.     
Descriptive statistics for each outcome measure based on the subjects who had 
complete data across all time points are found in Table 5.3.  A consistent increase across 
time points in the mean value of the outcome measure was seen for MUP peak-to-peak 
voltage, and a consistent decrease across time points in the mean value of the outcome 
measure was seen for MMT, HHD – elbow flexion, and the ALSFRS-R.     
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Table 5.1 Subject demographics and clinical summary at T0  
 
Variable All subjects (n = 10) 
Age (years) 62 ± 7 (53-75) 
Sex   7 male, 3 female 
Height (cm) 173 ± 9 (160-187) 
Weight (kg) 86.8 ± 20.2 (59.4-124.0) 
Time from symptom onset (months) 27 ± 18 (4-61) 
Area of onset  1 bulbar, 9 limb (8 UE, 1 LE) 
ALS classification  9 sALS, 1 fALS 
Side of muscle testing 4 left, 6 right 
Time from T0 (days) T2:  59 ± 3 (55-64) 
T4:  109 ± 9 (98-129) 
T6:  175 ± 10 (161-189) 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Abbreviations:  ALS, amyotrophic lateral sclerosis; fALS, familial amyotrophic lateral 
sclerosis; LE, lower extremity; sALS, sporadic amyotrophic lateral sclerosis; T0, 
baseline; T2, 2 month time point, T4, 4 month time point; T6, 6 month time point; UE, 
upper extremity. 
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Table 5.2 Longitudinal change in outcome measures for those subjects with complete T0 
and T6 data   
 
Outcome measure n T0 T6 Mean % change SRM 
MUNE (MUs) 7 159 ± 133 
(19-387) 
115 ± 81 
(13-228) 
-10.9 ± 57.9 
(-63.9 to 94.7) 
-0.63  
Maximum CMAP  
neg. peak amp. (mV) 
7 5.9 ± 2.8 
(3.1-11.2) 
6.2 ± 2.6 
(2.9-9.5) 
7.6 ± 23.5  
(-26.8 to 40.0)  
0.16  
Mean S-MUP  
neg. peak amp. (µV) 
7 68 ± 67 
(29-214) 
83 ± 61 
(36-211) 
55.2 ± 71.5 
(-54.2 to 151.2) 
0.22  
MUP  
peak-to-peak voltage 
(µV) 
7 575.4 ± 105.4 
(503.6-742.4) 
1089.2 ± 756.2 
(528.6-2642.5) 
91.3 ± 139.1 
(4.0 to 395.2) 
0.68  
MMT score  
(max. 50) 
7 35 ± 11 
(22-47) 
30 ± 15 
(11-46) 
-18.2 ± 21.4  
(-56.0 to 2.6) 
-0.87  
HHD – Scapular 
elevation  
peak force (lb) 
7 46.3 ± 8.9 
(36.6-57.9) 
40.6 ± 5.0 
(35.5-47.0) 
-9.8 ± 19.4  
(-33.9 to 26.0) 
-0.62  
HHD – Elbow flexion  
peak force (lb) 
7 27.1 ± 21.4  
(2.8-59.2) 
19.7 ± 14.6  
(0.0-35.5) 
-29.9 ± 39.3  
(-100.0 to 26.9) 
-0.80  
FVC (L) 
 
6 3.32 ± 1.04 
(2.09-5.08) 
2.78 ± 0.47 
(2.41-3.67) 
-12.3 ± 17.9  
(-34.1 to 15.3) 
-0.79  
SNIP (cm H2O) 
 
6 37 ± 27 
(11-85) 
39 ± 16 
(13-59) 
40.7 ± 106.1 
(-30.6 to 254.6) 
0.12  
ALSFRS-R score  
(max. 48) 
7 32 ± 8 
(18-44) 
26 ± 10
*
 
(15-42) 
-20.6 ± 17.1  
(-41.2 to 5.6) 
-1.11  
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Mean % change based on % change averaged across all subjects.   
*
 Significantly different from T0 (p < 0.05).   
Abbreviations:  ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating 
Scale; CMAP, compound muscle action potential; FVC, forced vital capacity; HHD, 
hand-held dynamometry; MMT, manual muscle testing; MU, motor unit; MUNE, motor 
unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak 
amplitude; S-MUP, surface-detected motor unit potential; SNIP, sniff nasal inspiratory 
pressure; SRM, standardized response mean; T0, baseline; T6, 6 month time point.   
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Figure 5.1 Comparison between T0 and T6 for each electrophysiological outcome 
measure.   Data is presented for those subjects with complete T0 and T6 data (n = 7 for 
each outcome measure).  The x-axis for each graph represents the time point.  MUNE (p 
= 0.15) (A), maximum CMAP (p = 0.68) (B), mean S-MUP (p = 0.59) (C), and MUP 
peak-to-peak voltage (p = 0.12) (D).   
Abbreviations:  CMAP, compound muscle action potential; MU, motor unit; MUNE, 
motor unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak 
amplitude; ns, not significant; S-MUP, surface-detected motor unit potential; T0, 
baseline; T6, 6 month time point.  
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Figure 5.2 Comparison between T0 and T6 for each measure of muscle strength.  Data is 
presented for those subjects with complete T0 and T6 data (n = 7 for each outcome 
measure).  MMT (p = 0.089) (A), HHD – scapular elevation (p = 0.15) (B), and HHD – 
elbow flexion (p = 0.079) (C).   
Abbreviations:  HHD, hand-held dynamometry; MMT, manual muscle testing; ns, not 
significant; T0, baseline; T6, 6 month time point.  
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Figure 5.3 Comparison between T0 and T6 for measures of pulmonary function and the 
ALSFRS-R.  Data is presented for those subjects with complete T0 and T6 data.                
* 
indicates a significant difference between T0 and T6.  FVC (n = 6) (p = 0.11) (A), SNIP 
(n = 6) (p = 0.79) (B), and ALSFRS-R (n = 7) (p < 0.05) (C).   
Abbreviations:  ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating 
Scale; FVC, forced vital capacity; ns, not significant; SNIP, sniff nasal inspiratory 
pressure; T0, baseline; T6, 6 month time point. 
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Figure 5.4 Frequency distributions of S-MUP data comparing results between T0 (closed 
bars) (124 S-MUPs) and T6 (open bars) (103 S-MUPs) for those subjects with complete 
T0 and T6 data (n = 7, respectively).  The negative peak amplitudes of the S-MUPs have 
been normalized to the negative peak amplitude of the maximum CMAP for each subject 
at each time point.  The y-axis represents the percentage of the total number of S-MUPs 
per time point.   
Abbreviations:  CMAP, compound muscle action potential; S-MUP, surface-detected 
motor unit potential; T0, baseline; T6, 6 month time point.     
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Table 5.3 Longitudinal change in outcome measures for those subjects with complete data across all time points   
 
Outcome measure n T0 T2 T4 T6 
MUNE (MUs) 6 183 ± 130 
(36-387) 
159 ± 101 
(18-274) 
198 ± 172 
(26-489) 
128 ± 81 
(13-228) 
Maximum CMAP  
neg. peak amp. (mV) 
6 6.2 ± 3.0 
(3.1-11.2) 
6.6 ± 2.3 
(3.9-9.5) 
6.7 ± 2.8 
(3.5-11.2) 
6.6 ± 2.5 
(2.9-9.5) 
Mean S-MUP  
neg. peak amp. (µV) 
6 43 ± 21 
(29-84) 
69 ± 70 
(30-211) 
57 ± 42 
(23-134) 
81 ± 66 
(36-211) 
MUP peak-to-peak  
voltage (µV) 
6 582.4 ± 113.7 
(503.6-742.4) 
652.8 ± 176.0 
(502.2-987.7) 
728.1 ± 365.7 
(446.4-1440.9) 
830.3 ± 351.1 
(528.6-1508.9) 
MMT score  
(max. 50) 
6 37 ± 11 
(22-47) 
36 ± 11 
(21-45) 
34 ± 12 
(16-47) 
32 ± 15 
(11-46) 
HHD – Scapular 
elevation peak force (lb) 
6 45.7 ± 9.6 
(36.6-57.9) 
39.9 ± 5.7 
(35.3-49.9) 
40.6 ± 7.4 
(29.4-52.2) 
40.1 ± 5.3 
(35.5-47.0) 
HHD – Elbow flexion  
peak force (lb) 
6 31.1 ± 20.2 
(6.7-59.2) 
29.5 ± 19.8 
(6.7-57.1) 
24.5 ± 16.7 
(6.4-50.5) 
23.0 ± 12.8 
(6.7-35.5) 
FVC (L) 5 2.96 ± 0.65 
(2.09-3.72) 
3.01 ± 0.34 
(2.53-3.42) 
2.83 ± 0.40 
(2.20-3.16) 
2.60 ± 0.20 
(2.41-2.88) 
SNIP (cm H2O) 5 27 ± 14 
(11-40) 
29 ± 12 
(16-39) 
38 ± 14 
(17-56) 
35 ± 14 
(13-46) 
ALSFRS-R score  
(max. 48) 
6 33 ± 9 
(18-44) 
30 ± 9 
(20-42) 
29 ± 10 
(17-43) 
26 ± 11 
(15-42) 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Abbreviations:  ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; CMAP, compound muscle action 
potential; FVC, forced vital capacity; HHD, hand-held dynamometry; MMT, manual muscle testing; MU, motor unit; MUNE, motor 
unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak amplitude; S-MUP, surface-detected motor unit 
potential; SNIP, sniff nasal inspiratory pressure; T0, baseline; T2, 2 month time point; T4, 4 month time point; T6, 6 month time point.   
 
132 
 
 
5.3 DISCUSSION 
5.3.1 Overall sensitivity to change results 
The results of this study have established DE-STA MUNE as applied to the UT as 
a practical technique for monitoring the progression of ALS in the context of a 
longitudinal study.  The results demonstrated a moderate degree of sensitivity to change 
for MUNE.  However, variability in maximum CMAP, mean S-MUP and, consequently, 
MUNE values between time points indicated a need for future research regarding 
potential sources of error associated with the technique.      
The ALSFRS-R was the only outcome measure for which a significant change 
was observed from T0 to T6.  Correspondingly, this measure had the largest absolute 
SRM of any of the outcome measures, indicating that it changed by the largest 
magnitude, and thus was the most sensitive to change (Table 5.2).
33
  The magnitude of 
the decline in this outcome measure (6.29 points over 6 months) was consistent with the 
rate of change for the natural history of the disease of 0.9-1.0 points per month that has 
been commonly reported.
35
  MMT and HHD – elbow flexion, which demonstrated trends 
toward statistical significance (p < 0.10) for their changes over 6 months, were calculated 
to have the second and third largest absolute SRMs, respectively.  Alongside these 
outcome measures, FVC was the only other measure classified as having a large SRM, 
and was calculated to have a slightly higher p-value.  Continuing along these lines, 
placement of the remaining outcome measures in ascending order according to their p-
values resulted in their arrangement in descending order with respect to their SRMs, 
owing to the similarity between the paired samples t-statistic and SRM calculations.
33
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Although the differences were not statistically significant for the majority of 
outcome measures, the directions of the mean changes from T0 to T6 were consistent with 
what is known about the progression of the disease.  Exceptions to this finding were the 
mean increases observed for maximum CMAP and SNIP.  However, these measures were 
found to have the smallest SRMs of any of the outcome measures, indicating that their 
changes from T0 to T6 were of very small magnitude (Table 5.2).  Despite the minimal 
mean change observed for maximum CMAP, variability at intermediate time points was 
observed for individual subjects, as will be discussed shortly.  The absence of the mean 
decline anticipated for SNIP was likely related in part to measurement error associated 
with the technique.  The sensitivity to change of the results for this outcome measure may 
have been improved through the use of a more standardized, commercially available 
pressure transducer to minimize the effects of measurement error.      
MUNE expressed a moderate magnitude of change (SRM, -0.63), with a mean 
decline from T0 to T6.  As anticipated, an overall decline in MUNE was seen for each 
subject, with the exception of two subjects for whom an increase in MUNE was observed 
(Figure 5.1A).  Two subjects’ MUNE values declined more than the minimal detectable 
difference (MDD95) of 111 MUs calculated previously (Chapter 4), while neither of the 
subjects who demonstrated increases in MUNE changed more than the MDD95.  Indeed, 
the change score for one of the subjects who demonstrated an increase in MUNE (18 
MUs, subject 5) was less than the absolute change score for any other subject.  However, 
owing to the low absolute MUNE values for this subject, this change translated into the 
largest % change of any subject (approximately 95%), highlighting the caution that must 
be exercised in interpreting % change results.   
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5.3.2 Subjects 
The demographic and clinical characteristics of the sample of patients under study 
(middle-aged to older adults, a greater proportion of males, predominantly limb onset and 
sporadic ALS) were consistent with the characteristics most common in the broader 
disease population.
36
  There was a great deal of variability between subjects with respect 
to symptom duration as of T0 (Table 5.1).  This heterogeneity was further reflected in the 
range of subject scores on the ALSFRS-R at T0, indicative of varying degrees of disease 
progression (Table 5.2).     
5.3.3 Hand-held dynamometry data collection   
A limitation of the use of the HHD ‘break’ test to assess quantitative muscle 
strength is that its ability to assess stronger muscles is dependent upon the strength of the 
evaluator.
37, 38
  The inability of the evaluator to break the contraction of any subject at 
any time point in the assessment of scapular elevation (with the exception of one subject 
for whom pain during the contraction was likely an important  contributing factor) speaks 
to the strength of the proximal muscle groups, including the UT, that are involved in this 
movement.  The strength of these muscle groups limited the sensitivity to change of 
HHD; any declines in peak force that may have been occurring were not detected, as 
levels did not fall below the threshold set by the evaluator’s strength.37  Thus, changes 
over time that yielded a moderate SRM for HHD as applied to scapular elevation were 
not attributable to detected changes in the strength of the subjects.  In contrast, 
contractions were broken commonly in the assessment of elbow flexion, which involves 
muscle groups with less force-producing capacity.  This allowed for the more sensitive 
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assessment of changes in strength over the course of the study, reflected by the large 
SRM calculated for this outcome measure (Table 5.2).   
Performance of HHD testing in an upright seated position for both muscle groups 
would have avoided the need to alter the protocol for those subjects who were unable to 
tolerate the supine position as a result of the progression of the disease.  Although testing 
in this position would have been more difficult to standardize, it may have increased the 
number of contractions that were broken for scapular elevation, owing to the influence of 
gravity, and the ability of the evaluator to exert greater levels of force.  
5.3.4 Longitudinal variability in MUNE, maximum CMAP, and mean S-MUP  
Inconsistent changes in MUNE were typically observed for individual subjects 
when the intermediate 2 and 4 month time points were taken into consideration.  These 
fluctuations in MUNE values for individual subjects were reflected in the mean MUNE 
values across time points (Table 5.3).  While a similar study also observed inconsistent 
changes in MUNE for individual subjects,
27
 consistent declines in mean MUNE values 
were still observed, as was the case for other similar studies.
10, 12, 15, 16
 
Fluctuations in MUNE values over time were as a result of inconsistent changes 
in maximum CMAP and mean S-MUP values for these subjects.  For example, one of the 
subjects that declined more than the MDD95 overall demonstrated fluctuations in MUNE 
at intermediate time points (e.g. T4 MUNE was larger than T0 MUNE).  This inconsistent 
pattern of change was driven by large oscillations in maximum CMAP values between 
time points, while mean S-MUP values remained fairly constant.  Similar results of an 
inconsistent pattern of change were found for one of the subjects that demonstrated an 
increase in MUNE from T0 to T6.  In the face of a relatively consistent mean S-MUP size, 
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this change was also driven by fluctuations in the maximum CMAP at each of the 
intermediate time points, with an increase in the maximum CMAP of 2 mV (40%) from 
T0 to T6.    
We would have anticipated stable or, with the eventual outpacing of collateral 
reinnervation by denervation, consistently declining maximum CMAP values for each 
subject as was reflected in mean maximum CMAP values in previous longitudinal 
studies.
10, 12, 15, 16, 27
  The fluctuations in maximum CMAP values that were observed 
instead for a number of subjects likely stemmed from sources of error related to data 
collection (e.g. failure to position the active electrode optimally over the motor point of 
the muscle at each time point).   
Mean S-MUP values also demonstrated inconsistent changes across time points 
for a number of subjects, in contrast with the consistent increases in mean values 
demonstrated previously in similar studies using various MUNE techniques.
10, 12, 16
  For 
example, extensive fluctuations in mean S-MUP values across time points were observed 
for one subject for whom MUNE changed more than the MDD95.  Furthermore, while the 
majority of subjects exhibited an increase in mean S-MUP size from T0 to T6, a consistent 
decrease in this measure was observed for one subject (subject 5) (Figure 5.1C).  This 
decline was likely as a result of measurement error, as the maximum CMAP for this 
subject remained relatively constant.  Again, unanticipated changes in mean S-MUP size 
for these subjects may have resulted from potential sources of error associated with the 
data collection process.  
Measurement error may have resulted from the failure to collect a representative 
sample of S-MUPs, potentially related to the lack of a standardized protocol regarding the 
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collection of data from various needle electrode depths in this large proximal muscle.  
Another potential source of error relates to the influence of contractile intensity on the 
pool of MUs from which S-MUPs are sampled.  While we initially planned for each 
subject to contract at 10-20% of their maximal voluntary contraction-root mean square 
(MVC-RMS), this contractile level was often diverged from in order to improve the 
complexity of the composite intramuscular EMG signal.  Coupled with the variability 
associated with calculating the referential MVC-RMS value without the aid of a 
dynamometer, any inconsistencies in contractile intensity between time points for a given 
subject may have added variability to the collection of the mean S-MUP.  Further 
discussion of these potential sources of variability has been presented in Chapter 3.  An 
additional potential source of variability relates to the upper motor neuron (UMN) 
component of the disease.  With the loss of UMNs, an impaired descending drive may 
hamper a subject’s ability to recruit MUs from the pool under study.39  This may have 
inhibited the collection of a representative sample of S-MUPs at a single time point, with 
the progression of UMN loss for a given subject contributing variability to the 
longitudinal study of the mean S-MUP.   
DE-STA MUNE and each of the components of the equation as applied to the UT 
have been shown to yield highly reliable results in subjects with ALS when tested twice 
with a brief interval of time between tests (Chapter 4).  Thus, the variability in the results 
may point to the need for more stringent control and/or consideration of various sources 
of error in the context of a longitudinal study involving disease progression.     
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5.3.5 S-MUP and MUP data collection results 
Measures of the MUNE data collection process yielded very similar results at T0 
and T6, which were consistent with the study of the technique in the UT reported in 
Chapter 4.  On average, slightly less than the target of 20 acceptable S-MUPs were 
obtained for the mean S-MUP calculation at both time points, reflecting the somewhat 
more challenging nature of the data collection protocol in this disease population.  
Despite the collection of fewer acceptable S-MUPs, the reliability of the technique has 
been shown to be robust (Chapter 4).   
Unimodal, positively skewed S-MUP frequency distributions were detected at 
both T0 and T6 (Figure 5.4).  On average, S-MUP size at T6 was found to be a larger 
percentage of maximum CMAP size than at T0, indicative of collateral reinnervation.  
These findings of collateral reinnervation were echoed in the mean S-MUP results, which 
demonstrated a mean increase from T0 to T6 (Table 5.2).  The largest absolute change 
score was found for subject 1, amounting to an increase of approximately 151%.  The 
extensive degree of collateral reinnervation for this subject was also evident in the S-
MUP frequency distribution results.  The individual S-MUPs making up the mean value 
for this subject at T6 were 10.1-16.1% of the corresponding maximum CMAP size, while 
the S-MUPs for each of the other subjects were less than or equal to 4.2% of the 
maximum CMAP at this time point (Figure 5.4). 
A moderate SRM was calculated for the change in MUP peak-to-peak voltage 
over time, with each subject demonstrating an increase from T0 to T6 (Table 5.2, Figure 
5.1D).  While this parameter is influenced by differing factors during the data collection 
process than S-MUP amplitude which make it less closely reflective of collateral 
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reinnervation,
40
 the demonstrated increases were concordant with the increases generally 
found for the surface-detected signal.   
5.3.6 Trends across outcome measures 
Examining the results of individual subjects across outcome measures revealed 
many clear trends in the data.  For example, subjects 1 and 5 not only demonstrated the 
largest mean S-MUP values at each time point but, along with subject 8, the smallest 
maximum CMAP and MUNE values throughout the study.  These three subjects also 
consistently demonstrated markedly lower MMT and HHD – elbow flexion values than 
each of the other subjects.  Furthermore, the lowest ALSFRS-R scores at each study time 
point were observed for subjects 1 and 8.  In contrast, subject 10 demonstrated the largest 
values for MUNE at every time point, corresponding with the smallest mean S-MUP 
values, and one of the largest maximum CMAP values throughout the duration of the 
study.  The ALSFRS-R scores for this subject were also consistently larger than for each 
of the other subjects.  These parallel results across outcome measures reflect the ability of 
each measure to consistently distinguish between subjects with differing levels of disease 
severity in various UE muscle groups, be it at the electrophysiological or clinical (muscle 
strength or functional) level.   
5.3.7 Mean percentage change data  
In order to take into account the variability between subjects associated with the 
change in each outcome measure, conclusions regarding sensitivity to change were based 
on statistical comparisons between T0 and T6, as well as SRM results.  However, mean 
percentage change values were calculated in addition for each outcome measure for the 
purpose of comparing the present results to those of previous studies (Table 5.2).
14, 27
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De Carvalho and Swash (2010)
14
 found that each clinical and lower motor neuron 
neurophysiological measure assessed changed significantly over the 6 month duration of 
the study.  Based on mean % change results, MUNE was found to change by a similar 
amount as the neurophysiological index,
13
 with these two measures changing more than 
any other outcome measure.  In contrast with the present study, which found MUNE to 
decline by roughly 11%, their study found MUNE to decline by approximately 40% over 
6 months in the abductor digiti minimi muscles.  Similarly, van Dijk et al. (2010)
27
 found 
MUNE to decline by approximately 49% over 8 months in the thenar muscles, which was 
more than any other outcome measure.  Discrepancies between the results of these 
previous studies and the current findings may be as a result of different degrees of disease 
involvement and rates of progression of small, distal muscle groups of the hand versus a 
large proximal muscle group, or differences in levels of variability between MUNE 
techniques.  
5.3.8 Limitations and future study 
While missing data was a limitation of this study, the reasons behind each of the 
missed study visits were outside the control of the subjects and the evaluator, including 
the loss to follow-up of three subjects.  The opportunity for loss to follow-up of subjects 
is a weakness of any study with a longitudinal design.
9
  This limitation was magnified in 
the study of a progressive, fatal disease, although only two subjects were lost due to ill 
health or death over the 6 month follow-up period.  
 The recruitment of subjects for this study was limited to those patients who were 
well enough to participate, and for whom it was feasible to travel to the tertiary care 
center for study visits.  While similar studies have also used sample sizes of 10 
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subjects,
12, 16
 the power of the study to detect significant changes in the outcome 
measures over time would have been increased with a larger sample size.  Specifically, 
based on the present results, a sample size of approximately 20 subjects would have been 
required to achieve power of 80% to detect a significant difference between T0 and T6 in 
MUNE.  A small number of similar studies were also 6 months in duration,
12, 14
 although 
the majority of longitudinal studies of the sensitivity to change of MUNE techniques 
have been 8-15 months in duration.  The evaluation of a larger sample size over a longer 
duration may have provided further information on the longitudinal performance of 
MUNE in comparison with each of the other outcome measures.     
 Future study into the potential sources of error associated with DE-STA MUNE 
as applied to the UT is warranted.  In particular, the influence of needle electrode depth 
on the results of the technique is an aspect of the data collection protocol that could be 
readily assessed.  It may also be necessary to evaluate the reliability of the technique 
when performed on different days, separated by enough time to better reflect the 
conditions of a longitudinal study, but not so much time as to allow for important MU 
loss and/or collateral reinnervation.    
5.3.9 Summary 
This study has been the first to evaluate the sensitivity to change of DE-STA 
MUNE and quantitative MUP data in comparison with clinical outcome measures in 
subjects with ALS.  While previous studies of the sensitivity to change of various MUNE 
techniques were limited to the evaluation of distal muscle groups, the present study was 
particularly novel in its application of MUNE to a proximal muscle group.  The 
feasibility of the longitudinal application of DE-STA MUNE to the UT was established, 
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and the results demonstrated a moderate degree of sensitivity to change for MUNE over 
the 6 month study period.  Future investigation into potential sources of error associated 
with the technique may aid in further establishing and optimizing DE-STA MUNE for 
use as an outcome measure.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
 
5.4 REFERENCES 
1. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation of 
the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry 1971; 
34:121-131.  
2. Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stalberg E, Wuopio R. A pilot 
trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 
1993; 56:197-200.  
3. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, 
placebo-controlled trial of memantine for functional disability in amyotrophic lateral 
sclerosis. Amyotroph Lateral Scler 2010; 11:456-460.  
4. Bromberg MB, Fries TJ, Forshew DA, Tandan R. Electrophysiologic endpoint 
measures in a multicenter ALS drug trial. J Neurol Sci 2001; 184:51-55.  
5. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. The use of 
statistical mune in a multicenter clinical trial. Muscle Nerve 2004; 30:463-469.  
6. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. Revised statistical 
motor unit number estimation in the celecoxib/ALS trial. Muscle Nerve 2007; 35:228-
234.  
7. Boe SG, Stashuk DW, Doherty TJ. Motor unit number estimation by decomposition-
enhanced spike-triggered averaging: Control data, test-retest reliability, and contractile 
level effects. Muscle Nerve 2004; 29:693-699.  
8. Doherty T, Simmons Z, O'Connell B, Felice KJ, Conwit R, Chan KM, et al. Methods 
for estimating the numbers of motor units in human muscles. J Clin Neurophysiol 1995; 
12:565-584.  
9. Portney LG, Watkins MP. Foundations of clinical research: Applications to practice. 
Prentice Hall: New Jersey; 2008. 892 p.  
10. Felice KJ. A longitudinal study comparing thenar motor unit number estimates to 
other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 1997; 
20:179-185.  
11. Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang MX, et al. 
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. 
Neurology 2007; 68:1402-1410.  
12. Yuen EC, Olney RK. Longitudinal study of fiber density and motor unit number 
estimate in patients with amyotrophic lateral sclerosis. Neurology 1997; 49:573-578.  
144 
 
 
13. de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. 
Neurology 2005; 64:1783-1785.  
14. de Carvalho M, Swash M. Sensitivity of electrophysiological tests for upper and 
lower motor neuron dysfunction in ALS: A six-month longitudinal study. Muscle Nerve 
2010; 41:208-211.  
15. Liu XX, Zhang J, Zheng JY, Zhang S, Xu YS, Kang DX, et al. Stratifying disease 
stages with different progression rates determined by electrophysiological tests in patients 
with amyotrophic lateral sclerosis. Muscle Nerve 2009; 39:304-309.  
16. Arasaki K, Kato Y, Hyodo A, Ushijima R, Tamaki M. Longitudinal study of 
functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve 
2002; 25:520-526.  
17. Boekestein WA, Schelhaas HJ, van Putten MJAM, Stegeman DF, Zwarts MJ, van 
Dijk JP. Motor unit number index (MUNIX) versus motor unit number estimation 
(MUNE): A direct comparison in a longitudinal study of ALS patients. Clin 
Neurophysiol 2012; 123:1644-1649.  
18. Boe SG, Stashuk DW, Doherty TJ. Motor unit number estimates, quantitative motor 
unit analysis and clinical outcome measures in amyotrophic lateral sclerosis. Suppl Clin 
Neurophysiol 2009; 60:181-188.  
19. Lewis RA. Motor unit number estimation in the upper trapezius muscle. Suppl Clin 
Neurophysiol 2009; 60:131-134.  
20. Aids to the investigation of peripheral nerve injuries. Her Majesty's Stationary Office: 
London; 1943.  
21. Miller RG. Measurement of strength: Summary. Amyotroph Lateral Scler Other 
Motor Neuron Disord 2002; 3:S51-S54.  
22. Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral 
sclerosis: Evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler 
Other Motor Neuron Disord 2002; 3:5-13.  
23. Fitting JW, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: A 
sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann 
Neurol 1999; 46:887-893.  
24. H ritier F, Rahm F, Pasche P, Fitting JW. Sniff nasal inspiratory pressure: A 
noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med 1994; 
150:1678-1683.  
145 
 
 
25. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The 
ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of 
respiratory function. J Neurol Sci 1999; 169:13-21.  
26. Brooks BR, Miller RG, Swash M, Munsat TL. El escorial revisited: Revised criteria 
for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor 
Neuron Disord 2000; 1:293-299.  
27. Van Dijk JP, Schelhaas HJ, Van Schaik IN, Janssen HMHA, Stegeman DF, Zwarts 
MJ. Monitoring disease progression using high-density motor unit number estimation in 
amyotrophic lateral sclerosis. Muscle Nerve 2010; 42:239-244.  
28. Great Lakes ALS Study Group (GLALS). GLALS clinical evaluator manual. 1999.  
29. The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS). Reliability 
studies: Outcome measures in amyotrophic lateral sclerosis research. 2007.  
30. Doherty TJ, Stashuk DW. Decomposition-based quantitative electromyography: 
Methods and initial normative data in five muscles. Muscle Nerve 2003; 28:204-211.  
31. Northeast ALS Consortium (NEALS). ALS clinical trials - Outcome measures. DVD-
R.  
32. Kasarskis EJ, Dempsey-Hall L, Malley Thompson M, Chi Luu L, Mendiondo M, 
Kryscio R. Rating the severity of ALS by caregivers over the telephone using the 
ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6:50-54.  
33. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for 
orthopedic evaluation. Med Care 1990; 28:632-642.  
34. Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Erlbaum 
Associates, Publishers: Hillsdale; 1988. 567 p.  
35. Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med 
Rehabil Clin N Am 2008; 19:495-508.  
36. McGuire V, Nelson LM. Epidemiology of ALS. In: Mitsumoto H, Przedborski S, 
Gordon PH, editors. Amyotrophic lateral sclerosis. Taylor & Francis: New York; 2006. 
17-42 p.  
37. Andres PL, Thibodeau LM, Finison LJ, Munsat TL. Quantitative assessment of 
neuromuscular deficit in ALS. Neurol Clin 1987; 5:125-141.  
38. Stratford PW, Balsor BE. A comparison of make and break tests using a hand-held 
dynamometer and the kin-com. J Orthop Sports Phys Ther 1994; 19:28-32.  
146 
 
 
39. Boe SG, Stashuk DW, Doherty TJ. Motor unit number estimates and quantitative 
motor unit analysis in healthy subjects and patients with amyotrophic lateral sclerosis. 
Muscle Nerve 2007; 36:62-70.  
40. Stashuk DW, Doherty TJ. Normal motor unit action potential. In: Brown WF, Bolton 
CF, Aminoff MJ, editors. Neuromuscular function and disease: Basic, clinical, and 
electrodiagnostic aspects. W.B. Saunders Company: Philadelphia; 2002. Vol. 1, 291-310 
p.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
 
CHAPTER 6 
INFLUENCE OF NEEDLE ELECTRODE DEPTH ON DECOMPOSITION-
ENHANCED SPIKE-TRIGGERED AVERAGING MOTOR UNIT NUMBER 
ESTIMATION IN THE UPPER TRAPEZIUS 
6.0 INTRODUCTION 
The sensitivity to change of decomposition-enhanced spike-triggered averaging 
(DE-STA) motor unit number estimation (MUNE) was evaluated previously as applied to 
the upper trapezius (UT) muscle in subjects with amyotrophic lateral sclerosis (ALS) 
(Chapter 5).  The study established the feasibility of longitudinal application of DE-STA 
MUNE and quantitative motor unit potential (MUP) analysis to the UT.  However, the 
results also pointed to the need for additional study regarding potential sources of error 
associated with the technique that may be better controlled.     
One potential source of error associated with any MUNE technique is the failure 
to collect a representative sample of surface-detected motor unit potentials (S-MUPs) 
from which to calculate a mean S-MUP.
1
  DE-STA requires the collection of 
intramuscularly-detected MUPs that serve as triggers to isolate corresponding S-MUPs.  
Therefore, the sample of S-MUPs is completely dependent upon the sample of MUPs 
collected.  In order to sample from different MUPs, the data collection protocol involves 
adjusting the position of the concentric needle electrode to different depths, angles, and, 
in some instances, points of insertion between contractions, thereby sampling 
corresponding S-MUPs from different areas of the muscle.
2, 3
  However, this sampling 
procedure may require greater standardization in order to ensure that a representative 
sample is collected; particularly when examining large muscles such as the UT.     
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It is well established that the characteristics of an electromyographic (EMG) 
signal for a given motor unit (MU) are impacted in part by the position of the detecting 
electrode relative to the muscle fibers of the MU.
4
  Numerous studies have demonstrated 
that S-MUP size tends to be smaller for MUs located at greater intramuscular depths than 
for MUs located more superficially, as a result of the larger distance between the surface 
electrode and the MU.
5-8
  In calculating a MUNE, maximum compound muscle action 
potential (CMAP) values are influenced similarly by the depths of contributing MUs.  
Thus, it is important to collect a representative sample of S-MUPs as they originally 
contributed to the maximum CMAP.  
Barkhaus and Nandedkar (1994)
5
 examined the influence of needle electrode 
depth on the MUNE results for the traditional spike-triggered averaging (STA) technique 
in the biceps brachii (BB) of control subjects.  In keeping with the principles described 
above, MUNE values based on S-MUPs corresponding with deeper needle electrode 
positions tended to be larger than MUNE values based on S-MUPs corresponding with 
superficial needle electrode depths.        
To date, however, the impact of the depth of the needle electrode on the results of 
DE-STA MUNE, including the characteristics of quantitative MUP data, has yet to be 
studied.  Such an evaluation of the impact of this potential source of error may inform 
efforts to improve the standardization of the data collection protocol, leading to the 
further establishment and optimization of the utility of the technique as an outcome 
measure.  
Thus, the purpose of this study was to evaluate the influence of needle electrode 
depth on the results of DE-STA MUNE and quantitative MUP analysis in the UT of 
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control subjects by comparing the results obtained across superficial, intermediate and 
deep needle electrode depths.    
6.1 METHODS 
6.1.1 Subjects 
Individuals between the ages of 18-80 with no known neuromuscular or 
musculoskeletal disease were eligible to participate in this study (n = 18).  All subjects 
gave written, informed consent in accordance with The University of Western Ontario 
Health Sciences Research Ethics Board, which approved this study.     
6.1.2 Electromyographic data collection and analysis  
EMG signals were acquired using decomposition-based quantitative 
electromyography (DQEMG) (version 3.2) and Acquire EMG software on a Neuroscan 
Comperio (Neuroscan Medical Systems, El Paso, TX).  Self-adhering Silver Mactrode
® 
electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface signals, 
and 25 mm x 30 gauge TECA
™
 elite Disposable Concentric Needle Electrodes 
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass 
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.
2, 3
   
The experimental protocol was performed three times for each subject, with the 
needle electrode maintained as consistently as possible at one of three depths within the 
muscle for each test.  These depths of needle electrode insertion were referred to as 
superficial, intermediate, and deep, and were judged relative to one another, thus varying 
across subjects.
6, 9
  For each subject, the first test was completed at a superficial needle 
electrode depth, chosen as a depth that went minimally into the muscle; just beyond the 
skin and subcutaneous tissue.  Subsequently, testing was completed at an intermediate 
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(approximately 2-6 mm deeper than the superficial position) and, lastly, deep 
(approximately 2-6 mm deeper than the intermediate position) needle electrode depth.        
The right UT was tested for each subject and subjects were seated upright in a 
straight back chair with their feet on the floor.  Surface electrodes were cut in strips (1 cm 
x 3.5 cm) for use as the active and reference electrodes, with a full-sized electrode 
serving as a ground.  The skin was cleansed with isopropyl alcohol and surface electrodes 
positioned appropriately.  The active electrode was positioned transversely over the belly 
of the muscle, approximately midway between the acromion process and C7 spinous 
process, with the reference electrode placed over the acromion process, and the ground 
electrode over the deltoid.
10
 
A handheld bipolar stimulator was used in order to elicit a maximum CMAP, with 
the spinal accessory nerve stimulated posterior to the sternocleidomastoid.
10
  If necessary, 
the active electrode was moved in small increments to a position where the CMAP 
negative peak amplitude was maximized and the rise time minimized.  Following optimal 
positioning of the active electrode, the surface electrode positions were reinforced with 
surgical tape to ensure that no movement occurred during the study.  Gradually, the 
stimulation intensity was increased until the CMAP negative peak amplitude reached a 
plateau.  Automatically positioned markers indicating onset, negative peak, positive peak, 
and end of the maximum CMAP were reviewed and manually adjusted if necessary.  
Subsequently, size-related parameters of the maximum CMAP including negative peak 
amplitude were calculated automatically. 
Following the determination of the maximal voluntary contraction-root mean 
square (MVC-RMS) (described in Chapter 3), the concentric needle electrode was 
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inserted into the UT, approximately 2-10 mm proximal or distal to the active surface 
electrode.  Subjects were asked to perform minimal isometric contractions while an 
optimal needle position at the depth of interest was located that minimized the rise times 
of the motor unit potentials (MUPs) of the first two to three recruited MUs.  With the 
needle manually maintained in this position by the evaluator, the subject was instructed to 
increase the contraction force to approximately 10-20% of the MVC-RMS.  Each sub-
maximal isometric contraction was maintained for 30 s, during which the subject 
received visual and auditory feedback from the EMG signal and % MVC-RMS 
information displayed on the screen to assist in the maintenance of a stable contraction.  
Contractions were performed until a minimum of 20 MUP trains were collected, with 
each contraction separated by a rest period of approximately 30-60 s, or as required by 
the subject.  The angle of the needle position was adjusted between contractions to collect 
data from different portions of the muscle, while maintaining the appropriate depth.  If 
necessary, the needle was inserted at a new site at approximately the same depth to 
complete the collection of MUP trains.
2, 3
    
Following EMG signal decomposition and the review of the acceptability of 
acquired MUPs, S-MUPs, and MUP trains, as has been previously described (Chapters 1, 
3), the onset, positive peak, negative peak, and end markers of the MUP templates, and 
negative onset, negative peak, and positive peak markers of the S-MUP templates were 
checked visually and repositioned if necessary.   
Descriptive statistics for various parameters were calculated automatically based 
on all accepted MUPs, S-MUPs, and MUP trains.  Additionally, the mean S-MUP was 
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned 
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based on their onsets.  Lastly, the MUNE was calculated automatically through division 
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of 
the maximum CMAP previously obtained.
2
   
As mentioned, the experimental protocol and subsequent review of the data was 
performed three times on the same day for each subject.  Following the completion of 
each test, all electrodes were removed and, with a minimum of 5 min between sessions, a 
new set of electrodes applied.  The electrode positions were not marked during any of the 
tests.  Data analysis was completed only following collection of all three sets of data for a 
given subject so that the evaluator was blinded to the results of the assessments until data 
collection was complete.   
6.1.3 Statistics  
Mean values along with their standard deviations and ranges are presented 
throughout.  A one-way repeated measures analysis of variance (ANOVA) was used to 
compare the values of maximum CMAP, mean S-MUP, MUNE, and various MUP 
parameters across needle electrode depths.  The independent variable was needle 
electrode depth, with three testing conditions: superficial, intermediate, and deep.  An a 
priori alpha level of 0.05 was used to denote significance.  If Mauchly’s Test of 
Sphericity was significant, a Greenhouse-Geisser correction was applied to the overall p-
value for the repeated measures ANOVA.  If the overall p-value was found to be 
significant, post hoc multiple comparison tests were performed.  Two-tailed, paired t-tests 
were used for pairwise comparisons, with a Bonferroni adjustment applied to an alpha 
level of 0.05 (0.05/3 comparisons = 0.017).
11
  SPSS adjusted Bonferroni p-values are 
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reported for each post hoc test.  All statistical analyses were performed using IBM
®
 
SPSS
®
 Statistics 19 (SPSS, Inc., Chicago, IL).   
6.2 RESULTS 
6.2.1 Subjects 
Eighteen subjects (8 males, 10 females) aged 32 ± 12 years (23-59 years) 
participated in this study.  These subjects had an average height of 172 ± 13 cm (147-191 
cm), and weight of 72.1 ± 13.6 kg (53.4-93.0 kg).   
6.2.2 Data collection results and S-MUP frequency distributions  
On average, 21 ± 4, 21 ± 3, and 22 ± 4 acceptable S-MUPs were obtained (from 
36 ± 9, 38 ± 10, and 39 ± 10 MUP trains collected in total) for each subject from 
superficial, intermediate and deep needle electrode depths, respectively.  These S-MUPs 
were obtained from 6 ± 2 (superficial), 5 ± 2 (intermediate), and 5 ± 1 (deep) 
contractions.  Thus, on average, 4 ± 2 (superficial), and 5 ± 1 (intermediate, deep) 
acceptable S-MUPs per contraction were collected.  The mean MU identification rates 
(percentage of expected firings detected) based on the samples of accepted MUP trains 
were 62 ± 9% (superficial), 59 ± 7% (intermediate), and 57 ± 6% (deep).  The frequency 
distributions of S-MUP negative peak amplitudes, as a percentage of maximum CMAP 
negative peak amplitudes from superficial (0.50 ± 0.40 % maximum CMAP [0.09-2.46 % 
maximum CMAP]), intermediate (0.42 ± 0.39 % maximum CMAP [0.05-2.22 % 
maximum CMAP]), and deep needle electrode depths (0.33 ± 0.35 % maximum CMAP 
[0.02-2.43 % maximum CMAP]) are illustrated in Figure 6.1.       
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Figure 6.1 Frequency distributions of S-MUP data from all subjects comparing results  
between superficial (closed bars) (386 S-MUPs), intermediate (open bars) (386 S-MUPs), 
and deep (checkered bars) (390 S-MUPs) needle electrode depths.  The negative peak 
amplitudes of the S-MUPs have been normalized to the negative peak amplitude of the 
maximum CMAP for each subject at each needle electrode depth testing condition.  The 
y-axis represents the percentage of the total number of S-MUPs per needle electrode 
depth.   
Abbreviations:  CMAP, compound muscle action potential; S-MUP, surface-detected 
motor unit potential.   
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6.2.3 Maximum CMAP, mean S-MUP, and MUNE: Needle electrode depth effects 
Mean maximum CMAP values were 11.4 ± 2.1 (6.8-16.1) mV (superficial), 11.2 
± 1.9 (7.4-14.9) mV (intermediate), and 11.0 ± 2.3 (7.0-15.8) mV (deep), with no 
significant differences found among needle electrode depth testing conditions (p > 0.05) 
(Figure 6.2A).  On average, mean S-MUP values were 35 ± 18 (16-99) µV (superficial), 
28 ± 21 (8-98) µV (intermediate), and 21 ± 16 (9-78) µV (deep).  A significant difference 
among needle electrode depths was found for this parameter, F(2, 34) = 19.82, p < 0.001.  
Pairwise comparisons revealed that mean S-MUP was significantly smaller for 
intermediate vs. superficial (p < 0.05), deep vs. superficial (p < 0.001), and deep vs. 
intermediate (p < 0.05) needle electrode depths (Figure 6.2B).  Mean MUNE values were 
381 ± 157 (109-765) MUs (superficial), 563 ± 387 (111-1660) MUs (intermediate), and 
711 ± 363 (131-1415) MUs (deep).  There was also a significant difference among the 
three needle electrode depths for this parameter, F(2, 34) = 13.82, p < 0.001.  Pairwise 
comparisons revealed that MUNE was significantly larger for deep vs. superficial needle 
electrode depths (p < 0.001).  While not statistically significant, the remaining pairwise 
comparisons demonstrated trends toward larger MUNE values for intermediate vs. 
superficial (p = 0.059), and deep vs. intermediate (p = 0.054) needle electrode depths 
(Figure 6.2C).   
6.2.4 Motor unit potential parameters: Needle electrode depth effects 
Significant differences among needle electrode depths were also found for area, 
F(2, 34) = 3.33, p < 0.05, and area-to-amplitude ratio (AAR), for which a Greenhouse-
Geisser correction was used, F(1.34, 22.81) = 4.05, p < 0.05.  However, no significant 
differences were found for any of the pairwise comparisons for either parameter (Table 
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6.1).  Lastly, no significant differences among needle electrode depths were found for 
MUP peak-to-peak voltage, duration, phases, turns, or mean firing rate (p > 0.05) (Table 
6.1).   
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Figure 6.2 Maximum CMAP (A), mean S-MUP (B), and MUNE (C) across superficial, 
intermediate, and deep needle electrode depth testing conditions.  Error bars represent 
SD.  
*
 indicates a significant difference from superficial needle electrode depth. 
                       
†
 indicates a significant difference from intermediate needle electrode depth.  Mean S-
MUP intermediate vs. superficial (p < 0.05), deep vs. superficial (p < 0.001), deep vs. 
intermediate (p < 0.05), MUNE deep vs. superficial (p < 0.001).  Results are based on 
SPSS adjusted Bonferroni p-values.   
Abbreviations:  CMAP, compound muscle action potential; int., intermediate; MU, motor 
unit; MUNE, motor unit number estimation; neg. peak amp., negative peak amplitude; S-
MUP, surface-detected motor unit potential; sup., superficial.   
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Table 6.1 MUP parameters across superficial, intermediate, and deep needle electrode 
depths 
 
Parameter Superficial Intermediate Deep 
Peak-to-peak voltage (µV) 348.5 ± 82.7 
(231.8-501.9) 
372.8 ± 90.9 
(243.7-602.2) 
377.2 ± 96.0 
(236.5-568.7) 
Duration (ms) 13.3 ± 1.5 
(9.4-16.2) 
13.4 ± 1.6 
(10.0-16.2) 
13.4 ± 2.2 
(9.9-19.0) 
Area (µVms) 581.0 ± 166.4 
(292.6-983.0) 
657.8 ± 196.0 
(372.5-1137.4) 
699.2 ± 218.6 
(403.9-1183.9) 
AAR (ms) 1.7 ± 0.2 
(1.3-1.9) 
1.8 ± 0.2 
(1.4-2.1) 
1.9 ± 0.3 
(1.5-2.7) 
Phases 2.4 ± 0.4 
(1.6-3.0) 
2.5 ± 0.3 
(2.1-3.0) 
2.4 ± 0.4 
(1.7-3.1) 
Turns 3.0 ± 0.4 
(2.2-3.6) 
2.9 ± 0.3 
(2.3-3.5) 
3.1 ± 0.5 
(2.2-3.9) 
Mean firing rate (Hz) 11.2 ± 1.4 
(7.9-13.1) 
11.2 ± 1.3 
(8.6-14.3) 
11.0 ± 1.4 
(8.1-14.4) 
Values expressed as mean ± SD.  Data in parentheses indicate range. 
Abbreviations:  AAR, area-to-amplitude ratio; MUP, motor unit potential.   
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6.3 DISCUSSION 
This has been the first study to evaluate the effect of needle electrode depth on the 
results of DE-STA MUNE, including quantitative MUP data.  In the face of consistent 
maximum CMAP values, a significant decrease in mean S-MUP size with each increase 
in needle electrode depth resulted in increases in MUNE values.  This increase was 
significant from superficial to deep needle electrode depths, and showed statistical trends 
with increasing needle electrode depth for each of the other pairwise comparisons (Figure 
6.2).  The S-MUP frequency distribution results were consistent with these findings, with 
S-MUP size found to represent a smaller percentage of maximum CMAP size, on 
average, with increasing needle electrode depth (Figure 6.1).   
The findings of attenuation of S-MUP amplitude are related to the increased 
distance between the triggering MU (detected with the intramuscular electrode) and the 
surface electrode, resulting in increased volume conduction as has been previously 
demonstrated.
5, 7, 8
  The extent of this impact of MU-surface electrode distance on mean 
S-MUP values resulted in an important influence on MUNE results.  The present findings 
for mean S-MUP and MUNE are consistent with those from the study of the influence of 
needle electrode depth on the results of conventional STA MUNE in the BB.
5
     
In the only other study to evaluate DE-STA MUNE in the UT of control subjects, 
an assessment of the inter-rater reliability of the technique found mean S-MUP size to be 
significantly smaller and MUNE values significantly larger for one rater than for the 
other (Chapter 3).  Based on the results of the current study, these systematic biases may 
have resulted from a tendency toward the collection of data from deeper needle electrode 
depths for this rater.   
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 No significant differences were found between needle electrode depths for any of 
the MUP parameters (Table 6.1).  Similarly, previous studies evaluating the influence of 
various needle electrode depths in the BB on MUP parameters did not find significant 
differences for amplitude,
12, 13
 duration,
12
 and phases.
12, 13
  However, comparing 
superficial and deep needle electrode depths, the study by Falck et al. (1995)
13
 found 
duration, area, thickness (AAR), and size index to be significantly smaller superficially.  
Similarly, a study by Buchthal et al. (1954)
9
 that was also in the BB found peak-to-peak 
amplitude and duration to be significantly smaller superficially.  The latter two studies 
attributed their results to the larger contribution of the cannula of the needle electrode to 
MUPs acquired at superficial depths.
9, 13
  Discrepancies among the results of each of the 
studies, including those found presently, may relate to the differences in the data 
collection techniques used, the muscles groups under study, and the depths of needle 
insertion that were evaluated.   
 While these MUP parameters do not influence the results of MUNE, owing to the 
role of MUPs as simply triggers to isolate corresponding S-MUPs, they do offer insight 
into the characteristics of the MUs at various needle electrode depths.  The present 
finding that there were no significant differences between depths for any of the MUP 
parameters may indicate that the morphological and physiological features of MUs in the 
UT do not vary systematically with respect to muscle depth.  
The results of this study demonstrate the importance of collecting a sample of S-
MUPs from the UT corresponding with various needle electrode depths, not only to 
collect a representative sample from different portions of the muscle, but also to 
minimize any error related to the influence of needle electrode depth on S-MUP size.  
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Needle electrode depth is certainly an important factor in the UT, which was found to 
have an average depth of 6.2 ± 2.8 mm in a study of 18 subjects,
14
 and to be located 7.7 
mm (4.6-10.2 mm) below the surface of the skin, on average, in a study of 9 female 
subjects.
15
  While the current data collection protocol for the technique involves 
adjustments to the position of the needle electrode between contractions,
2, 3
 more detailed 
standardization of this aspect of the protocol may be required, particularly when 
examining large muscles such as the UT.  Such standardization may improve the 
reliability of mean S-MUP and MUNE results, and prove particularly valuable in studies 
of this muscle group involving multiple raters and/or a longitudinal study design.   
In both types of studies, there may be an increased likelihood of inconsistencies 
among data collection sessions in the adjustments made to the depth of the needle 
electrode.  As previously mentioned, this source of error may have played a role in the 
systematic biases found in the assessment of the inter-rater reliability of the technique in 
control subjects (Chapter 3).  Should needle electrode depth have a similarly important 
influence over the results of the technique in the UT in subjects with ALS, this factor 
may have also contributed to the unanticipated fluctuations found for mean S-MUP and 
MUNE values in the longitudinal study of the disease in this muscle group (Chapter 5).   
In line with the findings of favorable levels of intra-rater reliability for maximum 
CMAP values in control subjects (Chapter 3) and subjects with ALS (Chapter 4) in the 
UT, no significant differences were found between testing conditions for this parameter 
in the present study.  These findings of consistent maximum CMAP values across tests 
lie in contrast with the variability in maximum CMAP values observed between time 
points in the longitudinal study of ALS in this muscle group (Chapter 5).  Once again, the 
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discrepancies among these results likely stem from the different testing conditions of the 
studies, pointing to the need for better standardization of the protocol in studies involving 
longer intervals of time between tests.  
 As significant differences were found between mean S-MUP values for each 
pairwise comparison of needle electrode depths, standardization of the protocol should 
involve the collection of data systematically from each of superficial, intermediate, and 
deep sites within the UT.  Roughly equivalent numbers of S-MUPs should be sampled 
from each depth toward the collection of a minimum of 20 S-MUPs.
6
  At each depth, the 
angle and, when necessary, insertion site of the needle electrode should continue to be 
adjusted between contractions.       
A limitation of this study was that the depths of needle electrode insertion were 
determined based on rough approximations, instead of being based on consistently 
measured depths for each data collection session.  While the present approach would be 
practical for application to study subjects in a clinical EMG setting, the optimal depths to 
represent superficial, intermediate, and deep levels of insertion in the UT should be 
determined and implemented in future studies of the influence of this variable.  An 
additional limitation of this study was that the order of testing of needle electrode depths 
was not randomized.  However, the assumption of sphericity (that the variances within 
each set of difference scores will be relatively equal and correlated with each other)
11
 was 
not violated for any of the parameters other than AAR and mean FR, to which 
appropriate correction factors were subsequently applied.   
Following the determination of standard distances that are optimal to represent 
superficial, intermediate, and deep depths in the UT, research should begin by addressing 
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whether modifications to the protocol involving the collection of data systematically from 
each depth improves the intra- and inter-rater reliability of the technique in control 
subjects.  Furthermore, evaluation of the influence of needle electrode depth on the 
results of the technique in other muscle groups to which it is commonly applied (e.g. 
thenar muscles, first dorsal interosseous) would elucidate whether the present findings 
may be more broadly applicable, or are important primarily in the UT.  Should these 
modifications to the protocol prove too technically challenging or fail to improve the 
reliability of the technique in the UT, future study should address whether collecting data 
solely from a superficial needle electrode depth improves reliability.  While not allowing 
for an accurate MUNE calculation, such a modification may be easier to standardize, and 
still allow for the calculation of a reliable MUNE that enables an assessment of relative 
longitudinal change.        
In summary, this study has clearly demonstrated the important influence of needle 
electrode depth on MUNE and mean S-MUP results obtained using DE-STA MUNE as 
applied to the UT in control subjects.  The results of the study point to opportunities for 
better standardization of the data collection protocol in order to minimize this source of 
error and further establish and optimize DE-STA MUNE for use as an outcome measure.   
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CHAPTER 7 
GENERAL DISCUSSION AND SUMMARY 
7.0 GENERAL DISCUSSION  
It was the overall objective of this thesis to review the use of outcome measures 
systematically across amyotrophic lateral sclerosis (ALS) clinical trials, and to evaluate 
the utility of decomposition-enhanced spike-triggered averaging (DE-STA) motor unit 
number estimation (MUNE) as an outcome measure, with a particular focus on its 
application to the upper trapezius (UT).   
These objectives were achieved through a series of five studies.  First, a 
systematic review identified the vast array of outcome measures that have been used in 
ALS randomized controlled trials, highlighting the particular heterogeneity in the 
selection of secondary outcome measures and the need for a clearer consensus regarding 
outcome measure selection (Chapter 2).  In contrast to the frequently used measures of 
function and muscle strength, MUNE has the advantage of being able to detect 
underlying disease progression (motor unit loss as well as collateral reinnervation),
1, 2
 but 
was found to be used infrequently in ALS clinical trials.   
Until the ability of a MUNE technique to sensitively detect change is established 
in the context of a positive clinical trial, it cannot yet be sufficiently ready for use as a 
primary outcome measure.
1, 3
  However, the use of MUNE as such in clinical trials would 
offer a number of benefits.  The sensitivity to change of MUNE would allow for studies 
with shorter durations and/or smaller sample sizes.
2
 
Given the capacity of MUNE to quantify the underlying progression of the 
disease, the use of a MUNE technique as a secondary outcome measure in a positive trial 
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would also allow for valuable insights.  Specifically, the technique could be used to 
determine whether the intervention’s primary mechanism of action was to alter the rate of 
denervation, or to enhance collateral reinnervation.
4, 5
  
DE-STA MUNE shares advantages with conventional spike-triggered averaging 
(STA) over other MUNE techniques of allowing for quantitative motor unit potential 
analysis and the study of proximal muscles.  Improving upon STA, the use of DE-STA 
MUNE as an outcome measure would have the added benefit of more efficient data 
collection from a potentially more representative sample of surface-detected motor unit 
potentials (S-MUPs) through the use of decomposition-based quantitative 
electromyography.
6, 7
  As an outcome measure, application of DE-STA MUNE to the UT 
may be clinically relevant, given its role as an accessory respiratory muscle, and the 
importance of respiratory failure as the typical cause of death in ALS.
8
    
Normative data were collected from this muscle group, and the reliability of DE-
STA MUNE was evaluated in control subjects (Chapter 3) and subjects with ALS 
(Chapter 4).  Applied to the UT in control subjects, the technique was found to be simple 
to perform, and MUNE results demonstrated moderate levels of intra- and inter-rater 
reliability.  However, inter-rater reliability was found to be poor for mean S-MUP results, 
and systematic biases between raters were found for mean S-MUP and MUNE (Chapter 
3).   
The study reported in Chapter 4 marked the first evaluation of the reliability of 
DE-STA MUNE in subjects with ALS.  Although a significant difference between tests 
was found for MUNE in the UT, application of the technique to the UT and biceps 
brachii (BB) found consistently high levels of intra-rater reliability (Chapter 4).  An 
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exception to this finding was the moderate level of reliability found for maximum 
compound muscle action potential (CMAP) results in the BB, owing to technical 
challenges associated with the stimulation of a relatively deep motor nerve.  In addition 
to finding the application of the technique to the UT to be highly practical and highly 
reliable in the population of interest, an assessment of the validity of DE-STA MUNE as 
applied to the UT established its ability to detect the underlying pathophysiology of the 
disease (Chapter 4).  Together, these results suggest promise for the utility of DE-STA 
MUNE in the UT as an outcome measure in the study of ALS.   
These studies led to an evaluation of the sensitivity to change of the technique in 
the UT of subjects with ALS in comparison with that of clinical outcome measures 
(Chapter 5).  As the first study to evaluate the sensitivity to change of DE-STA MUNE, 
the feasibility of its longitudinal application was established, and a moderate degree of 
sensitivity to change was demonstrated for MUNE.  However, variability in the results of 
DE-STA MUNE also pointed to the need for future study regarding potential sources of 
error associated with the data collection process.  Subsequently, the influence of needle 
electrode depth on the results of DE-STA MUNE in the UT was evaluated in control 
subjects, identifying significantly smaller mean S-MUP and larger MUNE results with 
increasing needle electrode depth (Chapter 6).  Taking this important source of error into 
account, the study made corresponding suggestions for improved standardization of the 
protocol, involving the systematic sampling of data from various needle electrode depths.  
This series of studies was novel in the evaluation of the proximal, potentially 
clinically relevant UT muscle; the majority of previous studies using MUNE have 
utilized techniques that limited their evaluations of the severity and progression of the 
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disease to distal muscle groups.  Each of the studies demonstrated the particularly 
practical nature of the data collection process as applied to the UT, with its easily 
accessible nerve supply.  Implementation of the suggestions for improved standardization 
of the DE-STA MUNE protocol in this muscle group may decrease variability in the 
results, and be particularly valuable in applications involving multiple raters and/or 
longitudinal study designs.   
7.1 LIMITATIONS    
 Many of the present studies had relatively small sample sizes.  The recruitment of 
patients with ALS was particularly challenging, as it was limited to those who were well 
enough overall to participate, and for whom it was feasible to travel to the tertiary care 
center for study visits.  The sample size in the cross-sectional evaluation of DE-STA 
MUNE was sufficient to demonstrate the ability of the technique to detect lower motor 
neuron involvement associated with the disease process (Chapter 4).  However, the power 
of the longitudinal study to detect significant changes in DE-STA MUNE and the other 
outcome measures under evaluation would have been improved with a larger sample 
(Chapter 5).   
The present results can only be generalized to those with characteristics similar to 
the samples under study.  Specifically, the studies involving subjects with ALS were 
confined to those patients receiving care through a tertiary care center who were well 
enough to participate, and felt inclined to volunteer.  These samples may not have been 
representative of the population of those living with ALS, as care in a multidisciplinary 
clinic may extend survival.
9
  In addition, those who were willing and able to participate 
may have had higher functional levels than the broader population of people with ALS.  
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 A key limitation of the DE-STA MUNE technique itself is the invasiveness of the 
data collection protocol.  However, the use of the concentric needle electrode resulted in 
only minimal subject discomfort, and did not lead to the discontinuation of participation 
for subjects in any of the studies.  The data collection protocol also requires subject 
cooperation and effort in the maintenance of steady voluntary contractions (although to a 
much lesser extent than STA).
7
  However, each subject (including one with 
frontotemporal dementia) successfully performed this aspect of the protocol, even with 
disease progression over the course of the longitudinal study.  
7.2 FUTURE STUDIES 
In order to establish the utility of DE-STA MUNE as applied to the UT further as 
an outcome measure, a number of follow-up studies are warranted.  Following the 
determination of standard needle electrode depths to represent superficial, intermediate, 
and deep locations in the UT, an evaluation should be conducted as to whether 
systematically sampling data across each depth improves the intra- and inter-rater 
reliability of the technique in control subjects.   
Furthermore, while high levels of intra-rater reliability have been established for 
the technique as applied to the UT in subjects with ALS, evaluations should be conducted 
to build on these results.  A study of intra-rater reliability with tests separated by longer 
periods of time (e.g. performed on consecutive days) would better reflect the conditions 
of a longitudinal study, but still avoid important progression of the disease between tests.  
Additionally, an evaluation of the inter-rater reliability of the technique is necessary, 
given the multicenter nature of the majority of ALS clinical trials.  Both of these 
evaluations should incorporate the present suggestions for improved standardization of 
171 
 
 
the protocol, involving the systematic sampling of data from various needle electrode 
depths.  
Should these studies reveal favorable levels of reliability for the improved 
standardization of the protocol, the logical progression would be to carry out a study of 
the sensitivity to change of the technique in subjects with ALS similar to that reported in 
Chapter 5, this time involving a larger sample size and extended study duration.   
The simultaneous evaluation of a second muscle group in addition to the UT in 
each of these proposed studies would be advantageous.  The study reported in Chapter 4 
demonstrated challenges associated with the collection of a maximum CMAP from the 
BB that were encountered previously using other MUNE techniques.
10-12
  However, distal 
upper extremity muscle groups such as the thenar muscles
13
 and first dorsal 
interosseous
14
 have been shown to be assessed readily using DE-STA MUNE.  An initial 
assessment of whether needle electrode depth significantly influences the results of the 
technique in one or more of these additional muscle groups would elucidate whether the 
findings in the UT (Chapter 6) may be more broadly applicable.  From here, the 
simultaneous assessment of a proximal and distal muscle group would allow for a 
comparative evaluation of the properties of DE-STA MUNE in muscles representing 
different sources of innervation, and thus potentially differing degrees and rates of 
disease progression.    
7.3 SUMMARY  
This series of studies has demonstrated the heterogeneity in the use of outcome 
measures across ALS clinical trials, and found DE-STA MUNE to be promising for use 
in such a role.  These studies marked the first to evaluate the reliability and sensitivity to 
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change of DE-STA MUNE as applied to subjects with ALS in any muscle group.  In 
particular, as a novel, potentially clinically relevant muscle group to study using MUNE, 
application of the technique to the UT was found to be highly practical.  As applied to 
this muscle group in subjects with ALS, the technique also demonstrated high levels of 
intra-rater reliability, the ability to detect the underlying pathophysiology of the disease, 
and a moderate degree of sensitivity to change.  Further evaluation found needle 
electrode depth to exert an important influence over the results of DE-STA MUNE in the 
UT, with corresponding suggestions being made for improved standardization of the data 
collection protocol.  Incorporation of these proposed improvements may aid in further 
establishing and optimizing DE-STA MUNE for use in studies of ALS natural history 
and severity, and as an outcome measure in ALS clinical trials.    
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APPENDIX A 
Summary of included clinical trials 
 
Intervention First author  Year n Duration Outcome measures  
     Primary Secondary 
Acetylcysteine Louwerse 1995 110 12 months survival  MMT, MVIC (UE, LE and grip 
strength), FVC, Barthel Index, 
Rankin scale, Frenchay Dysarthria 
Assessment (modification) 
Amino acid therapy Tandan 1996 95 6 months MMT, max. isometric muscle 
torque
*
 
Norris score, semiquantitative 
estimation of bulbar function, 
ADL scores, time to dial phone 
no., no. rotations of pencil in 30 s, 
FVC, CMAP amplitude, 
spontaneous activity, fiber density, 
MUNE 
Aminophylline Berto 2007 25 72 hr FVC, PImax, PEmax, respiratory 
muscle endurance, MVV, 
MVIC – grip strength† 
 
Antioxidant therapy Ellis 1997 10 12 months AALS blood markers of oxidative 
damage 
Recombinant 
methionyl human 
brain-derived 
neurotrophic factor 
(BDNF) 
Bradley 1999 1135 9 months FVC, survival
*
 syllable repetition (PATA), time to 
walk 15 ft., ALSFRS, incidence of 
select respiratory events, FVC, 
SIP-PDS, Ashworth scale 
Branched-chain amino 
acids (BCAA) 
Beghi 1993 126 12 months survival, MMT, modified 
Norris score
‡
, modified 
AALS
*
  
 
Celecoxib Cudkowicz 2006 300 12 months MVIC – UE survival, CSF PGE2 levels, MVIC 
– LE, MVIC – grip strength, VC, 
ALSFRS-R, MUNE 
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Recombinant human 
ciliary neurotrophic 
factor (rhCNTF) 
Cedarbaum 1996 730 9 months MVIC – UE and LE FVC, PIF, time to walk 15 ft., 
Purdue pegboard test, oral-labial-
lingual dexterity, ALSFRS, 
modified Schwab and England 
scale, GCIC scale 
rhCNTF Miller 1996 570 6 months MVIC (UE and LE) and FVC 
combination megascore 
MVIC – UE, MVIC – LE, FVC, 
SIP, survival 
Creatine monohydrate Groeneveld 2003 175 16 months  survival  MVIC – UE, FVC, ALSFRS,  
SF-36 
Creatine monohydrate Shefner  2004 104 6 months MVIC – UE  MVIC – grip strength,  
ALSFRS-R, MUNE  
Creatine monohydrate Rosenfeld 2008 107 9 months MVIC – UE  FVC, ALSFRS-R, SF-12, muscle 
fatigue  
Deprenyl Jossan 1994 10 9 months Norris score, spinal and 
bulbar score
†
 
 
Dextromethorphan Askmark 1993 14 7 months Norris score, spinal and 
bulbar score, MVIC,  MUNE, 
CMAP amplitude
†
  
 
Dextromethorphan Blin 1996 49 12 months modified Norris score, 
survival
†
 
 
Dextromethorphan Gredal 1997 45 12 months survival FVC, ALS Severity Scale 
Gabapentin Miller 1996 152 6 months MVIC – UE  FVC, MVIC – UE  
Gabapentin Miller 2001 204 9 months MVIC – UE  MVIC – UE, FVC,  survival, 
ALSFRS, time to walk 15 ft., rapid 
foot taps, SF-12, patient VASs 
Glatiramer acetate Meininger 2009 366 52 weeks ALSFRS-R survival 
Recombinant human 
granulocyte-colony 
stimulating factor  
(G-CSF) 
Nefussy 2010 39 12 months ALSFRS-R FVC, MMT, CMAP amplitude, 
NI, McGill single item QoL score, 
survival 
Recombinant growth 
hormone 
Smith 1993 75 18 months modification of TQNE, MMT, 
various serum levels
†
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Recombinant growth 
hormone 
Sacca 2011 40 12 months NAA/Cre + Cho ratio in 
motor cortex assessed by 
MRS 
survival, ALSFRS-R 
Indinavir Scelsa 2005 46 9 months ALSFRS MMT, FVC, SF-36 
Inspiratory muscle 
training 
Cheah 2009 19 20 weeks FVC, VC, lung volumes, 
MIP, MEP, SNIP
*
 
ALSFRS-R, SF-36, 6MWT, 
MVIC – grip strength, NI 
Recombinant human 
insulin-like growth 
factor-I (rhIGF-I) 
Lai 1997 266 9 months AALS AALS, FVC, SIP 
rhIGF-I Borasio 1998 183 9 months AALS SIP 
rhIGF-I Sorenson 2008 330 24 months MMT  survival, ALSFRS-R 
Recombinant 
interferon beta-1a 
(IFNbeta) 
Beghi 2000 61 12 months No. pts becoming non-self-
supporting 
MMT, Norris score, modified 
AALS bulbar section, FVC, 
CMAP latency, amplitude, and 
duration 
KNS-760704 Bozik 2009 102 12 weeks ALSFRS-R, VC
†
   
L-threonine Blin 1992 23 12 months modified Norris score MMT, MVIC – grip strength, 
patient VASs 
Lamotrigine Eisen 1993 67 18 months survival clinical deficit scores, cortical 
threshold and MEP/CMAP ratios 
to magnetic stimulation 
Lamotrigine Ryberg 2003 39 38 weeks Norris score, spinal and 
bulbar score
*
 
Norris score, spinal and bulbar 
score, CSF levels of amino acids 
Lithium Aggarwal 2010 84 5.4 months 
(mean) 
decrease ≥ 6 points on 
ALSFRS-R or death 
ALSFRS-R, SVC, ALSSQoL, 
QIDS-SR16, survival 
Memantine de Carvalho 2010 63 12 months ALSFRS FVC, MMT, patient VASs, 
medical VAS, SF-36,  MUNE, NI 
Methionine, vitamin 
E, and selenium 
Stevic 2001 28 12 months survival modified Norris score, MMT 
Oral supplementation: 
Milk whey proteins 
and modified starch 
Silva 2010 16 4 months anthropometric measures,  
various serum levels, 
ALSFRS-R
†
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Minocycline Gordon 2007 412 9 months ALSFRS-R FVC, MMT, McGill single-item 
QoL score, survival 
Nimodipine Miller 1996 87 7 months modification of TQNE None reported 
Org 2766 Hesselmans 1993 24 8 weeks sum score of manually and 
functionally tested muscles, 
MVIC – LE, jitter, fiber 
density, macro MUP, 
SEMAP
†
 
 
Pentoxifylline Meininger 2006 400 547 days survival ALSFRS-R, MMT 
Physostigmine 
salicylate 
Norris 1993 25 9 months Summated megascore:  Body 
weight, Norris score, Jamar 
grip strength, % FVC,  
% MVV 
None reported 
Riluzole Bensimon 1994 155 573 days 
(median) 
survival
‡
, functional status, 
modified Norris score
*
 
MMT, FVC, GCIC scale, patient 
VASs   
Riluzole Lacomblez 1996 959 18 months survival MMT, modified Norris score, VC, 
GCIC scale, patient VASs 
Riluzole Bensimon 2002 168 18 months survival  MMT, modified Norris score, 
modified CGI scale, FEV, SVC, 
VC ratio, patient VASs 
Selegiline Lange 1998 133 6 months AALS None reported 
Talampanel Pascuzzi 2010 59 9 months TQNE – arm strength 
megascore 
VC, TQNE – leg strength 
megascore, timed rapid alternating 
movement task, ALSFRS, survival 
TCH346 Miller 2007 553 24-44 weeks ALSFRS-R survival, FVC, MMT, ACE 
Intrathecal 
thyrotropin-releasing 
hormone (TRH) 
Munsat 1992 36 13 months TQNE None reported 
Topiramate Cudkowicz 2003 296 12 months MVIC – UE  FVC, MVIC – grip strength, 
ALSFRS, survival 
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Total lymphoid 
irradiation (TLI) 
Drachman 1994 61 24 months MVIC – LE and UE, MMT, 
time to swallow 4 oz. water 
using straw, time to walk 15 
ft., time to walk 25 ft., timed 
rise from 10 in. seat, activity 
indexes, survival
†
  
 
Repetitive TMS 
(rTMS) 
Di Lazzaro 2006 20 6 months ALSFRS-R MMT, MVIC – hand 
rTMS Di Lazzaro 2009 20 12 months ALSFRS-R MMT  
Valproic acid (VPA) Piepers 2009 163 12 months 
(mean) 
survival   ALSFRS-R 
Vitamin E  Desnuelle 2001 289 12 months modified Norris score – limb 
scale 
survival, Norris score – bulbar 
scale, MMT, patient VASs, SVC, 
FVC, SIP, ALS Health State Scale  
Vitamin E Graf 2005 160 18 months survival  modified Norris score, MMT, 
spasticity scale, ventilatory 
function, SIP/ALS-19 
Xaliproden Lacomblez 2004 
(study 
2) 
77 32 weeks MMT  modified Norris score, FVC 
Xaliproden Meininger 2004 867 18 months survival
‡
, time to VC < 50%
*
 VC, MMT, ALSFRS, Norris score, 
patient VASs, spasticity scale, 
GCIC scale, SIP 
Xaliproden Meininger 2004 1210 18 months survival
‡
, time to VC < 50%
*
 VC, MMT, ALSFRS, Norris score, 
patient VASs, spasticity scale, 
GCIC scale, SIP 
*
 More than one primary outcome measure listed. 
†
 Differentiation between primary and secondary outcome measures unclear.  
‡
 Study was statistically powered for this variable (considered as primary outcome measure). 
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Abbreviations:  6MWT, 6-minute walk test; AALS, Appel Amyotrophic Lateral Sclerosis Rating Scale; ACE, Addenbrooke’s 
Cognitive Examination; ADL, activities of daily living scores; ALSFRS, Amyotrophic Lateral Sclerosis Functional Rating Scale; 
ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; ALSSQoL, Amyotrophic Lateral Sclerosis-Specific 
Quality of Life Instrument; CGI, clinical global impression scale; CMAP, compound muscle action potential; CSF, cerebrospinal 
fluid; FEV, forced expiratory volume; FVC, forced vital capacity; GCIC, Global Clinical Impression of Change scale; LE, lower 
extremity; MEP, motor evoked potential; MMT, manual muscle testing; MRS, magnetic resonance spectroscopy; MUNE, motor unit 
number estimation; MUP, motor unit potential; MVIC, maximal voluntary isometric contraction; MVV, maximum voluntary 
ventilation; NI, neurophysiological index; PEmax/MEP, maximal expiratory pressure; PGE2, prostaglandin E2; PIF, peak inspiratory 
flow; PImax/MIP, maximal inspiratory pressure; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology – Self-Report; 
QoL, quality of life; SEMAP, supramaximal-evoked muscle action potential; SF-12, 12-item Short-Form survey; SF-36, 36-item 
Short-Form survey; SIP, Sickness Impact Profile; SIP/ALS-19, Sickness Impact Profile/Amyotrophic Lateral Sclerosis-19; SIP-PDS, 
Sickness Impact Profile – Physical Dimension Score; SNIP, sniff nasal inspiratory pressure; SVC, slow vital capacity; TQNE, Tufts 
Quantitative Neuromuscular Exam; UE, upper extremity; VAS, visual analogue scale; VC, vital capacity. 
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APPENDIX B 
Manual muscle testing grading scale 
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APPENDIX C 
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale 
1. Speech 
      4 Normal speech processes 
   3 Detectable speech disturbance 
  2 Intelligible with repeating 
   1 Speech combined with nonvocal communication 
 0 Loss of useful speech 
   2. Salivation 
     4 Normal 
     3 Slight but definite excess of saliva in mouth; may have nighttime drooling 
2 Moderately excessive saliva; may have minimal drooling 
1 Marked excess of saliva with some drooling 
 0 Marked drooling; requires constant tissue or handkerchief
3. Swallowing 
     4 Normal eating habits 
   3 Early eating problems – occasional choking 
 2 Dietary consistency changes 
   1 Needs supplemental tube feeding 
  0 NPO (exclusively parenteral or enteral feeding) 
 4. Handwriting 
     4 Normal 
     3 Slow or sloppy: all words are legible 
  2 Not all words are legible 
   1 Able to grip pen but unable to write 
  0 Unable to grip pen 
    5a. Cutting food and handling utensils (patients without gastrostomy) 
4 Normal 
     3 Somewhat slow and clumsy, but no help needed 
 2 Can cut most foods, although clumsy and slow; some help needed 
1 Food must be cut by someone, but can still feed slowly 
0 Needs to be fed 
    5b. Cutting food and handling utensils  
(alternate scale for patients with gastrostomy) 
   4 Normal 
     3 Clumsy but able to perform all manipulations independently 
2 Some help needed with closures and fasteners 
 1 Provides minimal assistance to caregiver 
  0 Unable to perform any aspect of task 
  6. Dressing and hygiene 
    4 Normal function 
    3 Independent and complete self-care with effort or decreased efficiency 
2 Intermittent assistance or substitute methods 
 1 Needs attendant for self-care 
   0 Total dependence 
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      7. Turning in bed and adjusting bed clothes 
  4 Normal 
     3 Somewhat slow and clumsy, but no help needed 
 2 Can turn alone or adjust sheets, but with great difficulty 
1 Can initiate, but not turn or adjust sheets alone 
 0 Helpless 
     8. Walking 
     4 Normal 
     3 Early ambulation difficulties 
   2 Walks with assistance 
   1 Nonambulatory functional movement 
  0 No purposeful leg movement 
   9. Climbing stairs 
     4 Normal 
     3 Slow 
     2 Mild unsteadiness or fatigue 
   1 Needs assistance 
    0 Cannot do 
    10. Dyspnea  
     4 None 
     3 Occurs when walking 
   2 Occurs with one or more of the following: eating, bathing, dressing (ADL) 
1 Occurs at rest, difficulty breathing when either sitting or lying 
0 Significant difficulty, considering using mechanical respiratory support 
11. Orthopnea  
    4 None 
     3 Some difficulty sleeping at night due to shortness of breath, 
 
does not routinely use more than two pillows 
 2 Needs extra pillows in order to sleep (more than two) 
1 Can only sleep sitting up 
   0 Unable to sleep 
    12. Respiratory insufficiency  
   4 None 
     3 Intermittent use of BiPAP 
   2 Continuous use of BiPAP during the night 
 1 Continuous use of BiPAP during the night and day 
 0 Invasive mechanical ventilation by intubation or tracheostomy 
 
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A 
revised ALS functional rating scale that incorporates assessments of respiratory function. J 
Neurol Sci 1999; 169:13-21. 
Abbreviations: ADL, activities of daily living; BiPAP, bilevel positive airway pressure; NPO, 
nothing by mouth. 
 
 
184 
 
 
APPENDIX D 
Ethical approval 
 
 
 
185 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
 
 
 
187 
 
 
APPENDIX E 
Rights and permissions 
License Number  2970830318030 
License date Aug 16, 2012 
Licensed content 
publisher 
Wolters Kluwer Health 
Licensed content 
publication 
Journal of Clinical Neurophysiology 
Licensed content 
title 
Methods for Estimating the Numbers of Motor Units in Human 
Muscles 
Licensed content 
author 
Timothy Doherty, Zachary Simmons, Barbara O'Connell, et al 
Licensed content 
date 
Jan 1, 1995 
Volume Number 12 
Issue Number 6 
Type of Use Dissertation/Thesis 
Requestor type Individual Account 
Title of your thesis 
/ dissertation  
Evaluation of the utility of decomposition-enhanced spike-triggered 
averaging motor unit number estimation as an outcome measure for 
the study of amyotrophic lateral sclerosis 
Expected 
completion date  
Oct 2012 
Estimated 
size(pages) 
190 
Billing Type Invoice 
 
Billing address 
  
Customer 
reference info 
None 
 
Total 0.00 USD 
 
188 
 
 
 
Supplier 
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Colleen Ives 
Customer address 
 
  License number 2946660439794 
License date Jul 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication 
Electroencephalography and Clinical 
Neurophysiology 
Licensed content title The role of electromyography in neurology 
Licensed content author Erik Stalberg,Björn Falck 
Licensed content date December 1997 
Licensed content volume number 103 
Licensed content issue number 6 
Number of pages 20 
Start Page 579 
End Page 598 
Type of Use reuse in a thesis/dissertation 
 
Portion figures/tables/illustrations 
 
Number of figures/tables/illustrations 1 
 
Format both print and electronic 
 
Are you the author of this Elsevier 
article? 
No 
 
Will you be translating? No 
 
Order reference number None 
 
Title of your thesis/dissertation  
Evaluation of the utility of decomposition-
enhanced spike-triggered averaging motor unit 
number estimation as an outcome measure for 
the study of amyotrophic lateral sclerosis 
 
Expected completion date Oct 2012 
 
Estimated size (number of pages) 190 
 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
  
189 
 
 
 
Supplier  
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Colleen Ives 
Customer address 
 
License number 2946670553778 
License date Jul 12, 2012 
Licensed content publisher Elsevier 
Licensed content publication Journal of Electromyography and Kinesiology 
Licensed content title 
EMG signal decomposition: How can it be 
accomplished and used? 
Licensed content author Dan Stashuk 
Licensed content date June 2001 
Licensed content volume number 11 
Licensed content issue number 3 
Number of pages 23 
Start Page 151 
End Page 173 
Type of Use reuse in a thesis/dissertation 
 
Intended publisher of new work other 
 
Portion figures/tables/illustrations 
 
Number of figures/tables/illustrations 1 
 
Format both print and electronic 
 
Are you the author of this Elsevier 
article? 
No 
 
Will you be translating? No 
 
Order reference number None 
 
Title of your thesis/dissertation  
Evaluation of the utility of decomposition-
enhanced spike-triggered averaging motor unit 
number estimation as an outcome measure for 
the study of amyotrophic lateral sclerosis 
 
Expected completion date Oct 2012 
 
Estimated size (number of pages) 190 
 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
 
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD 
  
190 
 
 
 
Dear Colleen Ives  
 
We hereby grant you permission to reprint the material detailed below at no charge in 
your thesis subject to the following conditions: 
 
1. If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must also be 
sought from that source. If such permission is not obtained then that material may not be 
included in your publication/copies. 
2. Suitable acknowledgment to the source must be made, either as a footnote or in a 
reference list at the end of your publication, as follows: 
“This article was published in Publication title, Vol number, Author(s), 
Title of article, Page Nos, Copyright Elsevier (or appropriate Society 
name) (Year).”  
3. Your thesis may be submitted to your institution in either print or electronic form. 
4. Reproduction of this material is confined to the purpose for which permission is hereby 
given. 
5. This permission is granted for non-exclusive world English rights only. For other 
languages please reapply separately for each one required. Permission excludes use in an 
electronic form other than submission. Should you have a specific electronic project in 
mind please reapply for permission 
6. This includes permission for the Library and Archives of Canada to supply single 
copies, on demand, of the complete thesis. Should your thesis be published commercially, 
please reapply for permission. 
 
Yours sincerely 
 
Jennifer Jones 
Rights Associate 
 
Elsevier Limited, a company registered in England and Wales with company 
number 1982084, whose registered office is The Boulevard, Langford Lane, 
Kidlington, Oxford, OX5 1GB, United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
191 
 
 
-----Original Message----- 
From: 
Sent: 19 July 2012 15:45 
To: Rights and Permissions (ELS) 
Subject: Obtain Permission 
This Email was sent from the Elsevier Corporate Web Site  
and is related to Obtain Permission form: 
---------------------------------------------------------------- 
Request From: 
Ms. Colleen Ives 
The University of Western Ontario 
 
Contact Details: 
Telephone:  
Email Address: 
 
Type Of Publication: Book 
Book Details: 
Title: Mosby's Medical Dictionary 
ISBN: 9780323052900 
Authors(s):  
Year: 2009 
Pages From : 14 
Pages To:  
Chapter Number:  
Title of Chapter: 
 
Type Of Content: 
Figures(s) 
Quantity of material: 
Quantity of Material Figures: 1 
Quantity of Material Excerpts:  
Are you the author: No  
Author at institute: No 
Format of the requested material be used: Print_Electronic 
Will you be translating the material? No 
Information about your proposed use: thesis 
 
- end - 
For further info regarding this automatic email, please contact: 
WEB APPLICATIONS TEAM ( esweb.admin@elsevier.co.uk ) 
Elsevier Limited. Registered Office: The Boulevard, Langford Lane, Kidlington, Oxford, 
OX5 1GB, United Kingdom, Registration No. 1982084 (England and Wales). 
 
 
 
192 
 
 
Supplier 
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Colleen Ives 
Customer address 
 
License number 2970210119717 
License date Aug 15, 2012 
Licensed content publisher Elsevier 
Licensed content publication Clinical Neurophysiology 
Licensed content title 
Intra- and inter-rater reliability of motor unit number 
estimation and quantitative motor unit analysis in the 
upper trapezius 
Licensed content author Colleen T. Ives,Timothy J. Doherty 
Licensed content date January 2012 
Licensed content volume number 123 
Licensed content issue number 1 
Number of pages 6 
Start Page 200 
End Page 205 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new work other 
Portion full article 
Format both print and electronic 
Are you the author of this Elsevier 
article? 
Yes 
Will you be translating? No 
Order reference number None 
Title of your thesis/dissertation  
Evaluation of the utility of decomposition-enhanced 
spike-triggered averaging motor unit number 
estimation as an outcome measure for the study of 
amyotrophic lateral sclerosis 
Expected completion date Oct 2012 
Estimated size (number of pages) 190 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
 
VAT/Local Sales Tax 0.00 USD / None GBP 
Total 0.00 USD 
  
 
193 
 
 
Supplier 
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Colleen Ives 
License number 2970210160234 
License date Aug 15, 2012 
Licensed content publisher Elsevier 
Licensed content publication Journal of the Neurological Sciences 
Licensed content title 
The ALSFRS-R: a revised ALS functional rating 
scale that incorporates assessments of respiratory 
function 
Licensed content author 
Jesse M. Cedarbaum,Nancy Stambler,Errol 
Malta,Cynthia Fuller,Dana Hilt,Barbara 
Thurmond,Arline Nakanishi 
Licensed content date 31 October 1999 
Licensed content volume number 169 
Licensed content issue number 1–2 
Number of pages 9 
Start Page 13 
End Page 21 
Type of Use reuse in a thesis/dissertation 
 
Intended publisher of new work other 
 
Portion figures/tables/illustrations 
 
Number of figures/tables/illustrations 1 
 
Format both print and electronic 
 
Are you the author of this Elsevier 
article? 
No 
 
Will you be translating? No 
 
Order reference number None 
 
Title of your thesis/dissertation  
Evaluation of the utility of decomposition-
enhanced spike-triggered averaging motor unit 
number estimation as an outcome measure for the 
study of amyotrophic lateral sclerosis 
 
Expected completion date Oct 2012 
 
Estimated size (number of pages) 190 
 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
 
VAT/Local Sales Tax 0.00 USD / None GBP 
Total 0.00 USD 
  
194 
 
 
CURRICULUM VITAE 
Colleen T. Ives 
 
POST-SECONDARY EDUCATION AND DEGREES   
 
2008-present  The University of Western Ontario 
London, Ontario, Canada 
Ph.D. Candidate (Health and Rehabilitation Sciences) 
 
2003-2008  University of Prince Edward Island 
Charlottetown, Prince Edward Island, Canada 
BSc (Hon.) (Foods and Nutrition) 
 
HONOURS AND AWARDS 
 
2011-2012 Queen Elizabeth II Graduate Scholarship in Science and Technology 
    
   Natural Sciences and Engineering Research Council of Canada 
2009-2010   Postgraduate Scholarship Extension (PGS MX)  
2008-2009   Alexander Graham Bell Canada Graduate Scholarship  
(CGS M)  
 
2008   Mrs. W. Chester S. McLure Memorial Award  
2
nd
 place standing, Family and Nutritional Sciences 
University of Prince Edward Island 
 
2008   Lydia Gordon Memorial Scholarship  
Family and Nutritional Sciences  
University of Prince Edward Island 
 
2007   University of Prince Edward Island Scholarship  
 
2006 Canadian Institutes of Health Research  
Health Professional Student Research Award  
 
2003   University of Prince Edward Island Entrance Award 
 
RELATED WORK EXPERIENCE 
 
08/2011-present Laboratory Technician/Research Assistant 
Autonomic Evaluation Laboratory 
Department of Clinical Neurological Sciences  
University Hospital, London, ON 
 
01/2011-04/2011 Graduate Teaching Assistant 
Health Sciences 3091B: Special Topics in Musculoskeletal Disorders in 
Rehabilitation 
School of Health Studies 
The University of Western Ontario 
195 
 
 
05/2006-07/2008 Research Assistant        
   Bioactives Research Interdisciplinary Opportunities Laboratory 
Department of Family and Nutritional Sciences  
University of Prince Edward Island 
 
09/2007-12/2007 Workshop Facilitator       
Foods and Nutrition 101: Nutrition for Living 
Department of Family and Nutritional Sciences  
University of Prince Edward Island 
 
PUBLICATIONS 
 
Ives CT, Doherty TJ. Intra- and inter-rater reliability of motor unit number estimation and 
quantitative motor unit analysis in the upper trapezius. Clin Neurophysiol 2012; 123:200-205. 
 
CONFERENCE PRESENTATIONS 
 
Ives CT. Evaluating DE-STA motor unit number estimation (MUNE) for use in ALS clinical 
trials. Exercise Neuroscience Group Biannual Meeting, Wilfrid Laurier University, Waterloo, 
ON. (2011, June). (Oral). 
 
Ives CT, Shoesmith CL, Doherty TJ. Evaluating DE-STA motor unit number estimation 
(MUNE) for use in ALS clinical trials. ALS Society of Canada 7
th
 Annual Research Forum, 
Toronto, ON. (2011, May). (Poster). 
 
Ives CT. Evaluating DE-STA motor unit number estimation (MUNE) for use in ALS clinical 
trials. Department of Clinical Neurological Sciences Annual Research Day, University Hospital, 
London, ON. (2011, February). (Oral) (Awarded 3
rd
 prize).   
 
Ives CT, Shoesmith CL, Doherty TJ. Intra-rater reliability and sensitivity to change of DE-STA 
motor unit number estimation (MUNE). 21
st
 International Symposium on ALS/MND, Orlando, 
FL. (2010, December). (Poster). 
 
Ives CT, Shoesmith CL, Doherty TJ. Intra-rater reliability of motor unit number estimation 
(MUNE) in the upper trapezius muscle. ALS Society of Canada 6
th
 Annual Research Forum, 
Toronto, ON. (2010, May). (Poster). 
 
Ives CT. Assessing a new outcome measure for use in ALS clinical trials. 23
rd
 Annual Western 
Research Forum, The University of Western Ontario, London, ON. (2010, February). (Oral). 
 
Ives CT. DE-STA MUNE in the upper trapezius as an outcome measure in ALS. Exercise 
Neuroscience Group Biannual Meeting, The University of Western Ontario, London, ON. (2009, 
June). (Oral).   
 
Ives CT, Gottschall-Pass K. Can blueberry leaf diets impact markers of metabolic syndrome? 
Presentation to the Prince Edward Island Health Research Institute, University of Prince Edward 
Island, Charlottetown, PE. (2006, August). (Oral). 
 
 
